Interpretation  Dexrazoxane  provides  long-term  cardioprotection  without  compromising  oncological  e  cacy  in  doxorubicin-treated  children  with  high-risk  ALL.,interpretation dexrazoxane long-term cardioprotection compromising oncological cacy doxorubicin-treated children high-risk,C0459471|C0086444|C0443252|G0000000|C2945640|C0027651|C1419788|C0013089|C0008059|C0332167
There were no differences in ESR level between the 2 groups at 6 weeks.,differences esr level 2 6 weeks,C1705241|C3811131|C0441889|G0000000|G0000000|C0439230
There was no difference in basic demographics between the 2 groups at enrollment (Table 1).,difference basic demographics 2 enrollment table 1,C1705241|C1527178|C0011298|G0000000|C1516879|C0039224|G0000000
We used comparison of two proportions for response to chemotherapy and toxicity between the amifostine group and the control group.,comparison proportions response chemotherapy toxicity amifostine control,C1707455|C1709707|C0871261|C0013216|C0040539|C0015020|C0243148
"patients with aggressive non-Hodgkin lymphoma (NHL), and the effect of dexrazoxane supplementation.",patients aggressive non-hodgkin lymphoma nhl dexrazoxane supplementation,C0030705|C0001807|C0024305|C0024299|C0024305|C0086444|C0242297
Toxicities were graded according to the World Health Organization (WHO) Common Toxicity Criteria.,toxicities graded health organization common toxicity criteria,C0600688|C0441800|C0018684|C0029237|C0205214|C0040539|C0243161
"Similarly,  subgroup  analysis  showed  dexrazoxane  protection  (p=0046)  for  the  left  ventricular  thickness-to-dimension  ratio  at  5  years  in  girls  (115,  044185),  but  not  in  boys  (019,  042  to  081).",subgroup analysis dexrazoxane protection p=0046 left ventricular thickness-to-dimension ratio 5 girls 115 044185 boys 019 042 081,C1079230|C0002778|C0086444|C1545588|C0369773|C0205091|C0018827|C1280412|C0456603|G0000000|C0870604|C1442061|G0000000|C0870221|C1442061|C1442061|C1442061
"The prolongation of QT dispersion has been linked to an increased heterogeneity of ventricular repolarization and has been shown to be associated with cardiac electrical instability and increased risk of serious cardiac arrhythmias [13, 14].",prolongation qt dispersion linked increased heterogeneity ventricular repolarization cardiac electrical instability increased risk cardiac arrhythmias 13 14,C0439590|C1552934|C0332624|C1517892|C0205217|C0019409|C0018827|G0000000|C0018787|C0013790|C1444783|C0205217|C0035647|C0018787|C0003811|C0450371|C0450371
Such a benefit was predicted if IVIG proved as effective as it is in Kawasaki disease.,benefit predicted ivig proved effective kawasaki disease,C0814225|C0681842|C0085297|G0000000|C1280519|G0000000|C0012634
"Approval was obtained from the Auckland Hospital Board Ethics Committee, and all patients or their parents gave written consent for participation in the study.",approval auckland hospital board ethics committee patients parents written consent participation study,C0205540|G0000000|C0019994|C0972401|C0015000|C2699414|C0030705|C0030551|C0043266|C1511481|C0679823|C0557651
Follow-up to 12 months was completed in the remaining 59 patients who are included in this report.,follow-up 12 months completed remaining 59 patients included report,C0589120|C0450371|C0439231|C0205197|C1527428|C0450371|C0030705|C0332257|C0684224
"Results  219 children with high-risk ALL were assessed, of whom  205  were  enrolled  and  randomly  assigned  treatment  ( gure  1).",219 children high-risk assessed 205 enrolled randomly assigned treatment gure 1,C1442061|C0008059|C0332167|C1516048|C1442061|G0000000|G0000000|C1516050|C0039798|G0000000|G0000000
"We present the results of a randomized, placebo-controlled trial of IVIG as an acute intervention in patients with ARF to determine whether there was a reduction in the extent and severity of carditis, more rapid resolution of inflammatory activity, or decreased chronic morbidity.",randomized placebo-controlled trial ivig acute intervention patients arf determine reduction extent severity carditis rapid resolution inflammatory activity decreased chronic morbidity,C0034656|C1706408|C0008976|C0085297|C0205178|C0886296|C0030705|C0035436|G0000000|C0301630|C0439792|C0439793|C0869523|C0456962|C1514893|C0333348|C0205177|C0205216|C0205191|C0026538
"Address correspondence to Sergio Gallegos-Castorena, Hospital Civil de Guadalajara Dr. Juan I.",address correspondence sergio gallegos-castorena hospital civil de guadalajara dr juan,C0376649|C0282413|C1653876|C1553364|C0019994|G0000000|C0011198|G0000000|C0013014|G0000000
"ConclusionsIVIG did not alter the natural history of ARF, with no detectable difference in the clinical, laboratory, or echocardiographic parameters of the disease process during the subsequent 12 months.",conclusionsivig alter natural history arf detectable difference clinical laboratory echocardiographic parameters disease process subsequent 12 months,G0000000|C0392747|C0205296|C0019664|C0035436|C3830527|C1705241|C0205210|C0022877|C0013516|C0449381|C0012634|C1184743|C0332282|C0450371|C0439231
Figure 3 illustrates individual transmitral E/A ratio changes.,figure 3 illustrates individual transmitral e/a ratio,G0000000|G0000000|G0000000|C0027361|G0000000|G0000000|C0456603
"The 10 patients who underwent supplementation with dexrazoxane exhibited a significant reduction of QT dispersion (67.4  8.1 vs. 49.5  4.2 ms, P < 0.001) and QTc dispersion (71.2  .7 vs. 51.4  4.3 ms, P < 0.001), while the 10 patients not supplemented with dexrazoxane did not (QT dispersion: 69.3  7.6 vs. 64.2  6.9 ms; QTc dispersion: 72.8  8.1 vs. 67.3  7.2 ms, ns).",10 patients underwent supplementation dexrazoxane exhibited reduction qt dispersion 674 81 495 42 ms < 0001 qtc dispersion 712 7 514 43 ms < 0001 10 patients supplemented dexrazoxane qt dispersion 693 76 642 69 ms qtc dispersion 728 81 673 72 ms ns,C0450371|C0030705|G0000000|C0242297|C0086444|C0015272|C0301630|C1552934|C0332624|C1442061|C0450371|C1442061|C0450371|C0039676|G0000000|G0000000|G0000000|C0332624|C1442061|G0000000|C1442061|C0450371|C0039676|G0000000|G0000000|C0450371|C0030705|C0242295|C0086444|C1552934|C0332624|C1442061|C0450371|C1442061|C0450371|C0039676|G0000000|C0332624|C1442061|C0450371|C1442061|C0450371|C0039676|C0038944
"Finally, increased QT dispersion after anthracycline-based chemotherapy may be an autonomic impairment, characterized by a reduction of parasympathetic activity [25].",finally increased qt dispersion anthracycline-based chemotherapy autonomic impairment characterized reduction parasympathetic activity 25,G0000000|C0205217|C1552934|C0332624|C0003234|C0013216|C0004388|C0221099|C1880022|C0301630|G0000000|C0205177|C0450371
One limitation of the present study is that the sample size was relatively small.,limitation study sample size,C0449295|C0557651|C0370003|C0456389
"Armando Martnez-Avalos, MD 2 Department of Pediatric Oncology, Instituto Nacional de Pediatria, Mexico, DF Mexico",armando martnez-avalos md 2 department pediatric oncology instituto nacional de pediatria mexico df mexico,G0000000|G0000000|G0000000|G0000000|C1704729|C0030755|C0027651|G0000000|G0000000|C0011198|G0000000|C0025885|G0000000|C0025885
Left ventricular ejection fraction (EF) and systolic and diastolic diameters were calculated.,left ventricular ejection fraction ef systolic diastolic diameters calculated,C0205091|C0018827|C0302131|C1264633|G0000000|C0039155|C0012000|C1301886|C0444686
"The end points assessed in this study were time to resolution of inflammation with assessment of time for the ESR to drop to #30 mm/h, time to quiescence of disease activity (joint symptoms) assessed clinically, and the difference in the frequency and severity of cardiac disease at each evaluation time point.",assessed study time resolution inflammation assessment time esr drop #30 mm/h time quiescence disease activity joint symptoms assessed clinically difference frequency severity cardiac disease evaluation time,C1516048|C0557651|C0040223|C1514893|C0021368|C1261322|C0040223|C3811131|C1321095|C0450371|C0456680|C0040223|C3820816|C0012634|C0205177|C0022417|C0683368|C1516048|G0000000|C1705241|C0376249|C0439793|C0018787|C0012634|C0220825|C0040223
"The patient, family, and cardiologists were unaware of the nature of the infusion being administered.",patient family cardiologists unaware nature infusion administered,C0030705|C0015576|C0175906|C0150114|C0349590|C0574032|C1521801
Abbreviations and Acronyms  anthracycline  cardiomyopathy  chemotherapy  ejection fraction  left ventricle/ventricular,abbreviations acronyms anthracycline cardiomyopathy chemotherapy ejection fraction left ventricle/ventricular,C0000723|C1956259|C0003234|C0878544|C0013216|C0302131|C1264633|C0205091|C0018827
Twelve children (20%) had positive throat culture for Streptococcus pyogenes on admission.,twelve children 20% positive throat culture streptococcus pyogenes admission,C0205458|C0008059|C0450371|C0439178|C0031354|C0010453|C0038402|G0000000|C0184666
study and a written consent was obtained from each patient.,study written consent patient,C0557651|C0043266|C1511481|C0030705
All patients received 4 cycles of intra-arterial cisplatin 150 mg/m2/dose every 2 weeks and intravenous doxorubicin 75 mg/m2/dose every 4 weeks before surgery.,patients received 4 cycles intra-arterial cisplatin 150 mg/m2/dose 2 weeks intravenous doxorubicin 75 mg/m2/dose 4 weeks surgery,C0030705|C1514756|G0000000|C1511572|C0694634|C0008838|C1442061|C0026410|G0000000|C0439230|C0348016|C0013089|C0450371|C0026410|G0000000|C0439230|C0038894
Two children in the doxorubicin plus dexrazoxane  group had missing data for ethnic origin.,children doxorubicin dexrazoxane missing data ethnic origin,C0008059|C0013089|C0086444|C1551393|C1511726|C0015031|C0079946
DLCL = diffuse large cell lymphoma; IPI = International Prognostic Index.,dlcl = diffuse cell lymphoma ipi = international prognostic,G0000000|G0000000|C0205219|C0007634|C0024299|C1512894|G0000000|C1512888|C0220901
"Cardiac  troponin-T  was  assayed  in  a  central  laboratory  by  use  of  the  Elecsys  Troponin-T  STAT  Immunoassay  (Roche  Diagnostics,  Indianapolis,  IN,  USA),  which  has  sensitivity  of  001  ng/mL.32,38  Haemolysed  samples  were  excluded.",cardiac troponin-t assayed central laboratory elecsys troponin-t stat immunoassay roche diagnostics indianapolis usa sensitivity 001 ng/ml3238 haemolysed samples excluded,C0018787|C0077404|C0005507|C0205099|C0022877|G0000000|C0077404|C0205548|C0020980|C0331965|C0011900|G0000000|C0041703|C0020517|C1442061|C0028074|G0000000|C0370003|C1554077
"In the carvedilol group, 12.5 mg once-daily oral carvedilol (Dilatrend; Roche SpA, Segrate MI, Italy) was started before CT and maintained for 6 months during CT. All patients received CT at a mean of every 3 weeks.",carvedilol 125 once-daily oral carvedilol dilatrend roche spa segrate mi italy started ct maintained 6 months ct patients received ct 3 weeks,C0054836|C1442061|C0332173|C0442027|C0054836|C0591468|C0331965|C1420002|G0000000|C3810814|C0022277|C1272689|C0007673|C1314677|G0000000|C0439231|C0007673|C0030705|C1514756|C0007673|G0000000|C0439230
"induced  long-term  cardiotoxicity,24  protects  myocardial  mitochondria  from  genetic  and  functional  lesions,26  reduces  apoptosis,36  and  decreases  metabolic  remodelling.37 We aimed to establish the e ect of dexrazoxane on  echocardiographic  measurements  in  survivors  of  highrisk  childhood  ALL,  5  years  after  completion  of  doxorubicin treatment.",induced long-term cardiotoxicity24 protects myocardial mitochondria genetic functional lesions26 reduces apoptosis36 decreases metabolic remodelling37 aimed establish ect dexrazoxane echocardiographic measurements survivors highrisk childhood 5 completion doxorubicin treatment,C0205263|C0443252|G0000000|G0000000|C0027061|C0026237|C0017296|C0205245|G0000000|G0000000|G0000000|C0442797|C0311400|G0000000|C1947946|C0443211|C0013806|C0086444|C0013516|C0242485|C0206194|G0000000|C0231335|G0000000|C0205197|C0013089|C0039798
Characteristics and Clinical Findings,characteristics clinical findings,C1521970|C0205210|C2607943
"QT intervals were measured manually in all the 12 leads in blinded fashion from the onset of the QRS complex to the end of the T wave, as previously described in [11,12].",qt intervals measured manually 12 leads blinded fashion onset qrs complex wave 1112,C1552934|C1272706|C0444706|C3842330|C0450371|C0023175|C0150108|G0000000|C0206132|G0000000|C0439855|C0678544|G0000000
"Procedures  All patients received two doses of 30 mg/m doxorubicin  during remission induction, and eight further 30 mg/m",procedures patients received doses 30 mg/m doxorubicin remission induction 30 mg/m,C0025664|C0030705|C1514756|C0178602|C0450371|C0026410|C0013089|C0544452|C0205263|C0450371|C0026410
Proportions  were  compared  with Fishers exact test.,proportions compared fishers exact test,C1709707|C1707455|C0325045|C2828393|C0022885
"Throughout  follow-up,  the  mean  Z  score  for  left  ventricular  end-systolic  dimension  was  close  to  zero  in  the  doxorubicin  plus  dexrazoxane  group,  but  was  signi cantly greater than zero in the doxorubicin group  (table  2,   gure  3C).",follow-up score left ventricular end-systolic dimension close doxorubicin dexrazoxane signi cantly doxorubicin table 2 gure 3c,C0589120|C0449820|C0205091|C0018827|C0489485|C0439534|C0587267|C0013089|C0086444|G0000000|G0000000|C0013089|C0039224|G0000000|G0000000|C4053564
Three consecutive QT intervals were measured and averaged for each lead.,consecutive qt intervals measured averaged lead,C1707491|C1552934|C1272706|C0444706|C1510992|C0023175
It was not well tolerated due to emesis.,tolerated emesis,G0000000|C0042963
"In the largest study of this condition, coronary aneurysms were detected in 14 of 79 patients (18%) treated with aspirin compared with 3 of 79 (4%) treated with aspirin",largest study condition coronary aneurysms detected 14 79 patients 18% treated aspirin compared 3 79 4% treated aspirin,C0443228|C0557651|C0012634|C0018787|C0002940|C0442726|C0450371|C0450371|C0030705|C0450371|C1522326|C0004057|C1707455|G0000000|C0450371|G0000000|C1522326|C0004057
"Amifostine (WR-2721) has emerged as an effective and tolerable pancytoprotectant [1, 2].",amifostine wr-2721 emerged effective tolerable pancytoprotectant 1 2,C0015020|C1420193|G0000000|C1280519|C4053931|G0000000|G0000000|G0000000
Kalay and Basar contributed equally to this article.,kalay basar contributed equally article,G0000000|G0000000|C1880177|G0000000|C1706852
Carvedilol on Anthracycline Cardiomyopathy,carvedilol anthracycline cardiomyopathy,C0054836|C0003234|C0878544
Both of these patients had been randomized to the IVIG group.,patients randomized ivig,C0030705|C0034656|C0085297
CT  chemotherapy; IVCT  isovolemic contraction time; IVRT  isovolumic,ct chemotherapy ivct isovolemic contraction time ivrt isovolumic,C0007673|C0013216|G0000000|G0000000|C1140999|C0040223|C3890944|G0000000
A patient in the carvedilol group who had low EF after CT and a patient from the control group who had decompensated heart failure and low EF were hospitalized.,patient carvedilol low ef ct patient control decompensated heart failure low ef hospitalized,C0030705|C0054836|C0205251|G0000000|C0007673|C0030705|C0243148|C0205434|C0018787|C0231174|C0205251|G0000000|C0701159
"The protective e ect of  dexrazoxane,  relative  to  doxorubicin  alone,  on  left  ventricular  wall  thickness  (di erence  between  groups:  047,  046048) and thickness-to-dimension ratio (066, 064068) were the only statistically signi cant characteristics  at 5 years.",protective ect dexrazoxane relative doxorubicin left ventricular wall thickness di erence 047 046048 thickness-to-dimension ratio 066 064068 statistically signi characteristics 5,G0000000|C0013806|C0086444|C0080103|C0013089|C0205091|C0018827|C0677535|C1280412|C3538902|G0000000|C1442061|G0000000|C1280412|C0456603|C1442061|G0000000|C0038215|G0000000|C1521970|G0000000
"early,  intensive  treatments  are  becoming  increasingly  apparent.8",intensive treatments increasingly apparent8,C0162425|C0087111|G0000000|G0000000
"Therefore, prevention of CMP has great clinical importance.",prevention cmp clinical,C0199176|G0000000|C0205210
"When it is considered that oxidative stress is a major pathogenetic mechanism, antioxidant properties of carvedilol may be responsible for the benecial effects of the drug that occurred in our study.",considered oxidative stress major pathogenetic mechanism antioxidant properties carvedilol responsible benecial effects drug occurred study,C0750591|C0311404|C0038435|C0205082|C0543483|C0441712|C0003402|C0871161|C0054836|C1273518|G0000000|C1280500|C0013227|C1709305|C0557651
"The clinical usefulness of anthracyclines, which have been shown to be effective in treating various tumors, is limited by their cardiotoxicity.",clinical anthracyclines effective treating tumors limited cardiotoxicity,C0205210|C0003234|C1280519|C1522326|C0027651|C0439801|C0876994
"We and others have shown that such patients  had  clinically  signi cant  left  ventricular  e ects  that  continued  to  be  progressive  even  decades  after  the  completion of doxorubicin treatment.911 On the basis of  these   ndings,  we  reduced  doses  of  doxorubicin  given  to children  and  adolescents  with  ALL  treated  in  the  1980s,  so  that  standard-risk  patients  received  a  low  cumulative  dose  (4560  mg/m),  which  was  associated  with  a  much  lower  risk  of  delayed  cardiotoxicity,  and  high-risk patients received a 345360 mg/m cumulative  doxorubicin  dose.32,43  Although  the  frequency  of  overt  congestive heart failure was much reduced, follow-up of  patients treated in this way suggested that there was still  a  risk  of  delayed  left  ventricular  abnormalities  in  the  patients with high-risk ALL.911",patients clinically signi left ventricular ects continued progressive decades completion doxorubicin treatment911 basis ndings reduced doses doxorubicin children adolescents treated 1980s standard-risk patients received low cumulative dose 4560 mg/m lower risk delayed cardiotoxicity high-risk patients received 345360 mg/m cumulative doxorubicin dose3243 frequency overt congestive heart failure reduced follow-up patients treated suggested risk delayed left ventricular abnormalities patients high-risk all911,C0030705|G0000000|G0000000|C0205091|C0018827|C0013806|C0549178|C0205329|C2981279|C0205197|C0013089|G0000000|C1527178|G0000000|C0392756|C0178602|C0013089|C0008059|C0205653|C1522326|G0000000|C4053991|C0030705|C1514756|C0205251|C1511559|C0178602|G0000000|C0026410|C0441994|C0035647|C0205421|C0876994|C0332167|C0030705|C1514756|G0000000|C0026410|C1511559|C0013089|G0000000|C0376249|G0000000|C0742742|C0018787|C0231174|C0392756|C0589120|C0030705|C1522326|C1705535|C0035647|C0205421|C0205091|C0018827|C0000768|C0030705|C0332167|G0000000
The individual data are shown in Figure 2.,individual data figure 2,C0027361|C1511726|G0000000|G0000000
"Although an acute episode of rheumatic fever is preceded by a streptococcal the mechanism that triggers ARF has not been elucidated.5,6 There is no proven pharmacological treatment that alters the natural history of rheumatic carditis, although corticosteroids and aspirin are frequently administered.",acute episode rheumatic fever preceded streptococcal mechanism triggers arf elucidated56 proven pharmacological treatment alters natural history rheumatic carditis corticosteroids aspirin frequently administered,C0205178|C0332189|G0000000|C0015967|C0332152|C0038402|C0441712|C0032930|C0035436|G0000000|C0456369|C0031330|C0039798|C0392747|C0205296|C0019664|G0000000|C0869523|C0001617|C0004057|C0332183|C1521801
"Subgroup analysis showed dexrazoxane protection (p=004) for left ventricular fractional shortening at  5  years  in  girls  (117,  024211),  but  not  in  boys  (010,  087  to  068).",subgroup analysis dexrazoxane protection p=004 left ventricular fractional shortening 5 girls 117 024211 boys 010 087 068,C1079230|C0002778|C0086444|C1545588|C0369773|C0205091|C0018827|C1264633|C0441636|G0000000|C0870604|C1442061|G0000000|C0870221|C1442061|C1442061|C1442061
"No  patients  had  known  or  suspected  cardiac  disease  or  symptoms,  or  were  taking  cardiac  drugs.",patients suspected cardiac disease symptoms cardiac drugs,C0030705|C0332147|C0018787|C0012634|C0683368|C0018787|C0013227
"To  standardise  left  ventricular  data  by  age  or  body  surface  area  and  adjust  for  changes  associated  with  growth, we expressed echocardiographic measurements  in Z scores, which are the number of SDs the recorded  measurement is above or below the predicted value.",standardise left ventricular data age body surface adjust growth expressed echocardiographic measurements scores sds recorded measurement predicted,G0000000|C0205091|C0018827|C1511726|C0001779|C0242821|C0205148|G0000000|C0018270|G0000000|C0013516|C0242485|C0449820|C3813719|C0034869|C0242485|C0681842
Control EF was below 50% in 1 patient in the carvedilol group and in 5 in the control group.,control ef 50% 1 patient carvedilol 5 control,C0243148|G0000000|C0450371|G0000000|C0030705|C0054836|G0000000|C0243148
E-mail address: fgaletta@med.unipi.it (F. Galetta).,e-mail address fgaletta@medunipiit galetta,C0013849|C0376649|G0000000|G0000000
"Whether dexrazoxane offers protection against late-onset cardiac toxicity and predicts prognosis in patients treated with anthracycline, remains to be demonstrated with further studies.",dexrazoxane offers protection late-onset cardiac toxicity predicts prognosis patients treated anthracycline remains demonstrated studies,C0086444|G0000000|C1545588|C4025592|C0018787|C0040539|G0000000|C0033325|C0030705|C1522326|C0003234|G0000000|G0000000|C0947630
"In conclusion, anthracycline-based chemotherapy causes early increase of QT interval dispersion.",conclusion anthracycline-based chemotherapy increase qt interval dispersion,C1707478|C0003234|C0013216|C0442805|C1552934|C1272706|C0332624
Cardiac drugs were administered as required.,cardiac drugs administered required,C0018787|C0013227|C1521801|C1514873
"However,  in girls, the mean Z score di ered signi cantly between  groups  from  2  years  onwards,  with  the  score  in  the  doxorubicin  plus  dexrazoxane  group  close  to  zero  throughout  follow-up  and  the  score  was  signi cantly  di erent from zero from 1 year onwards in the doxorubicin  group  (table  2,   gure  4C).",girls score di ered signi cantly 2 onwards score doxorubicin dexrazoxane close follow-up score signi cantly di erent 1 onwards doxorubicin table 2 gure 4c,C0870604|C0449820|C3538902|C1852551|G0000000|G0000000|G0000000|G0000000|C0449820|C0013089|C0086444|C0587267|C0589120|C0449820|G0000000|G0000000|C3538902|G0000000|G0000000|G0000000|C0013089|C0039224|G0000000|G0000000|C4053564
"This effect could lead to alterations in NaK channels activity and changes in the membrane currents, with subsequently inhomogeneity of ventricular repolarization.",lead alterations nak channels activity membrane currents subsequently inhomogeneity ventricular repolarization,C0023175|C1515926|C1336579|C0439799|C0205177|C0025255|C0521116|G0000000|G0000000|C0018827|G0000000
"The comparisons between the two groups for gender, age, and extension of disease were made using the chi-square test.",comparisons gender age extension disease chi-square test,C1707455|C0079399|C0001779|C0231448|C0012634|C1552646|C0022885
"We  previously  reported  that  dexrazoxane  reduced  the number and the extent (maximum value per patient)  of serum cardiac troponin-T elevations during treatment  in  this  same  population,32  suggesting  a  reduction  in",reported dexrazoxane reduced extent maximum patient serum cardiac troponin-t elevations treatment population32 suggesting reduction,C0684224|C0086444|C0392756|C0439792|C0806909|C0030705|C0229671|C0018787|C0077404|C0702240|C0039798|G0000000|C1705535|C0301630
Complete response Partial response,complete response partial response,C0205197|C0871261|C0728938|C0871261
Received 5 December 2006; accepted 26 April 2007.,received 5 december 2006 accepted 26 april 2007,C1514756|G0000000|C3830550|G0000000|C1272684|C0450371|C3715024|G0000000
"This trial has been completed and is  registered with ClinicalTrials.gov, number NCT00165087.",trial completed registered clinicaltrialsgov nct00165087,C0008976|C0205197|C1514821|G0000000|G0000000
We  regarded  induction  failure and induction death as events at day 0.,regarded induction failure induction death events day 0,G0000000|C0205263|C0231174|C0205263|C0011065|C0441471|C0332173|G0000000
"We then estimated the  mean Z score at 0, 1, 2, 3, 4, and 5 years in each treatment  group from this mixed model, and we plotted the mean  Z  scores  over  time.",estimated score 0 1 2 3 4 5 treatment mixed model plotted scores time,C0750572|C0449820|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0039798|C0205430|C3161035|G0000000|C0449820|C0040223
Results of Doppler Examination on Carvedilol Group p Value,doppler examination carvedilol,C0554756|G0000000|C0054836
"Therefore, dexrazoxane can reduce the arrhythmic risk in patients treated with epirubicin.",dexrazoxane reduce arrhythmic risk patients treated epirubicin,C0086444|G0000000|G0000000|C0035647|C0030705|C1522326|C0014582
"Mean Z scores for left ventricular fractional shortening  were signi cantly reduced in both groups at completion  of doxorubicin treatment ( gure 3A, table 2), indicating  that  left  ventricular  function  was  signi cantly  worse  in  survivors than  in  age-expected  norms.",scores left ventricular fractional shortening signi cantly reduced completion doxorubicin treatment gure 3a table 2 indicating left ventricular function signi cantly worse survivors age-expected norms,C0449820|C0205091|C0018827|C1264633|C0441636|G0000000|G0000000|C0392756|C0205197|C0013089|C0039798|G0000000|C1420849|C0039224|G0000000|G0000000|C0205091|C0018827|C0031843|G0000000|G0000000|C0332271|C0206194|C0001779|C0205307
All patients received standard care for children with ARF.,patients received standard care children arf,C0030705|C1514756|C1442989|C1947933|C0008059|C0035436
"Because of the known difficulties concerning definition of the end of the T wave, all ECGs were analyzed twice by two observers.",difficulties definition wave ecgs analyzed observers,C1299586|C1550452|C0678544|C0013798|C0936012|C0870992
Aim of the present study was to assess the effect of epirubicin-based chemotherapy on QT dispersion in patients with non-Hodgkin lymphoma (NHL) and its possible improvement by dexrazoxane supplementation.,aim study assess epirubicin-based chemotherapy qt dispersion patients non-hodgkin lymphoma nhl improvement dexrazoxane supplementation,C1947946|C0557651|C1516048|C0014582|C0013216|C1552934|C0332624|C0030705|C0024305|C0024299|C0024305|C2986411|C0086444|C0242297
Aortic regurgitation was considered moderate if the diameter of the regurgitant jet was 15% to 30% of the diameter of the left ventricular outflow tract with flow reversal in upper descending aorta.19 Reversal in lower descending aorta was required for severe regurgitation.,aortic regurgitation considered moderate diameter regurgitant jet 15% 30% diameter left ventricular outflow tract flow reversal upper descending aorta19 reversal lower descending aorta required severe regurgitation,C0003483|C0232605|C0750591|C0205081|C1301886|G0000000|C0336862|C0450371|C0450371|C1301886|C0205091|C0018827|G0000000|C1185740|C0806140|C0443290|C1282910|C0205386|G0000000|C0443290|C0441994|C0205386|C0003483|C1514873|C0205082|C0232605
"c Department of Reproduction and Ageing, University of Pisa School of Medicine, Via Roma, 67, 56126 Pisa, Italy",department reproduction ageing university pisa school medicine roma 67 56126 pisa italy,C1704729|C0035150|C0001811|C0041740|C3743276|C0036375|C0013227|C0018422|C0450371|G0000000|C3743276|C0022277
There were no statistical signicant differences between the two groups for chemotherapy-related toxicity.,statistical signicant differences chemotherapy-related toxicity,C0038215|G0000000|C1705241|C0013216|C0040539
*One child in the doxorubicin plus  dexrazoxane group had missing data for ethnic origin.,*one child doxorubicin dexrazoxane missing data ethnic origin,C0205447|C0008059|C0013089|C0086444|C1551393|C1511726|C0015031|C0079946
"All the patients underwent 12-lead ECG and echocardiogram before and after cyclophosphamideepirubicin infusion, and after dexrazoxane supplementation.",patients underwent 12-lead ecg echocardiogram cyclophosphamideepirubicin infusion dexrazoxane supplementation,C0030705|G0000000|C0450371|C1623258|C0013516|G0000000|C0574032|C0086444|C0242297
Time since treatment completion (years),time treatment completion,C0040223|C0039798|C0205197
Isolated pulmonary or tricuspid regurgitation in the absence of left heart valvulitis was not considered evidence of carditis.,isolated pulmonary tricuspid regurgitation absence left heart valvulitis considered evidence carditis,C0205409|C0024109|C0443327|C0232605|C0332197|C0205091|C0018787|G0000000|C0750591|C3887511|C0869523
"In  clinical  trials  undertaken  in  the  1970s,  before  the  recognition that high cumulative doses were associated",clinical trials undertaken 1970s recognition cumulative doses,C0205210|C0008976|G0000000|G0000000|C0524637|C1511559|C0178602
"Fabio Galetta a,*, Ferdinando Franzoni a, Giulia Cervetti b, Nadia Cecconi b, Angelo Carpi c,",fabio galetta a* ferdinando franzoni giulia cervetti nadia cecconi angelo carpi,G0000000|G0000000|G0000000|G0000000|G0000000|C2291389|G0000000|C2700321|G0000000|G0000000|C0043262
Twenty-eight patients diagnosed with osteosarcoma without prior therapy were included in the study.,twenty-eight patients diagnosed osteosarcoma prior therapy included study,C0724000|C0030705|C0011900|C0029463|C0332152|C0039798|C0332257|C0557651
/ Biomedicine & Pharmacotherapy 59 (2005) 541544,/ biomedicine pharmacotherapy 59 2005 541544,G0000000|C1879848|C0013216|C0450371|G0000000|G0000000
Amifostine and its active metabolite WR-1065 protect normal cells without reducing the effectiveness of chemotherapy.,amifostine active metabolite wr-1065 protect normal cells reducing effectiveness chemotherapy,C0015020|C0205177|C0870883|C1420193|G0000000|C0205307|C0007634|C0392756|C1280519|C0013216
"Four of these developed subclinical carditis only, and 4 developed clinical carditis.",developed subclinical carditis 4 developed clinical carditis,G0000000|C0205211|C0869523|G0000000|G0000000|C0205210|C0869523
"Standard-risk patients received a low cumulative dose of  doxorubicin and were not thought to be at as great a risk  for late cardiac e ects during the period of follow-up in  this  study,  so  only  high-risk  patients  were  eligible  for  inclusion in the study.",standard-risk patients received low cumulative dose doxorubicin risk late cardiac ects period follow-up study high-risk patients eligible inclusion study,C4053991|C0030705|C1514756|C0205251|C1511559|C0178602|C0013089|C0035647|C0205087|C0018787|C0013806|C0439531|C0589120|C0557651|C0332167|C0030705|C1548635|C0007637|C0557651
it may serve also in identifying patients who are at risk of arrhythmic events.,serve identifying patients risk arrhythmic events,G0000000|G0000000|C0030705|C0035647|G0000000|C0441471
"We did not observe the commonly reported secondary effects associated with amifostine of slight somnolence, dizziness, sneezing, and facial ushing [17].",observe commonly reported secondary effects amifostine slight somnolence dizziness sneezing facial ushing 17,C1441672|G0000000|C0684224|C0027627|C1280500|C0015020|C2937276|C0013144|C0012833|C0037383|C0015450|G0000000|C0450371
"The nephrotoxicity presented in our study was higher than that reported by Petrilli et al., possibly because we use a higher dose of cisplatin per cycle [14].",nephrotoxicity study reported petrilli al dose cisplatin cycle 14,C0599918|C0557651|C0684224|G0000000|C0202311|C0178602|C0008838|C1511572|C0450371
"Twenty patients 60 years of age with newly-diagnosed NHL, scheduled to receive ProMECEcytaBOM chemotherapy, were studied.",twenty patients 60 age newly-diagnosed nhl scheduled receive promececytabom chemotherapy studied,C0724000|C0030705|C0450371|C0001779|C0750546|C0024305|C0086960|C1514756|G0000000|C0013216|C0557651
"Recent work has indicated that intravenous immunoglobulin (IVIG) may be of benefit in immune-mediated cardiac disorders.7,8 This is seen particularly in Kawasaki disease, in which the use of high-dose IVIG markedly reduces the prevalence of coronary artery abnormalities.9",intravenous immunoglobulin ivig benefit immune-mediated cardiac disorders78 kawasaki disease high-dose ivig markedly reduces prevalence coronary artery abnormalities9,C0348016|C0021027|C0085297|C0814225|C0439662|C0018787|G0000000|G0000000|C0012634|C0444956|C0085297|C0522501|G0000000|C0033105|C0018787|C0003842|G0000000
"at baseline, after epirubicin infusion (N  20) (2 hours) and after supplementation (N  10) or not (N  10) with dexrazoxane (3 hours).",baseline epirubicin infusion 20 2 hours supplementation 10 10 dexrazoxane 3 hours,C0168634|C0014582|C0574032|C0450371|G0000000|C0439227|C0242297|C0450371|C0450371|C0086444|G0000000|C0439227
"Serum calcium was monitored every 24 h; if symptomatic hypocalcemia developed, 200 mg/kg of calcium gluconate was administered as an IV bolus.",serum calcium monitored 24 symptomatic hypocalcemia developed 200 mg/kg calcium gluconate administered iv bolus,C0229671|C0006675|C0030695|C0450371|C0231220|C0020598|G0000000|C1442061|C0439272|C0006675|C0017714|C1521801|C0022326|C1511237
Renal toxicity developed in 20% of patients receiving amifostine compared to 30% in the control group (p = .318).,renal toxicity developed 20% patients receiving amifostine compared 30% control = 318,C0022646|C0040539|G0000000|C0450371|C0030705|C1514756|C0015020|C1707455|C0450371|C0243148|G0000000|C1442061
Measurement of QT interval and QT dispersion,measurement qt interval qt dispersion,C0242485|C1552934|C1272706|C1552934|C0332624
Recent animal studies and experimental observations showed that carvedilol prevented development of CMP due to chemotherapeutics.,animal studies experimental observations carvedilol prevented development cmp chemotherapeutics,C0003062|C0947630|C1517586|C0302523|C0054836|C0309872|C0243107|G0000000|G0000000
"In transmitral pulsed Doppler examination, the peak velocities of early (E) and late diastolic ow (A), the E/A ratio, isovolumic relaxation time, and isovolemic contraction time were measured as previously described (16).",transmitral pulsed doppler examination peak velocities late diastolic ow e/a ratio isovolumic relaxation time isovolemic contraction time measured 16,G0000000|C1947910|C0554756|G0000000|C0444505|C0439830|C0205087|C0012000|G0000000|G0000000|C0456603|G0000000|C0035028|C0040223|G0000000|C1140999|C0040223|C0444706|C0450371
In only 4 patients was the antibiotic course prescribed and taken appropriately.,4 patients antibiotic prescribed appropriately,G0000000|C0030705|C0003232|C0278329|G0000000
It is reported in 36% of patients receiving 50100 mg/m2; in higher-dose regimens it is as high as 90% [15].,reported 36% patients receiving 50100 mg/m2 higher-dose regimens 90% 15,C0684224|C0450371|C0030705|C1514756|G0000000|C0026410|C0444956|C2945654|C0450371|C0450371
Doxorubicin was given as either an intravenous push or as  an intravenous bolus (up to 15 min).,doxorubicin intravenous push intravenous bolus 15 min,C0013089|C0348016|C1719958|C0348016|C1511237|C0450371|C0702093
p005 for comparison of the mean  Z score for the doxorubicin group with zero.,p005 comparison score doxorubicin,G0000000|C1707455|C0449820|C0013089
This product is made by cold ethanol fractionation of human plasma and adjusted to a pH of 4.,product cold ethanol fractionation human plasma adjusted ph 4,C1514468|C0009264|C0001962|C0016640|C0086418|C0032105|C0456081|C0450407|G0000000
The patients were randomized to carvedilol or control groups.,patients randomized carvedilol control,C0030705|C0034656|C0054836|C0243148
"All were indigenous Maori (37%) or Pacific Island New Zealanders (63%), the latter predominantly of Samoan ethnicity.",indigenous maori 37% pacific island zealanders 63% samoan ethnicity,C1512704|C0024770|C0450371|G0000000|C0022130|G0000000|C0450371|C1556103|C0015031
Diastolic functions were evaluated according to changes in mitral inow parameters.,diastolic functions evaluated mitral inow parameters,C0012000|C0542341|C0220825|C0746591|G0000000|C0449381
"graphic studies, with particular attention paid to color gain consistency and standardization of views.",graphic studies attention paid color gain consistency standardization views,G0000000|C0947630|C0004268|C0871051|C0009393|C1517378|C0332529|C0038136|C0449911
"No significant difference in reduction in carditis when assessed with and without subclinical carditis was seen at 1 year, whether assessed on the basis of affected patients or affected",difference reduction carditis assessed subclinical carditis 1 assessed basis patients,C1705241|C0301630|C0869523|C1516048|C0205211|C0869523|G0000000|C1516048|C1527178|C0030705
Baseline 80.2  18.4 75.1  13.9 1.08  0.2 64.3  19.9 57.6  19.6,baseline 802 184 751 139 108 02 643 199 576 196,C0168634|C1442061|C1442061|C1442061|C1442061|C1442061|C0450371|C1442061|C1442061|C1442061|C1442061
Acute rheumatic fever (ARF) continues to produce sig-,acute rheumatic fever arf continues produce sig-,C0205178|G0000000|C0015967|C0035436|C0549178|G0000000|C1515092
Isolates of group A streptococcus grown from throat cultures were sent for M typing.,isolates streptococcus grown throat cultures typing,C1764827|C0038402|G0000000|C0031354|C0010453|C0441704
"In line, in a study with epirubicin, authors revealed an increased clearance of the anthracycline when dexrazoxane had been administered which could lead to a decreased epirubicin exposure [27].",study epirubicin authors revealed increased clearance anthracycline dexrazoxane administered lead decreased epirubicin exposure 27,C0557651|C0014582|C3812881|C0443289|C0205217|C0449297|C0003234|C0086444|C1521801|C0023175|C0205216|C0014582|C0274281|C0450371
"Funding US National Institutes of Health, Childrens Cardiomyopathy Foundation, University of Miami Womens  Cancer Association, Lance Armstrong Foundation, Roche Diagnostics, P zer, and Novartis.",funding national institutes health childrens cardiomyopathy foundation university miami womens cancer association lance armstrong foundation roche diagnostics zer novartis,C0243098|C3245503|C0021622|C0018684|G0000000|C0878544|C0016617|C0041740|C1551421|G0000000|C0006826|C0004083|C0522666|G0000000|C0016617|C0331965|C0011900|G0000000|G0000000
No  children had dose-limiting side-e ects in either treatment  group.,children dose-limiting side-e ects treatment,C0008059|C1512043|C0441987|C0013806|C0039798
Aspirin relieves symptoms but does not influence outcome.,aspirin relieves symptoms influence outcome,C0004057|C1301676|C0683368|C4054723|C1274040
"Manuscript received March 29, 2006; revised manuscript received June 27, 2006,",manuscript received march 29 2006 revised manuscript received june 27 2006,C0600659|C1514756|C3829202|C0450371|G0000000|C1527075|C0600659|C1514756|C3829443|C0450371|G0000000
BackgroundAcute rheumatic fever (ARF) remains the leading cause of acquired heart disease in children worldwide.,backgroundacute rheumatic fever arf remains leading acquired heart disease children worldwide,G0000000|G0000000|C0015967|C0035436|G0000000|C0332152|C0439661|C0018787|C0012634|C0008059|G0000000
Patients without carditis were discharged at 2 weeks on restricted activity.,patients carditis discharged 2 weeks restricted activity,C0030705|C0869523|C0030685|G0000000|C0439230|C0443288|C0205177
"Despite these studies, many patients worldwide with ARF continue to receive salicylates and steroids.",studies patients worldwide arf continue receive salicylates steroids,C0947630|C0030705|G0000000|C0035436|C0549178|C1514756|C0036077|C0038317
Minor thickening of the mitral valve in 4 patients was attributed to acute rather than chronic rheumatic fever.,minor thickening mitral valve 4 patients attributed acute chronic rheumatic fever,C0026193|C0205400|C0746591|C0184252|G0000000|C0030705|C0449234|C0205178|C0205191|G0000000|C0015967
This may result in impairment of cardiac contractility and the development of CMP.,result impairment cardiac contractility development cmp,C1274040|C0221099|C0018787|C0026820|C0243107|G0000000
Comparison of left ventricular ejection fraction (EF) at baseline (black bars) and after chemotherapy (white bars) in the 2 groups.,comparison left ventricular ejection fraction ef baseline black bars chemotherapy white bars 2,C1707455|C0205091|C0018827|C0302131|C1264633|G0000000|C0168634|C0005680|C0687760|C0013216|C0007457|C0687760|G0000000
Twentynine received IVIG and 32 received placebo between March 1992 and October 1995.,twentynine received ivig 32 received placebo march 1992 october 1995,G0000000|C1514756|C0085297|C0450371|C1514756|C0032042|C3829202|G0000000|C3828732|G0000000
Sarcoplasmic reticulum Ca2ATPase (SERCA2) may be another key factor in ANTinduced cardiotoxicity.,sarcoplasmic reticulum ca2atpase serca2 key factor antinduced cardiotoxicity,C0682566|C0035295|G0000000|G0000000|G0000000|C1521761|G0000000|C0876994
Aspirin was used for relief of symptomatic arthritis only; 75% in the control group and 55% in the IVIG group were treated until resolution of symptoms.,aspirin relief symptomatic arthritis 75% control 55% ivig treated resolution symptoms,C0004057|C0564405|C0231220|C0003864|C0450371|C0243148|C0450371|C0085297|C1522326|C1514893|C0683368
"ECGs were recorded at each evaluation, but a chest radiograph was performed only at baseline and the 6-month follow-up.",ecgs recorded evaluation chest radiograph performed baseline 6-month follow-up,C0013798|C0034869|C0220825|C0817096|C1306645|C0884358|C0168634|C0332177|C0589120
A p value 0.05 was accepted as signicant.,005 accepted signicant,C1442061|C1272684|G0000000
"were M typed; of these, 5 could not be typed, 2 were NZ 1437, 1 was M53, and 1 was M53/80.",typed 5 typed 2 nz 1437 1 m53 1 m53/80,C0332307|G0000000|C0332307|G0000000|C0027978|G0000000|G0000000|G0000000|G0000000|C0450371
Blood pressure was monitored before and every 5 min for 30 min.,blood pressure monitored 5 min 30 min,C0005767|C0033095|C0030695|G0000000|C0702093|C0450371|C0702093
"Four patients died in the control group, and only 1 patient died in the carvedilol group.",patients died control 1 patient died carvedilol,C0030705|C0011065|C0243148|G0000000|C0030705|C0011065|C0054836
"b Department of Hematology, University of Pisa School of Medicine, Via Roma, 67, 56126 Pisa, Italy",department hematology university pisa school medicine roma 67 56126 pisa italy,C1704729|C0018943|C0041740|C3743276|C0036375|C0013227|C0018422|C0450371|G0000000|C3743276|C0022277
Another 3 patients with low EF were given medical therapy (not hospitalized).,3 patients low ef medical therapy hospitalized,G0000000|C0030705|C0205251|G0000000|C0199168|C0039798|C0701159
Another hypothesis on the increased QT dispersion after anthracycline-based chemotherapy is the pathological picture of anthracycline cardiotoxicity that is characterized by disruption of heart mitochondrial and sarcoplasmatic reticular membranes [20] by drug-induced free radical formation in specific myocardial compartments [21].,hypothesis increased qt dispersion anthracycline-based chemotherapy pathological picture anthracycline cardiotoxicity characterized disruption heart mitochondrial sarcoplasmatic reticular membranes 20 drug-induced free radical formation specific myocardial compartments 21,C1512571|C0205217|C1552934|C0332624|C0003234|C0013216|C0030664|C0441468|C0003234|C0876994|C1880022|C0332453|C0018787|C0026237|G0000000|C0439739|C0025255|C0450371|C0458082|C0332296|C0302912|C0220781|C0205369|C0027061|C1185625|C0450371
They concluded amifostine did not protect against ototoxicity produced by high-dose cisplatin combined with etoposide and bleomycin [16].,concluded amifostine protect ototoxicity produced high-dose cisplatin combined etoposide bleomycin 16,C0917903|C0015020|G0000000|C0235280|G0000000|C0444956|C0008838|C0205195|C0015133|C0005740|C0450371
"Doxorubicin and other anthracycline drugs are active  agents in treatment of childhood ALL, but their use has  been limited by acute and delayed cardiac toxic e ects.",doxorubicin anthracycline drugs active agents treatment childhood limited acute delayed cardiac toxic ects,C0013089|C0003234|C0013227|C0205177|C0450442|C0039798|C0231335|C0439801|C0205178|C0205421|C0018787|C0600688|C0013806
p  0.05 considered statistically signicant.,005 considered statistically signicant,C1442061|C0750591|C0038215|G0000000
"Patients who underwent supplementation with dexrazoxane hydrochloride exhibited a significant attenuation of QT dispersion (67.4  8.1 vs. 49.5  4.2 ms, P < 0.001) and QTc dispersion (71.2  7.7 vs. 51.4  4.3 ms, P < 0.001) in",patients underwent supplementation dexrazoxane hydrochloride exhibited attenuation qt dispersion 674 81 495 42 ms < 0001 qtc dispersion 712 77 514 43 ms < 0001,C0030705|G0000000|C0242297|C0086444|C1512523|C0015272|C0599946|C1552934|C0332624|C1442061|C0450371|C1442061|C0450371|C0039676|G0000000|G0000000|G0000000|C0332624|C1442061|C0450371|C1442061|C0450371|C0039676|G0000000|G0000000
Age (yrs) Female (%) BMI (kg/m2) Baseline LVEF (%),age yrs female % bmi kg/m2 baseline lvef %,C0001779|G0000000|C0015780|G0000000|G0000000|C0022718|C0168634|C0428772|G0000000
"Patients were randomly allocated to receive 1 g/kg IVIG on days 1 and 2 and 0.4 g/kg on days 14 and 28, or they received a placebo infusion.",patients randomly allocated receive 1 g/kg ivig days 1 2 04 g/kg days 14 28 received placebo infusion,C0030705|G0000000|G0000000|C1514756|G0000000|C1300563|C0085297|C0439228|G0000000|G0000000|C0450371|C1300563|C0439228|C0450371|C0450371|C1514756|C0032042|C0574032
Grade 1 cardiac toxicity was present in only 2 patients of the control group (p = .175).,grade 1 cardiac toxicity 2 patients control = 175,C0441800|G0000000|C0018787|C0040539|G0000000|C0030705|C0243148|G0000000|C1442061
"Also, they all presented transient asymptomatic hypocalcemia.",transient asymptomatic hypocalcemia,C0040704|C0231221|C0020598
"We  calculated  the  predicted  value  for  each  outcome  in  healthy children with a regression model,9,10,39,40 by use of  data  from  285  healthy  children  measured  at  the  same  centre and in the same manner as the study patients.39,40  The  Pediatric  Measurements  Writing  Group  of  the  American  Society  of  Echocardiography  Pediatric  and  Congenital  Heart  Disease  Council  recommends  that  when  normative  data  are  available,  the  measurements  of  cardiovascular  structures  should  be  expressed  as",calculated predicted outcome healthy children regression model9103940 data 285 healthy children measured centre manner study patients3940 pediatric measurements writing american society echocardiography pediatric congenital heart disease council recommends normative data measurements cardiovascular structures expressed,C0444686|C0681842|C1274040|C3898900|C0008059|C0684320|G0000000|C1511726|C1442061|C3898900|C0008059|C0444706|C0205099|G0000000|C0557651|G0000000|C0030755|C0242485|C0043266|C0596070|C0037455|C0013516|C0030755|C0009678|C0018787|C0012634|C1551807|C0034866|G0000000|C1511726|C0242485|C0007226|C0678594|G0000000
After CT 58.4  17.9 68.0  14.2 0.87  0.2 72.7  2.0 78.8  18.3,ct 584 179 680 142 087 02 727 20 788 183,C0007673|C1442061|C1442061|C1442061|C1442061|C1442061|C0450371|C1442061|C0450371|C1442061|C1442061
"All statistical procedures and curve fitting for statistical analysis were performed by means of personal computer programs (StatView, Abacus Concepts, Inc., SAS Institute, Cary, NC).",statistical procedures curve fitting statistical analysis performed personal computer programs statview abacus concepts sas institute cary nc,C0038215|C0025664|C0205134|C0036572|C0038215|C0002778|C0884358|C1519021|C0009622|C0376691|G0000000|C3878323|C0178566|C0605290|C0021622|G0000000|C0027964
Absence of data from a patient for a given period means  that  no  echocardiograms  were  obtained  during  that  period.,absence data patient period echocardiograms period,C0332197|C1511726|C0030705|C0439531|C0013516|C0439531
The production of free radicals is catalyzed by an anthracyclineiron complex [15].,production free radicals catalyzed anthracyclineiron complex 15,C0033268|C0332296|C0302912|G0000000|G0000000|C0439855|C0450371
No therapeutic agent has been shown to alter the clinical outcome of the acute illness.,therapeutic agent alter clinical outcome acute illness,C0087111|C0450442|C0392747|C0205210|C1274040|C0205178|C0221423
"Possible explanations for a lack of demonstrable efficacy of IVIG in this study include the pathogenesis of ARF, the dose and type of IVIG preparation used, and the power of the study.",explanations lack demonstrable efficacy ivig study pathogenesis arf dose type ivig preparation power study,C0681841|C0332268|C0332265|C1280519|C0085297|C0557651|C0543483|C0035436|C0178602|C0332307|C0085297|C1521827|C0032863|C0557651
It has been demonstrated that ANT-induced CMP is characterized by minimal LV enlargement and global systolic dysfunction (17).,demonstrated ant-induced cmp characterized minimal lv enlargement global systolic dysfunction 17,G0000000|C0003455|G0000000|C1880022|C0547040|C0023128|C0020564|C0205246|C0039155|C0031847|C0450371
The baseline characteristics are shown in Table 1.,baseline characteristics table 1,C0168634|C1521970|C0039224|G0000000
Peak E velocity (cm/s) Peak A velocity (cm/s) E/A ratio IVRT (ms) IVCT (ms) *p  0.05 considered statistically signicant.,peak velocity cm/s peak velocity cm/s e/a ratio ivrt ms ivct ms *p 005 considered statistically signicant,C0444505|C0439830|C0439392|C0444505|C0439830|C0439392|G0000000|C0456603|C3890944|C0039676|G0000000|C0039676|C0369773|C1442061|C0750591|C0038215|G0000000
Intravenous Immunoglobulin in Acute Rheumatic Fever,intravenous immunoglobulin acute rheumatic fever,C0348016|C0021027|C0205178|G0000000|C0015967
"This delay may have allowed the inflammatory process to advance, potentially negating any benefit of IVIG.",delay allowed inflammatory process advance negating benefit ivig,C0205421|C0683607|C0333348|C1184743|C0725066|G0000000|C0814225|C0085297
"The ProMECEcytaBOM chemotherapy consisted of intravenous epirubicin (a bolus dose of 40 mg/m2), followed by intravenous cyclophosphamide (650 mg/m2) and intravenous etoposide (120 mg/m2) on day 1, and intravenous prednisolone (60 mg/m2) on days 114.",promececytabom chemotherapy consisted intravenous epirubicin bolus dose 40 mg/m2 intravenous cyclophosphamide 650 mg/m2 intravenous etoposide 120 mg/m2 day 1 intravenous prednisolone 60 mg/m2 days 114,G0000000|C0013216|C0332529|C0348016|C0014582|C1511237|C0178602|C0450371|C0026410|C0348016|C0010583|C1442061|C0026410|C0348016|C0015133|C1442061|C0026410|C0332173|G0000000|C0348016|C0032950|C0450371|C0026410|C0439228|C1442061
Graph representing the values of QT and QTc dispersion (mean  S.D.),graph representing values qt qtc dispersion sd,C0681493|C1882932|C0042295|C1552934|G0000000|C0332624|C2699239
"To our knowledge, the are few randomized prospective studies evaluating amifostine in previously untreated children receiving chemotherapy eliminating the possibility of",knowledge randomized prospective studies evaluating amifostine untreated children receiving chemotherapy eliminating possibility,C0376554|C0034656|C0023981|C0947630|C0220825|C0015020|C0332155|C0008059|C1514756|C0013216|G0000000|C0332149
"In line with that conclusion, our patients with systolic dysfunction had mild or moderately increased LV diameters, but in patients receiving carvedilol, LV diameters did not increase.",conclusion patients systolic dysfunction mild moderately increased lv diameters patients receiving carvedilol lv diameters increase,C1707478|C0030705|C0039155|C0031847|C2945599|C0205081|C0205217|C0023128|C1301886|C0030705|C1514756|C0054836|C0023128|C1301886|C0442805
"Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy Nihat Kalay, MD,* Emrullah Basar, MD,* Ibrahim Ozdogru, MD,* Ozlem Er, MD, Yakup Cetinkaya, MD,* Ali Dogan, MD,* Tugrul Inanc, MD, Abdurrahman Oguzhan, MD,* Namik Kemal Eryol, MD,* Ramazan Topsakal, MD,* Ali Ergin, MD* Kayseri, Turkey",protective effects carvedilol anthracycline-induced cardiomyopathy nihat kalay md* emrullah basar md* ibrahim ozdogru md* ozlem er md yakup cetinkaya md* ali dogan md* tugrul inanc md abdurrahman oguzhan md* namik kemal eryol md* ramazan topsakal md* ali ergin md* kayseri turkey,G0000000|C1280500|C0054836|C0003234|C0878544|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C3810541|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0041400
"Fifty-nine patients were treated, of whom 39 had carditis (including 4 subclinical) and/or migratory polyarthritis (n539).",fifty-nine patients treated 39 carditis including 4 subclinical and/or migratory polyarthritis n539,C3830128|C0030705|C1522326|C0450371|C0869523|C0332257|G0000000|C0205211|G0000000|C0232901|C0162323|G0000000
"Epirubicin-based chemotherapy causes an early increase of the QT and QTc dispersion, which is attenuated by dexrazoxane",epirubicin-based chemotherapy increase qt qtc dispersion attenuated dexrazoxane,C0014582|C0013216|C0442805|C1552934|G0000000|C0332624|C0332161|C0086444
www.thelancet.com/oncology   Vol 11   October 2010,wwwthelancetcom/oncology 11 october 2010,C0027651|C0450371|C3828732|G0000000
Summary Background  Doxorubicin  chemotherapy  is  associated  with  cardiomyopathy.,summary background doxorubicin chemotherapy cardiomyopathy,C1552616|C1706907|C0013089|C0013216|C0878544
Findings  100  children  were  assigned  to  doxorubicin  (66  analysed)  and  105  to  doxorubicin  plus  dexrazoxane  (68 analysed).,findings 100 children assigned doxorubicin 66 analysed 105 doxorubicin dexrazoxane 68 analysed,C2607943|C1442061|C0008059|C1516050|C0013089|C0450371|G0000000|C1442061|C0013089|C0086444|C0450371|G0000000
The study was conducted between June 2001 and September 2002 in the Hematology Unit of our institution.,study conducted june 2001 september 2002 hematology unit institution,C0557651|C0004927|C3829443|G0000000|C3828193|G0000000|C0018943|C0439148|C0018704
"At end of 6 months of follow-up, 1 patient in the carvedilol group and 4 in control had died.",6 months follow-up 1 patient carvedilol 4 control died,G0000000|C0439231|C0589120|G0000000|C0030705|C0054836|G0000000|C0243148|C0011065
"Girls  given  dexrazoxane  rather than doxorubicin alone had a signi cantly better  left ventricular fractional shortening (di erence between  groups: 117, 024211) than did boys (010, 087 to  068;  table  2,   gures  4A  and  4B).",girls dexrazoxane doxorubicin signi cantly left ventricular fractional shortening di erence 117 024211 boys 010 087 068 table 2 gures 4a 4b,C0870604|C0086444|C0013089|G0000000|G0000000|C0205091|C0018827|C1264633|C0441636|C3538902|G0000000|C1442061|G0000000|C0870221|C1442061|C1442061|C1442061|C0039224|G0000000|G0000000|C1420849|C1420850
"By definition, no patient had a past history of rheumatic fever.",definition patient history rheumatic fever,C1550452|C0030705|C0019664|G0000000|C0015967
Analysis of these patients with and without carditis showed no influence of aspirin on cardiac outcome.,analysis patients carditis influence aspirin cardiac outcome,C0002778|C0030705|C0869523|C4054723|C0004057|C0018787|C1274040
a non-invasive marker of risk for clinically important ventricular arrhythmias and cardiac mortality in individuals with and without heart disease [37].,non-invasive marker risk clinically ventricular arrhythmias cardiac mortality individuals heart disease 37,C0205303|C0005516|C0035647|G0000000|C0018827|C0003811|C0018787|C0026565|C0027361|C0018787|C0012634|C0450371
"Assessment of valve involvement, clinically and with echocardiography, on enrollment and 1 year later.",assessment valve involvement clinically echocardiography enrollment 1,C1261322|C0184252|C1314939|G0000000|C0013516|C1516879|G0000000
Number of cycles Control echocardiography,cycles control echocardiography,C1511572|C0243148|C0013516
"If the end of the T wave could not be identified, the lead was not included.",wave identified lead included,C0678544|C0205396|C0023175|C0332257
Number at risk Doxorubicin  Doxorubicin plus dexrazoxane,risk doxorubicin doxorubicin dexrazoxane,C0035647|C0013089|C0013089|C0086444
We considered p < .05 as statistically signicant.,considered < 05 statistically signicant,C0750591|G0000000|C0450371|C0038215|G0000000
The first infusion of IVIG or placebo was begun within 72 hours of admission to hospital or as soon as possible after the diagnosis of ARF could be made with high probability.,infusion ivig placebo begun 72 hours admission hospital diagnosis arf probability,C0574032|C0085297|C0032042|C0439659|C0450371|C0439227|C0184666|C0019994|C0011900|C0035436|C0033204
Histologic examination for response to chemotherapy was available for all patients except one in the control group.,histologic examination response chemotherapy patients control,C0205462|G0000000|C0871261|C0013216|C0030705|C0243148
cumulative doxorubicin dose for patients with high-risk  ALL to 300 mg/m on protocol 95-01.,cumulative doxorubicin dose patients high-risk 300 mg/m protocol 95-01,C1511559|C0013089|C0178602|C0030705|C0332167|C1442061|C0026410|C0442711|C0450371
"and Departments of Molecular Medicine (R.V.A., L.M.C.)",departments molecular medicine rva lmc,C1704729|C1521991|C0013227|G0000000|C1419876
The between-group di erence  was signi cant for years 35.,between-group di erence signi 35,C0441833|C3538902|G0000000|G0000000|C0450371
TOXICITY PREVENTION WITH AMIFOSTINE IN PEDIATRIC OSTEOSARCOMA PATIENTS TREATED WITH CISPLATIN AND DOXORUBICIN,toxicity prevention amifostine pediatric osteosarcoma patients treated cisplatin doxorubicin,C0040539|C0199176|C0015020|C0030755|C0029463|C0030705|C1522326|C0008838|C0013089
Toxicity grade was accumulative with each cycle and the nal grade was taken as the valid one.,toxicity grade accumulative cycle nal grade valid,C0040539|C0441800|C4055506|C1511572|G0000000|C0441800|C2349099
Doxorubicin Doxorubicin plus dexrazoxane p value*,doxorubicin doxorubicin dexrazoxane value*,C0013089|C0013089|C0086444|C1522609
"To further reduce  the risk of late cardiotoxicity, we assessed the potential  cardioprotective  e ects  of  dexrazoxanean  agent  which,  at  the  time  that  this  study  was  undertaken  (19962000),  had  been  shown  to  prevent  or  attenuate  early cardiotoxicity in adults with advanced malignancies",reduce risk late cardiotoxicity assessed potential cardioprotective ects dexrazoxanean agent time study undertaken 19962000 prevent attenuate cardiotoxicity adults advanced malignancies,G0000000|C0035647|C0205087|C0876994|C1516048|C3245505|G0000000|C0013806|G0000000|C0450442|C0040223|C0557651|G0000000|G0000000|C0309872|C0599946|C0876994|C0001675|C0205179|C0006826
Key Words: rheumatic heart disease n proteins n echocardiography n immune system,key rheumatic heart disease proteins echocardiography immune system,G0000000|G0000000|C0018787|C0012634|C0033684|C0013516|C0439662|C0449913
"Guadalupe Guerrero-Avenda no, MD 2 Department of Radiology, Hospital General de Mexico, Mexico, DF Mexico",guadalupe guerrero-avenda md 2 department radiology hospital de mexico mexico df mexico,G0000000|C3829921|G0000000|G0000000|C1704729|C0034599|C0019994|C0011198|C0025885|C0025885|G0000000|C0025885
"a Department of Internal Medicine, University of Pisa School of Medicine, Via Roma, 67, 56126 Pisa, Italy",department internal medicine university pisa school medicine roma 67 56126 pisa italy,C1704729|C0205102|C0013227|C0041740|C3743276|C0036375|C0013227|C0018422|C0450371|G0000000|C3743276|C0022277
"Grades for valvar regurgitation were as follows: nil (including physiological or trivial valvar regurgitation),13,14 mild (including subclinical but pathological regurgitation),15-18 moderate, and severe.12,19 The minimal criteria to allow a diagnosis of pathological regurgitation included a substantial color jet seen in 2 planes extending well beyond the valve leaflets with continuous-wave or pulsed Doppler holodiastolic (aortic regurgitation) or holosystolic (mitral regurgitation) with well-defined, high-velocity spectral envelope.16 Mitral regurgitation was considered moderate if there was a broad high-intensity proximal jet filling half the left atrium or a lesser volume high-intensity jet producing prominent blunting of pulmonary venous inflow.",grades valvar regurgitation nil including physiological trivial valvar regurgitation1314 mild including subclinical pathological regurgitation15-18 moderate severe1219 minimal criteria diagnosis pathological regurgitation included substantial color jet 2 planes extending valve leaflets continuous-wave pulsed doppler holodiastolic aortic regurgitation holosystolic mitral regurgitation well-defined high-velocity spectral envelope16 mitral regurgitation considered moderate broad high-intensity proximal jet filling half left atrium lesser volume high-intensity jet producing prominent blunting pulmonary venous inflow,C0441800|C0184252|C0232605|C0442734|C0332257|C0205463|G0000000|C0184252|G0000000|C2945599|C0332257|C0205211|C0030664|C0450371|C0205081|G0000000|C0547040|C0243161|C0011900|C0030664|C0232605|C0332257|G0000000|C0009393|C0336862|G0000000|C1049866|C0439792|C0184252|C1708664|C0549178|C1947910|C0554756|G0000000|C0003483|C0232605|G0000000|C0746591|C0232605|C0442825|C0205250|C1883073|G0000000|C0746591|C0232605|C0750591|C0205081|C0332464|C4081854|C0205107|C0336862|G0000000|C2825407|C0205091|C0018792|C0547044|C0449468|C4081854|C0336862|G0000000|C0205402|C1997138|C0024109|C0042449|G0000000
"However, dexrazoxane is a more potent chelating agent than anthracyclines and acts by removing the iron from the complex, and therefore preventing cardiac damage [16].",dexrazoxane potent chelating agent anthracyclines acts removing iron complex preventing cardiac damage 16,C0086444|C3245505|C3537131|C0450442|C0003234|C0079613|C0849355|C0302583|C0439855|C0309872|C0018787|C0010957|C0450371
Doxorubicin  Doxorubicin plus dexrazoxane,doxorubicin doxorubicin dexrazoxane,C0013089|C0013089|C0086444
"Patients with carditis remained on bed/chair rest in hospital until the ESR was ,30 mm/h.",patients carditis remained bed/chair rest hospital esr 30 mm/h,C0030705|C0869523|G0000000|C0004916|C0035253|C0019994|C3811131|C0450371|C0456680
"From  this  mixed  model, we obtained mean Z scores, adjusted for age and  sex,  at  5  years  for  children  with  and  without  abnormal  cardiac troponin T during treatment.",mixed model scores adjusted age sex 5 children abnormal cardiac troponin treatment,C0205430|C3161035|C0449820|C0456081|C0001779|C0009253|G0000000|C0008059|C0205161|C0018787|C0041199|C0039798
"Baseline evaluation included complete physical examination, blood counts, chemistry, audiometry and tympanometry, urianalysis, and ejection fraction by echocardiography.",baseline evaluation included complete physical examination blood counts chemistry audiometry tympanometry urianalysis ejection fraction echocardiography,C0168634|C0220825|C0332257|C0205197|C0031809|G0000000|C0005767|C0439157|C0007996|C0004286|C0085853|G0000000|C0302131|C1264633|C0013516
"doses every 3 weeks during intensi cation after remission,  for  a  cumulative  doxorubicin  dose  of  300  mg/m.",doses 3 weeks intensi cation remission cumulative doxorubicin dose 300 mg/m,C0178602|G0000000|C0439230|G0000000|C0007447|C0544452|C1511559|C0013089|C0178602|C1442061|C0026410
"The di erence between the doxorubicin  plus  dexrazoxane  and  doxorubicin  groups  was  not  signi cant  at  5  years  (041,  95%  CI  107  to  026).",di erence doxorubicin dexrazoxane doxorubicin signi 5 041 95% ci 107 026,C3538902|G0000000|C0013089|C0086444|C0013089|G0000000|G0000000|C1442061|C0450371|C0008107|C1442061|C1442061
Total sample Fractional shortening,total sample fractional shortening,C0439175|C0370003|C1264633|C0441636
A substance that would protect normal cells from the toxic effects of therapy without reducing its effectiveness would be ideal.,substance protect normal cells toxic effects therapy reducing effectiveness ideal,C0439861|G0000000|C0205307|C0007634|C0600688|C1280500|C0039798|C0392756|C1280519|C1512612
"Overall, carditis was considered present when there was echocardiographic mild or greater left heart valvulitis.16 Clinical carditis was considered present when there was a diagnostic murmur.",carditis considered echocardiographic mild left heart valvulitis16 clinical carditis considered diagnostic murmur,C0869523|C0750591|C0013516|C2945599|C0205091|C0018787|G0000000|C0205210|C0869523|C0750591|C0011900|C0018808
CONCLUSIONS Prophylactic use of carvedilol in patients receiving ANT may protect both systolic and (J Am Coll Cardiol 2006;48:225862)  2006 by,conclusions prophylactic carvedilol patients receiving ant protect systolic coll cardiol 200648225862 2006,C1707478|C0355642|C0054836|C0030705|C1514756|C0003455|G0000000|C0039155|C3272373|G0000000|G0000000|G0000000
"In our study, we observed ototoxicity in 100% of patients receiving amifostine, and 76% of controls.",study observed ototoxicity 100% patients receiving amifostine 76% controls,C0557651|C1441672|C0235280|C1442061|C0030705|C1514756|C0015020|C0450371|C0243148
Treatment assignment was obtained  through a telephone call by the treating physician or study  personnel at participating sites to a centralised registrar at  the Dana-Farber Cancer Institute to conceal allocation.,treatment assignment telephone call treating physician study personnel participating sites centralised registrar dana-farber cancer institute conceal allocation,C0039798|C1516050|C0039457|C0679006|C1522326|C0031831|C0557651|C0024752|C0679823|C0205145|G0000000|C0557514|G0000000|C0006826|C0021622|C0443189|C1706778
"Assessment of dexrazoxane as a cardioprotectant in  doxorubicin-treated children with high-risk acute  lymphoblastic leukaemia: long-term follow-up of  a prospective, randomised, multicentre trial",assessment dexrazoxane cardioprotectant doxorubicin-treated children high-risk acute lymphoblastic leukaemia long-term follow-up prospective randomised multicentre trial,C1261322|C0086444|G0000000|C0013089|C0008059|C0332167|C0205178|C0229613|C0023418|C0443252|C0589120|C0023981|G0000000|C0439743|C0008976
"We   tted  a  repeatedmeasures  linear  mixed  model  in  SAS  PROC  MIXED  (version 9.2), in which the mean Z score was modelled as  a  linear,  quadratic,  and  cubic  function  of  time  of  echocardiograhy by use of all data from every patient at  every  timepoint.",tted repeatedmeasures linear mixed model sas proc mixed version 92 score modelled linear quadratic cubic function time echocardiograhy data patient timepoint,G0000000|G0000000|C0205132|C0205430|C3161035|C0605290|C1418943|C0205430|C0333052|C0450371|C0449820|C3161035|C0205132|G0000000|C1880194|C0031843|C0040223|G0000000|C1511726|C0030705|C2348792
The reason for the cardioprotective effects of carvedilol in ANT-induced CMP is not fully known.,reason cardioprotective effects carvedilol ant-induced cmp,C0392360|G0000000|C1280500|C0054836|C0003455|G0000000
All tests were two-tailed with  set  at 005.,tests two-tailed set 005,C0022885|C0205448|C0036849|C1442061
*p value is for comparison of the doxorubicin group with the doxorubicin plus dexrazoxane group.,*p comparison doxorubicin doxorubicin dexrazoxane,C0369773|C1707455|C0013089|C0013089|C0086444
"On echocardiography, 59% in the IVIG group and 69% in the placebo group had carditis at baseline.",echocardiography 59% ivig 69% placebo carditis baseline,C0013516|C0450371|C0085297|C0450371|C0032042|C0869523|C0168634
"Z  scores,41  and  therefore  Z  scores  were  used  in  this  study.",scores41 scores study,G0000000|C0449820|C0557651
Another dose-limiting toxicity of cisplatin is ototoxicity.,dose-limiting toxicity cisplatin ototoxicity,C1512043|C0040539|C0008838|C0235280
There were 17 patients with carditis in the IVIG group and 22 in the placebo group at baseline (Table 3 and Figure 2).,17 patients carditis ivig 22 placebo baseline table 3 figure 2,C0450371|C0030705|C0869523|C0085297|C0450371|C0032042|C0168634|C0039224|G0000000|G0000000|G0000000
"The blood parameters assessed weekly included ESR, C-reactive protein, and streptococcal serology for 6 weeks or until discharge if this was longer.",blood parameters assessed weekly included esr c-reactive protein streptococcal serology 6 weeks discharge,C0005767|C0449381|C1516048|C0332174|C0332257|C3811131|C0205332|C0033684|C0038402|C0036745|G0000000|C0439230|C0012621
All patients receiving amifostine developed grade 3 and 4 emesis in contrast to 7% in the control group despite the recommended support with ondansetron and dexamethasone.,patients receiving amifostine developed grade 3 4 emesis contrast 7% control recommended support ondansetron dexamethasone,C0030705|C1514756|C0015020|G0000000|C0441800|G0000000|G0000000|C0042963|C0009924|G0000000|C0243148|C0034866|C0183683|C0061851|C0011777
"troponin-T  concentrations during treatment predicted long-term left  ventricular  structure  or  function,  we  formed  the  dichotomous  covariate  abnormal  cardiac  troponin  T  during  treatment  (yes  or  no).",troponin-t concentrations treatment predicted long-term left ventricular structure function formed dichotomous covariate abnormal cardiac troponin treatment,C0077404|C0086045|C0039798|C0681842|C0443252|C0205091|C0018827|C0678594|C0031843|C0205431|C2827654|G0000000|C0205161|C0018787|C0041199|C0039798
"Another concern is the sequelae, which diminish the quality of life of survivors.",concern sequelae diminish quality life survivors,C2699424|C0243088|C0205216|C0332306|C0376558|C0206194
"At  5  years,  the  mean  Z  score  for  left  ventricular  fractional  shortening  for the doxorubicin plus dexrazoxane group did not di er  signi cantly from that in healthy children, whereas the  Z score for the doxorubicin group remained signi cantly  reduced (table 2).",5 score left ventricular fractional shortening doxorubicin dexrazoxane di er signi cantly healthy children score doxorubicin remained signi cantly reduced table 2,G0000000|C0449820|C0205091|C0018827|C1264633|C0441636|C0013089|C0086444|C3538902|C3810541|G0000000|G0000000|C3898900|C0008059|C0449820|C0013089|G0000000|G0000000|G0000000|C0392756|C0039224|G0000000
"Therefore the increase of QT dispersion might not only represent a risk factor for ventricular arrhythmias in patients treated with anthracycline, but may also be a simple and inexpensive index of early myocardial impairment.",increase qt dispersion represent risk factor ventricular arrhythmias patients treated anthracycline simple inexpensive myocardial impairment,C0442805|C1552934|C0332624|C1882932|C0035647|C1521761|C0018827|C0003811|C0030705|C1522326|C0003234|C0205352|G0000000|C0027061|C0221099
"The institutional review board  of  each  participating  institution  approved  the  study,  and  written informed consent was obtained from all participants  or their parents or guardians before the start of treatment.",institutional review board participating institution approved study written informed consent participants parents guardians start treatment,C0018704|C0282443|C0972401|C0679823|C0018704|C0205540|C0557651|C0043266|C1522154|C1511481|C0679646|C0030551|C1274041|C0439659|C0039798
"The dose of IVIG given to these patients was probably adequate, because the initial dose was similar to that used in Kawasaki disease.24 This initial dose was given over 2 days, a protocol designed to minimize the effects of volume loading on patients in incipient heart failure.",dose ivig patients adequate initial dose kawasaki disease24 initial dose 2 days protocol designed minimize effects volume loading patients incipient heart failure,C0178602|C0085297|C0030705|C0205410|C0205265|C0178602|G0000000|G0000000|C0205265|C0178602|G0000000|C0439228|C0442711|C1707689|G0000000|C1280500|C0449468|C1708715|C0030705|C0205256|C0018787|C0231174
"Recently, dexrazoxane has been proposed to be the only clinically proved cardioprotective agent against anthracycline induced cardiotoxicity.",dexrazoxane proposed clinically proved cardioprotective agent anthracycline induced cardiotoxicity,C0086444|C1553874|G0000000|G0000000|G0000000|C0450442|C0003234|C0205263|C0876994
"Data are number (%), mean (SD), or median (IQR) unless otherwise indicated.",data % sd median iqr,C1511726|G0000000|C2699239|C0549183|G0000000
"cultures, midstream urine, ECG, chest x-ray, and detailed echocardiography.",cultures midstream urine ecg chest x-ray detailed echocardiography,C0010453|G0000000|C0042036|C1623258|C0817096|C0034571|C1522508|C0013516
Systolic dysfunction was dened by EF 50%.,systolic dysfunction dened ef 50%,C0039155|C0031847|G0000000|G0000000|C0450371
TABLE 1 Chemotherapy-associated Toxicity,table 1 chemotherapy-associated toxicity,C0039224|G0000000|C0013216|C0040539
"Initial clinical assessment consisted of daily measurements of heart rate (awake and sleeping), temperature, joint involvement, and presence or absence of rash, chorea, or nodules.",initial clinical assessment consisted daily measurements heart rate awake sleeping temperature joint involvement presence absence rash chorea nodules,C0205265|C0205210|C1261322|C0332529|C0332173|C0242485|C0018787|C0871208|C0234422|C0037313|C0005903|C0022417|C1314939|C0150312|C0332197|C0015230|C0008489|C0028259
The primary end point in this study was systolic functions.,primary study systolic functions,C0205225|C0557651|C0039155|C0542341
"A further delay in diagnosis may occur as the Jones criteria for ARF become fulfilled over time, both before and after medical attention is received.",delay diagnosis occur jones criteria arf fulfilled time medical attention received,C0205421|C0011900|C1709305|C0443013|C0243161|C0035436|C1550543|C0040223|C0199168|C0004268|C1514756
Children  remaining  in the study did not di er on any clinical characteristic  from those who left the study: the mixed model adjusted  for missing follow-up data.42,children remaining study di er clinical characteristic left study mixed model adjusted missing follow-up data42,C0008059|C1527428|C0557651|C3538902|C3810541|C0205210|C1521970|C0205091|C0557651|C0205430|C3161035|C0456081|C1551393|C0589120|G0000000
"Additionally,  in  the  doxorubicin  group,  the  reduction  in  left  ventricular  fractional  shortening  was  signi cantly  greater  in  girls  than in boys across the 5-year period (table 2,  gures 4A  and  4B),  and  the  protective  e ect  of  dexrazoxane  was  seen predominantly in girls.",additionally doxorubicin reduction left ventricular fractional shortening signi cantly girls boys 5-year period table 2 gures 4a 4b protective ect dexrazoxane girls,G0000000|C0013089|C0301630|C0205091|C0018827|C1264633|C0441636|G0000000|G0000000|C0870604|C0870221|C0439234|C0439531|C0039224|G0000000|G0000000|C1420849|C1420850|G0000000|C0013806|C0086444|C0870604
Fifteen patients received amifostine and 13 did not.,fifteen patients received amifostine 13,C3715153|C0030705|C1514756|C0015020|C0450371
"However, other possible mechanisms may involve the protection of carvedilol.",mechanisms involve protection carvedilol,C0441712|G0000000|C1545588|C0054836
"Unfortunately, despite its broad effectiveness, ANT therapy is associated with irreversible dilated cardiomyopathy (CMP).",broad effectiveness ant therapy irreversible dilated cardiomyopathy cmp,C0332464|C1280519|C0003455|C0039798|G0000000|C0700124|C0878544|G0000000
Immunological mechanisms appear to be involved in the pathogenesis of ARF.,immunological mechanisms involved pathogenesis arf,C0205470|C0441712|C1314939|C0543483|C0035436
Baseline 69.8  15.2 68.7  13.0 1.03  0.2 72.7  16.1 73.3  18.7,baseline 698 152 687 130 103 02 727 161 733 187,C0168634|C1442061|C1442061|C1442061|C1442061|C1442061|C0450371|C1442061|C1442061|C1442061|C1442061
Clinical characteristics of the study populations are pre-,clinical characteristics study populations pre-,C0205210|C1521970|C0557651|C0032659|C0332152
"The mean EF of the carvedilol group was similar in basal and control echocardiographic examination, but the patients in the control group had signicantly lower EF at the end of the follow-up period compared with basal values (p  0.001) (Fig. 1).",ef carvedilol basal control echocardiographic examination patients control signicantly lower ef follow-up period compared basal values 0001 fig 1,G0000000|C0054836|C0205112|C0243148|C0013516|G0000000|C0030705|C0243148|G0000000|C0441994|G0000000|C0589120|C0439531|C1707455|C0205112|C0042295|G0000000|C0349966|G0000000
in cardiomyocytes due to chemotherapeutics (1113).,cardiomyocytes chemotherapeutics 1113,C0225828|G0000000|G0000000
"In Doppler study, whereas E velocities in the carvedilol group decreased, E velocities and E/A ratios were signicantly reduced in the control group.",doppler study velocities carvedilol decreased velocities e/a ratios signicantly reduced control,C0554756|C0557651|C0439830|C0054836|C0205216|C0439830|G0000000|C0456603|G0000000|C0392756|C0243148
"Therefore,  we  present  the  number  of  patients  and the corresponding number of echocardiograms done  in  20-month  intervals.",patients echocardiograms 20-month intervals,C0030705|C0013516|C0450371|C1272706
This effect was believed to be due to IVIG.,believed ivig,G0000000|C0085297
This study was approved by our local ethics committee.,study approved local ethics committee,C0557651|C0205540|C0205276|C0015000|C2699414
Previous studies have shown that LV diastolic functions might also be impaired in,previous studies lv diastolic functions impaired,C0205156|C0947630|C0023128|C0012000|C0542341|C0221099
"Response was considered good if more than 90% necrosis was obtained, partial for 6090%, and poor for less than 60%.",response considered 90% necrosis partial 6090% poor 60%,C0871261|C0750591|C0450371|C0027540|C0728938|G0000000|C0032854|C0450371
Received 16 November 2004; accepted 17 December 2004,received 16 november 2004 accepted 17 december 2004,C1514756|C0450371|C3828767|G0000000|C1272684|C0450371|C3830550|G0000000
"valves (Figure 2 and Table 4).16,17,21 Preliminary stratification had resulted in an equal proportion of patients with nil, mild, or severe carditis in the treated and placebo groups, but some imbalance occurred because of withdrawals.",valves figure 2 table 4161721 preliminary stratification equal proportion patients nil mild severe carditis treated placebo imbalance occurred withdrawals,C0184252|G0000000|G0000000|C0039224|G0000000|C0439611|C1514983|C0205163|C1709707|C0030705|C0442734|C2945599|C0205082|C0869523|C1522326|C0032042|C1397014|C1709305|C2349954
We have demonstrated that coadministration of carvedilol during CT preserves the LV systolic functions.,demonstrated coadministration carvedilol ct preserves lv systolic functions,G0000000|C0814472|C0054836|C0007673|G0000000|C0023128|C0039155|C0542341
Several studies have shown changes in resting membrane potential and action potential amplitude [2224].,studies resting membrane potential action potential amplitude 2224,C0947630|C0035253|C0025255|C3245505|C0441472|C3245505|C2346753|G0000000
"Many different chemical agents have been examined to prevent ANT-induced CMP (68), and some of them showed promising results.",chemical agents examined prevent ant-induced cmp 68 promising,C0220806|C0450442|C0332128|C0309872|C0003455|G0000000|C0450371|C1555307
"We excluded patients who had active cardiac disease, including myocardial infarction occurring within 12 months, active angina pectoris, symptomatic valvular heart disease, or uncontrolled congestive heart failure.",excluded patients active cardiac disease including myocardial infarction occurring 12 months active angina pectoris symptomatic valvular heart disease uncontrolled congestive heart failure,C1554077|C0030705|C0205177|C0018787|C0012634|C0332257|C0027061|C0021308|C1709305|C0450371|C0439231|C0205177|C0002962|G0000000|C0231220|C0184252|C0018787|C0012634|C0205318|C0742742|C0018787|C0231174
"nificant cardiac morbidity and mortality in young people in the developing world, where it remains the leading cause of acquired heart disease.1,2 In New Zealand, the incidence of ARF is 2.5 per 100 000 population, which compares with an incidence of 0.1 per 100 000 population in the United States.3 The incidence of 50 to 70 per 100 000 in Maori and Pacific Island children between 5 and 15 years of age is comparable to that seen in developing countries.4",nificant cardiac morbidity mortality people developing remains leading acquired heart disease12 zealand incidence arf 25 100 000 population compares incidence 01 100 000 population united states3 incidence 50 70 100 000 maori pacific island children 5 15 age comparable developing countries4,G0000000|C0018787|C0026538|C0026565|C0027361|G0000000|G0000000|C0332152|C0439661|C0018787|G0000000|G0000000|C0021149|C0035436|C0450371|C1442061|C1442061|C0032659|C1707455|C0021149|C0450371|C1442061|C1442061|C0032659|C0166872|G0000000|C0021149|C0450371|C0450371|C1442061|C1442061|C0024770|G0000000|C0022130|C0008059|G0000000|C0450371|C0001779|G0000000|G0000000|G0000000
"Patients were evaluated for renal, hearing and cardiac toxicity.",patients evaluated renal hearing cardiac toxicity,C0030705|C0220825|C0022646|C0018767|C0018787|C0040539
"Keywords osteosarcoma, amifostine, chemotherapy-related toxicity",keywords osteosarcoma amifostine chemotherapy-related toxicity,C1708608|C0029463|C0015020|C0013216|C0040539
The mechanism through which anthracycline therapy determines the prolongation of QT dispersion and by which cardioxane-therapy is able to modify these electrophysiological alterations is not well known.,mechanism anthracycline therapy determines prolongation qt dispersion cardioxane-therapy modify electrophysiological alterations,C0441712|C0003234|C0039798|G0000000|C0439590|C1552934|C0332624|C0524711|C0392747|C0013865|C1515926
"Role of the funding source  The  funding  sources  had  no  role  in  the  study  design,  data  collection,  data  analysis,  data  interpretation,  or  writing of the report.",role funding source funding sources role study design data collection data analysis data interpretation writing report,C0035820|C0243098|C0449416|C0243098|C0449416|C0035820|C0557651|C1707689|C1511726|C1516698|C1511726|C0002778|C1511726|C0459471|C0043266|C0684224
"Although diffuse and focal thickening of the mitral valve have been described in ARF,20 we have not attempted to include such observations in our assessment.",diffuse focal thickening mitral valve arf20 attempted observations assessment,C0205219|C0205234|C0205400|C0746591|C0184252|G0000000|C1516084|C0302523|C1261322
"Their success is often limited by toxicity to normal cells, which leads to reduction of doses and interruption in treatment.",success limited toxicity normal cells leads reduction doses interruption treatment,C0597535|C0439801|C0040539|C0205307|C0007634|C0023175|C0301630|C0178602|C0332453|C0039798
"However, there is no placebo-controlled clinical trial concerning prophylactic carvedilol use in preventing ANT-induced CMP.",placebo-controlled clinical trial prophylactic carvedilol preventing ant-induced cmp,C1706408|C0205210|C0008976|C0355642|C0054836|C0309872|C0003455|G0000000
"The corresponding author had full  access to all data, and had  nal responsibility to submit  the report for publication.",author access data nal responsibility submit report publication,C3812881|C0444454|C1511726|G0000000|C0678341|C1515023|C0684224|C0034036
"In fact, the iron-overload of cardiomyocytes determines the loss of functional Na channels; enhanced Na+ channel inactivation causes the reduction in the overshoot of cardiac action potential.",iron-overload cardiomyocytes determines loss functional channels enhanced na+ channel inactivation reduction overshoot cardiac action potential,C0282193|C0225828|G0000000|C1517945|C0205245|C0439799|C2349975|C0597484|C0439799|C0544461|C0301630|G0000000|C0018787|C0441472|C3245505
"Pediatric Hematology and Oncology, 24:403408, 2007 Copyright C(cid:1) Informa Healthcare USA, Inc. ISSN: 0888-0018 print / 1521-0669 online DOI: 10.1080/08880010701451244",pediatric hematology oncology 24403408 2007 copyright ccid1 informa healthcare usa issn 0888-0018 print / 1521-0669 online doi 101080/08880010701451244,C0030755|C0018943|C0027651|G0000000|G0000000|C0009993|G0000000|G0000000|C0086388|C0041703|G0000000|G0000000|C0033161|G0000000|G0000000|G0000000|C2348291|G0000000
These effects of carvedilol may be an underlying mechanism of its benecial effects on cardiac function.,effects carvedilol underlying mechanism benecial effects cardiac function,C1280500|C0054836|G0000000|C0441712|G0000000|C1280500|C0018787|C0031843
"ECGs with a duration of 10 s were recorded with a Cardiovit CS-100 (Schiller-AG, Baar, Switzerland), using the same system at 25 mm/s paper speed and standardized at 0.1 mV/ mm.",ecgs duration 10 recorded cardiovit cs-100 schiller-ag baar switzerland system 25 mm/s paper speed standardized 01 mv/ mm,C0013798|C0449238|C0450371|C0034869|G0000000|C0010182|C0002037|G0000000|C0039021|C0449913|C0450371|C0456681|C0030351|C0678536|G0000000|C0450371|C0428679|G0000000
The  between-group  comparison  showed  a  signi cant  di erence  during  the   rst 2 years after treatment completion but not thereafter.,between-group comparison signi di erence rst 2 treatment completion,C0441833|C1707455|G0000000|C3538902|G0000000|C1425219|G0000000|C0039798|C0205197
The aim of this study was to determine the protective effect of carvedilol in anthracycline (ANT)-induced cardiomyopathy (CMP).,aim study determine protective carvedilol anthracycline ant-induced cardiomyopathy cmp,C1947946|C0557651|G0000000|G0000000|C0054836|C0003234|C0003455|C0878544|G0000000
"Therefore, at a time when anthracycline dose escalation  is a useful treatment for leukaemia in adults,31 valid ation  of a cardioprotectant against anthracyclines is important.",time anthracycline dose escalation treatment leukaemia adults31 valid ation cardioprotectant anthracyclines,C0040223|C0003234|C0178602|G0000000|C0039798|C0023418|G0000000|C2349099|G0000000|G0000000|C0003234
A possible reason for the inability to reach statistically signicance between mortality rates may be the limited number of patients in this study.,reason inability reach statistically signicance mortality rates limited patients study,C0392360|G0000000|C2584321|C0038215|G0000000|C0026565|C0871208|C0439801|C0030705|C0557651
Patients in whom ANT therapy was planned were randomized to administration of carvedilol or placebo.,patients ant therapy planned randomized administration carvedilol placebo,C0030705|C0003455|C0039798|C1301732|C0034656|C0001554|C0054836|C0032042
"), Auckland, New Zealand; Green Lane Hospital (N.J.W., J.M.N., R.M.L.W.",auckland zealand green lane hospital njw jmn rmlw,G0000000|G0000000|C0332583|C1708639|C0019994|G0000000|G0000000|G0000000
"The study was designed as a prospective, randomized, doubleblind, placebo-controlled trial of IVIG.",study designed prospective randomized doubleblind placebo-controlled trial ivig,C0557651|C1707689|C0023981|C0034656|C0013072|C1706408|C0008976|C0085297
"One patient with carditis withdrew from the study after the first week (parental choice), and another with carditis withdrew after 6 months (emigration).",patient carditis withdrew study week parental choice carditis withdrew 6 months emigration,C0030705|C0869523|C2349954|C0557651|C0332174|C0030551|C0008300|C0869523|C2349954|G0000000|C0439231|C0013975
"Doppler study showed a signicant decrease of E velocities in the carvedilol group; however, other parameters were similar (Table 2).",doppler study signicant decrease velocities carvedilol parameters table 2,C0554756|C0557651|G0000000|C0392756|C0439830|C0054836|C0449381|C0039224|G0000000
Survival has improved in most pediatric cancer patients.,survival improved pediatric cancer patients,C0038952|C0184511|C0030755|C0006826|C0030705
Response to chemotherapy was signicantly better in the amifostine group.,response chemotherapy signicantly amifostine,C0871261|C0013216|G0000000|C0015020
Conclusion: amifostine did not reduce the ototoxicity and nephrotoxicity of our treatment regime.,conclusion amifostine reduce ototoxicity nephrotoxicity treatment regime,C1707478|C0015020|G0000000|C0235280|C0599918|C0039798|G0000000
"In  the  doxorubicin  group,  the  mean  Z  score  for  left  ventricular end-diastolic dimension was almost the same  as  in  healthy  children  throughout  follow-up.",doxorubicin score left ventricular end-diastolic dimension healthy children follow-up,C0013089|C0449820|C0205091|C0018827|C0442709|C0439534|C3898900|C0008059|C0589120
The primary  endpoints were late left ventricular structure and function abnormalities as assessed by echocardiography; analyses  were done including all patients with data available after treatment completion.,primary endpoints late left ventricular structure function abnormalities assessed echocardiography analyses including patients data treatment completion,C0205225|C2349179|C0205087|C0205091|C0018827|C0678594|C0031843|C0000768|C1516048|C0013516|C0002778|C0332257|C0030705|C1511726|C0039798|C0205197
After CT 70.5  17.1 73.9  14.3 0.98  0.2 75.6  17.8 72.3  23.1,ct 705 171 739 143 098 02 756 178 723 231,C0007673|C1442061|C1442061|C1442061|C1442061|C1442061|C0450371|C1442061|C1442061|C1442061|C1442061
"Children were diagnosed with high-risk ALL if they  met any of the following criteria: younger than 12 months  or older than 10 years and younger than 18 years, leucocyte  count  of  50 000  cells  or  more  per  L,  T-cell  phenotype,  presence of an anterior mediastinal mass, or presence of  any  lymphoblasts  in  a  sample  of  cerebrospinal   uid.",children diagnosed high-risk met criteria 12 months 10 18 leucocyte count 50 000 cells t-cell phenotype presence anterior mediastinal mass presence lymphoblasts sample cerebrospinal uid,C0008059|C0011900|C0332167|C0268621|C0243161|C0450371|C0439231|C0450371|C0450371|C0023516|C0750480|C0450371|C1442061|C0007634|C0039194|C0031437|C0150312|C0205094|C0025066|C0577559|C0150312|C0229613|C0370003|G0000000|C2349022
"Intraobserver and interobserver variability for QT dispersion measurements were < 3% and < 5%, respectively.",intraobserver interobserver variability qt dispersion measurements < 3% < 5%,G0000000|G0000000|C2827666|C1552934|C0332624|C0242485|G0000000|G0000000|G0000000|G0000000
Event-free  survival  was measured from the date of diagnosis to the  rst event  or  until  the  date  of  last  contact.,event-free survival measured diagnosis rst event contact,C0441471|C0038952|C0444706|C0011900|C1425219|C0441471|C0332158
"), both experienced in the assessment of children with rheumatic carditis, directly supervised the echocardio-",experienced assessment children rheumatic carditis directly supervised echocardio-,C0237607|C1261322|C0008059|G0000000|C0869523|C1947931|G0000000|G0000000
"Some authors showed that anthracyclines cause significant changes in myocardial depolarization and repolarization with prolongation of QTc, increased QT dispersion and the development of ventricular late potentials [2].",authors anthracyclines myocardial depolarization repolarization prolongation qtc increased qt dispersion development ventricular late potentials 2,C3812881|C0003234|C0027061|G0000000|G0000000|C0439590|G0000000|C0205217|C1552934|C0332624|C0243107|C0018827|C0205087|C3245505|G0000000
Diastolic functions were affected in our patients.,diastolic functions patients,C0012000|C0542341|C0030705
There were no differences in indexes of left ventricular function between the IVIG and placebo groups at baseline and at follow-up.,differences indexes left ventricular function ivig placebo baseline follow-up,C1705241|C0600653|C0205091|C0018827|C0031843|C0085297|C0032042|C0168634|C0589120
"In this study, the average duration of symptoms before the first infusion was 9 days, a reflection of the combined time to seek medical care and time for diagnosis to be made.",study average duration symptoms infusion 9 days reflection combined time seek medical care time diagnosis,C0557651|C1510992|C0449238|C0683368|C0574032|G0000000|C0439228|C0558058|C0205195|C0040223|G0000000|C0199168|C1947933|C0040223|C0011900
Carvedilol restores SERCA2 promoter activity in myocytes and it can block down-regulation of SERCA2 gene expression independent of its beta-blocking activity (23).,carvedilol restores serca2 promoter activity myocytes block down-regulation serca2 gene expression independent beta-blocking activity 23,C0054836|G0000000|G0000000|C0086860|C0205177|C0596981|C0028778|C0013081|G0000000|C0017337|C0185117|C0085862|C0330390|C0205177|C0450371
Number of Patients and Grades of Severity of Carditis at Timed Intervals,patients grades severity carditis timed intervals,C0030705|C0441800|C0439793|C0869523|C0392761|C1272706
"Exclusion criteria included patients with an ESR of ,30 mm/h, a past history of rheumatic fever, IgA deficiency, chorea alone, evidence of marked valve thickening, or other evidence of chronic valvulitis on echocardiography.",exclusion criteria included patients esr 30 mm/h history rheumatic fever iga deficiency chorea evidence marked valve thickening evidence chronic valvulitis echocardiography,C0680251|C0243161|C0332257|C0030705|C3811131|C0450371|C0456680|C0019664|G0000000|C0015967|C2825347|C0011155|C0008489|C3887511|C0522501|C0184252|C0205400|C3887511|C0205191|G0000000|C0013516
O grupo tratado com o misoprostol recebeu 25 ?g cada 2 horas durante um m??ximo de 24 horas para indu??o.,grupo tratado misoprostol recebeu 25 cada 2 horas durante um mximo de 24 horas para induo,G0000000|G0000000|C0085174|G0000000|C0450371|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0011198|C0450371|G0000000|C0030563|G0000000
"If the ideal pattern of uterine activites (at least 3 contractions per 10 minutes) was reached over 1 hour, misoprostol was no longer administered.",ideal pattern uterine activites 3 contractions 10 minutes reached 1 hour misoprostol administered,C1512612|C0449774|C0042149|G0000000|G0000000|C1140999|C0450371|C0439232|C2584321|G0000000|C0439227|C0085174|C1521801
"LDL cholesterol was determined by sequential preparatory ultracentrifugation (d ?- 1.006 kg/m 3 , Beckmann L7-65 ultracentrifuge, Rotor 50 Ti, 40,000 rpm, 4?C, 20 hours) and consecutive LDL cholesterol precipitation utilizing the Boehringer Mannheim high-density lipoprotein (HDL) cholesterol test kit.",ldl cholesterol determined sequential preparatory ultracentrifugation 1 006 kg/m 3 beckmann l7-65 ultracentrifuge rotor 50 ti 40 000 rpm 4c 20 hours consecutive ldl cholesterol precipitation utilizing boehringer mannheim high-density lipoprotein hdl cholesterol test kit,G0000000|C0008377|G0000000|C1548958|G0000000|C0041609|G0000000|C1442061|C1532718|G0000000|G0000000|C0441916|G0000000|G0000000|C0450371|C0039247|C0450371|C1442061|C0475506|C4053564|C0450371|C0439227|C1707491|G0000000|C0008377|C0032931|G0000000|G0000000|G0000000|C0205250|C0023820|C3715113|C0008377|C0022885|C0812225
The recovery rate was 97 ?? 7%.,recovery rate 97 7%,C0237820|C0871208|C0450371|G0000000
"In a relatively short time frame, we found marked differences in clinical course with a surprising consistency in patients included in the study after an acute myocardial infarction as well as after angioplasty alone.",short time frame marked differences clinical surprising consistency patients included study acute myocardial infarction angioplasty,C1282927|C0040223|C0080089|C0522501|C1705241|C0205210|G0000000|C0332529|C0030705|C0332257|C0557651|C0205178|C0027061|C0021308|C0162577
"Two corresponding biplane cine frames were 1.56-fold magnified, videodigitized (CAP-35B; Elmo, Tokyo, Japan), and stored (512 ?? 512 matrix size) for computer analysis in a cardiac work station (CARDIO 500, Kontron, Munich, Germany).",biplane cine frames 1 56-fold magnified videodigitized cap-35b elmo tokyo japan stored 512 512 matrix size computer analysis cardiac station cardio 500 kontron munich germany,G0000000|C1979871|C0180979|G0000000|C0450371|G0000000|G0000000|C0179586|G0000000|C0040371|C0022341|C1698986|C1442061|C1442061|C1704640|C0456389|C0009622|C0002778|C0018787|C1883167|C0018787|C1442061|G0000000|G0000000|C0017480
"For comparisons of age, blood glucose, and lipid values between groups we utilized the Mann-Whitney U test.",comparisons age blood glucose lipid values utilized mann-whitney test,C1707455|C0001779|C0005767|C0017725|C0023779|C0042295|G0000000|G0000000|C0022885
"In group B, antilipidemic therapy was determined by the family physician.",antilipidemic therapy determined family physician,G0000000|C0039798|G0000000|C0015576|C0031831
"Clinic visits and laboratory studies were scheduled for both groups at 4-week intervals for the first 6 months, at 2-month intervals for another 6 months, and at 3-month intervals in the second year of the study.",clinic visits laboratory studies scheduled 4-week intervals 6 months 2-month intervals 6 months 3-month intervals study,C0002424|C0545082|C0022877|C0947630|C0086960|C0332174|C1272706|G0000000|C0439231|C0332177|C1272706|G0000000|C0439231|C0332177|C1272706|C0557651
A stepwise regression model was used for multivariate analysis.,stepwise regression model multivariate analysis,G0000000|C0684320|C3161035|G0000000|C0002778
The protocol was approved by the Ethics Committee of our institution.,protocol approved ethics committee institution,C0442711|C0205540|C0015000|C2699414|C0018704
Patients and therapy: Patients with total cholesterol of ??200 to ??400 mg/dl and low-density lipoprotein (LDL) cholesterol of ??130 to ??300 mg/dl (after exclusion of secondary forms of hyperlipidemia) with an acute myocardial infarction (defined by new Q waves and increase of enzymes of ??3-fold the normal value) and/or who underwent emergency percutaneous transluminal coronary balloon angioplasty due to severe or unstable angina pectoris (defined by clinical symptoms and electrocardiographic [ECG] alterations during rest and/or exercise) were included in this study.,patients therapy patients total cholesterol 200 400 mg/dl low-density lipoprotein ldl cholesterol 130 300 mg/dl exclusion secondary forms hyperlipidemia acute myocardial infarction defined waves increase enzymes 3-fold normal and/or underwent emergency percutaneous transluminal coronary balloon angioplasty severe unstable angina pectoris defined clinical symptoms electrocardiographic ecg alterations rest and/or exercise included study,C0030705|C0039798|C0030705|C0439175|C0008377|C1442061|C1442061|C0439269|C0205251|C0023820|G0000000|C0008377|C1442061|C1442061|C0439269|C0680251|C0027627|C0348078|C0020473|C0205178|C0027061|C0021308|C1704788|C0678544|C0442805|C0014442|C0332462|C0205307|G0000000|G0000000|C0013956|C0522523|C0522520|C0018787|C0336867|C0162577|C0205082|C0443343|C0002962|G0000000|C1704788|C0205210|C0683368|C0013798|C1623258|C1515926|C0035253|G0000000|C0015259|C0332257|C0557651
Pravastatin was well tolerated and there were no adverse events in the early phase of treatment.,pravastatin tolerated adverse events phase treatment,C0085542|G0000000|G0000000|C0441471|C0205390|C0039798
"This study, like others, however, could not find an influence of intensive antilipidemic treatment on the development of restenoses after angioplasty.",study influence intensive antilipidemic treatment development restenoses angioplasty,C0557651|C4054723|C0162425|G0000000|C0039798|C0243107|C0333186|C0162577
Patients were blindly assigned to intensive antilipidemic therapy (group A) or standard care (group B).,patients blindly assigned intensive antilipidemic therapy standard care,C0030705|G0000000|C1516050|C0162425|G0000000|C0039798|C1442989|C1947933
A sample size of 80 patients per group was estimated to show a 30% difference of progression and a 14% difference in regression with 80% power and a p value of ??0.05 in a 1-sided test.,sample size 80 patients estimated 30% difference progression 14% difference regression 80% power 0 05 1-sided test,C0370003|C0456389|C0450371|C0030705|C0750572|C0450371|C1705241|C0242656|C0450371|C1705241|C0684320|C0450371|C0032863|G0000000|C0450371|C0457012|C0022885
"Lipid determinations: Triglycerides and cholesterol levels were manually determined by routine methods (triglycerides, ""GPO-PAP""; cholesterol, ""CHOD-PAP"" test kits; Boehringer Mannheim, Mannheim, Germany).",lipid determinations triglycerides cholesterol levels manually determined routine methods triglycerides gpo-pap cholesterol chod-pap test kits boehringer mannheim mannheim germany,C0023779|C0680730|C0041004|C0008377|C0441889|C3842330|G0000000|C0205547|C0025663|C0041004|C1740167|C0008377|C0082139|C0022885|C1690540|G0000000|G0000000|G0000000|C0017480
All patients received dietary counseling per the standards of the European Atherosclerosis Society.,patients received dietary counseling standards european atherosclerosis society,C0030705|C1514756|C0012155|C0010210|C0038137|C0239307|C0003850|C0037455
Patients with an acute infarction were included only if their lipids could be determined within 8 hours after onset of symptoms; those in the balloon angioplasty group with a history of infarction were included only when the infarction was ??3 months earlier.,patients acute infarction included lipids determined 8 hours onset symptoms balloon angioplasty history infarction included infarction 3 months earlier,C0030705|C0205178|C0021308|C0332257|C0023779|G0000000|G0000000|C0439227|C0206132|C0683368|C0336867|C0162577|C0019664|C0021308|C0332257|C0021308|G0000000|C0439231|C1279919
"Finally, because only a small number of patients was included in this single-center study, further larger studies are needed to confirm our findings.",finally patients included single-center study larger studies confirm findings,G0000000|C0030705|C0332257|C0037179|C0557651|C0549177|C0947630|C0521093|C2607943
"Of the 870 patients examined, 135 were eligible and randomized to either intensive treatment (group A) or controls (group B) (Figure 1).",870 patients examined 135 eligible randomized intensive treatment controls figure 1,C1442061|C0030705|C0332128|C1442061|C1548635|C0034656|C0162425|C0039798|C0243148|G0000000|G0000000
The intensive treatment group is shown on the left side (grid bars); the standard care group is shown on the right side (striped bars).,intensive treatment left grid bars standard care striped bars,C0162425|C0039798|C0205091|C1415284|C0687760|C1442989|C1947933|C1532935|C0687760
"After 6 months, 47 of 56 patients still observed in group A had an evaluable control angiogram and 127 non-angioplasty stenoses were measurable.",6 months 47 56 patients observed evaluable control angiogram 127 non-angioplasty stenoses measurable,G0000000|C0439231|C0450371|C0450371|C0030705|C1441672|C1516986|C0243148|C0002978|C1442061|C1518422|C1261287|C1513040
Rotation and angulations as well as tube-to-image intensifier distances were automatically recorded.,rotation angulations tube-to-image intensifier distances automatically recorded,C0035868|C0333179|C0175730|G0000000|C0012751|C3842331|C0034869
Further medication was equally prescribed in both groups (Table 1).,medication equally prescribed table 1,C0013227|G0000000|C0278329|C0039224|G0000000
"In group A, a stroke in 1 patient was determined to be cause of death by the family physician, but no autopsy was performed.",stroke 1 patient determined death family physician autopsy performed,C0038454|G0000000|C0030705|G0000000|C0011065|C0015576|C0031831|C0004398|C0884358
"The impact , however, of immediate initiation of antilipidemic therapy on coronary stenoses and clinical outcome in patients with acute coronary syndrome is unknown.",impact initiation antilipidemic therapy coronary stenoses clinical outcome patients acute coronary syndrome unknown,C1825598|C0589507|G0000000|C0039798|C0018787|C1261287|C0205210|C1274040|C0030705|C0205178|C0018787|C0039082|C0439673
LDL cholesterol was recalculated from the fractions.,ldl cholesterol recalculated fractions,G0000000|C0008377|G0000000|C1264633
"To illustrate the significant changes in coronary stenoses, we looked for increases or decreases in diameters of ??0.3 mm (??10-fold outside the measurement accuracy).",illustrate coronary stenoses looked increases decreases diameters 0 3 mm 10-fold measurement accuracy,G0000000|C0018787|C1261287|C0233426|C0205217|C0442797|C1301886|G0000000|G0000000|G0000000|C0450371|C0242485|C0443131
"The objectives of this prospective open-label, randomized, single-center study were to compare the effects of cholesterol-lowering therapy initiated immediately after an event with the effects of usual outpatient treatment on the course of coronary atherosclerosis and clinical outcome.",objectives prospective open-label randomized single-center study compare effects cholesterol-lowering therapy initiated event effects usual outpatient treatment coronary atherosclerosis clinical outcome,C0018017|C0023981|C1709323|C0034656|C0037179|C0557651|C1707455|C1280500|C0008377|C0039798|C1548602|C0441471|C1280500|C3538928|C0029921|C0039798|C0018787|C0003850|C0205210|C1274040
The significance level was set at p ??0.05.,significance level set 0 05,C0237881|C0441889|C0036849|G0000000|C0450371
Differences in quantitative angiography were tested by the 2-sided t test.,differences quantitative angiography tested 2-sided test,C1705241|C0392762|C0002978|C0392366|C0457012|C0022885
Randomization was stratified for gender and reason for inclusion (infarction and/or coronary angio-plasty).,randomization stratified gender reason inclusion infarction and/or coronary angio-plasty,C0034656|C0205363|C0079399|C0392360|C0007637|C0021308|G0000000|C0018787|C4071827
"Clinical events: Nonfatal myocardial infarction, coronary balloon angioplasty or bypass grafting, stroke, new onset of occlusive peripheral vascular disease, cardiovascular death, and all-cause mortality were prospectively defined as secondary end points.",clinical events nonfatal myocardial infarction coronary balloon angioplasty bypass grafting stroke onset occlusive peripheral vascular disease cardiovascular death all-cause mortality prospectively defined secondary,C0205210|C0441471|G0000000|C0027061|C0021308|C0018787|C0336867|C0162577|C0741847|C0332835|C0038454|C0206132|C1947917|C0205100|C0005847|C0012634|C0007226|C0011065|C0015127|C0026565|G0000000|C1704788|C0027627
Nine patients in group B withdrew their consent after learning to which group they were included.,patients withdrew consent learning included,C0030705|C2349954|C1511481|C0013621|C0332257
"For comparisons to baseline within the groups, the Wilcoxon signed-rank test was applied.",comparisons baseline wilcoxon signed-rank test applied,C1707455|C0168634|G0000000|C1519316|C0022885|C4048755
LDL cholesterol of ??130 mg/dl was achieved in 40 of 70 patients in group A with pravastatin therapy only.,ldl cholesterol 130 mg/dl achieved 40 70 patients pravastatin therapy,G0000000|C0008377|C1442061|C0439269|G0000000|C0450371|C0450371|C0030705|C0085542|C0039798
"In group B, 1 patient committed suicide and 1 died of colon cancer, which was unknown at the time of randomization.",1 patient committed suicide 1 died colon cancer unknown time randomization,G0000000|C0030705|C1171947|C0038661|G0000000|C0011065|C0009368|C0006826|C0439673|C0040223|C0034656
"For group comparisons, we used the chi-square test with continuity correction for dichotomous variables.",comparisons chi-square test continuity correction dichotomous variables,C1707455|C1552646|C0022885|C0595960|C1705565|C2827654|C0439828
"These findings correspond with the results of the Long-term Intervention with Pravastatin in Ischemic Disease study, 3 and may be caused by properties of pravastatin beyond its lipidlowering action, such as its anti-atherothrombotic or hematorheologic effects.",findings correspond long-term intervention pravastatin ischemic disease study 3 caused properties pravastatin lipidlowering action anti-atherothrombotic hematorheologic effects,C2607943|G0000000|C0443252|C0886296|C0085542|C0475224|C0012634|C0557651|G0000000|C0015127|C0871161|C0085542|G0000000|C0441472|G0000000|G0000000|C1280500
The time to event was calculated according to the Kaplan-Meier method with the log-rank test.,time event calculated kaplan-meier method log-rank test,C0040223|C0441471|C0444686|G0000000|C0025663|C1708728|C0022885
Statistical analysis: An intention-to-treat analysis was performed.,statistical analysis intention-to-treat analysis performed,C0038215|C0002778|C0162425|C0002778|C0884358
The increase in difference between 6 and 24 months was also significant (p ?- 0.021).,increase difference 6 24 months 0 021,C0442805|C1705241|G0000000|C0450371|C0439231|G0000000|C1442061
"In 8 of 70 patients, LDL cholesterol of ??130 mg/dl was achieved by combining pravastatin with cholestyramine and/or nicotinic acid.",8 70 patients ldl cholesterol 130 mg/dl achieved combining pravastatin cholestyramine and/or nicotinic acid,G0000000|C0450371|C0030705|G0000000|C0008377|C1442061|C0439269|G0000000|C0336789|C0085542|C0008402|G0000000|C0028040|C0001128
"Lipoprotein(a) (Lp(a)) was measured with a sandwich enzyme immunoassay (Immunozym Lp(a), Immuno, Heidelberg, Germany).",lipoprotein lp measured sandwich enzyme immunoassay immunozym lp immuno heidelberg germany,C0023820|C0037943|C0444706|G0000000|C0014442|C0020980|G0000000|C0037943|G0000000|G0000000|C0017480
"Correlated with other studies, such as the European Action on Secondary Prevention through Intervention to Reduce Events study, 24 standard care was unsatisfactory in our investigation.",correlated studies european action secondary prevention intervention reduce events study 24 standard care unsatisfactory investigation,C1707520|C0947630|C0239307|C0441472|C0027627|C0199176|C0886296|G0000000|C0441471|C0557651|C0450371|C1442989|C1947933|C0439856|C0220825
"There were 18 prespecified clinical events in 16 of 70 patients of group A and 34 events in 29 of 56 patients of group B during the study (p ?- 0.005, odds ratio 3.6, confidence intervals 1.6 to 7.8).",18 prespecified clinical events 16 70 patients 34 events 29 56 patients study 0 005 odds ratio 3 6 confidence intervals 1 6 7 8,C0450371|G0000000|C0205210|C0441471|C0450371|C0450371|C0030705|C0450371|C0441471|C0450371|C0450371|C0030705|C0557651|G0000000|C1442061|G0000000|C0456603|G0000000|G0000000|C0237529|C1272706|G0000000|G0000000|G0000000|G0000000
One nonfatal myocardial infarction occurred in group B.,nonfatal myocardial infarction occurred,G0000000|C0027061|C0021308|C1709305
The withdrawal of consent of 9 patients in the control group was not anticipated.,withdrawal consent 9 patients control anticipated,C2349954|C1511481|G0000000|C0030705|C0243148|C3840775
The compliance was ??90% according to pill count.,compliance 90% pill count,C0009563|C0450371|C0009905|C0750480
"In group B, 8 of 56 patients achieved a target value of an LDL cholesterol of ??130 mg/ dl, but only for a short period.",8 56 patients achieved target ldl cholesterol 130 mg/ dl short period,G0000000|C0450371|C0030705|G0000000|C1521840|G0000000|C0008377|C1442061|C0026410|C3642216|C1282927|C0439531
Selection of enddiastolic frames was done in an off-line analysis.,selection enddiastolic frames off-line analysis,C0036576|C0442709|C0180979|C1518543|C0002778
"The combined clinical end points were total mortality , cardiovascular death, nonfatal myocardial infarc-tion, need for coronary intervention, stroke, and new onset of peripheral vascular disease.",combined clinical total mortality cardiovascular death nonfatal myocardial infarc-tion coronary intervention stroke onset peripheral vascular disease,C0205195|C0205210|C0439175|C0026565|C0007226|C0011065|G0000000|C0027061|G0000000|C0018787|C0886296|C0038454|C0206132|C0205100|C0005847|C0012634
"Moreover, there is a lack of serial studies where the angiographic course is documented early (6 months) after initiation of therapy followed by a longer period of follow-up.",lack serial studies angiographic documented 6 months initiation therapy period follow-up,C0332268|C0031082|C0947630|C0002978|C1301725|G0000000|C0439231|C0589507|C0039798|C0439531|C0589120
"Moreover, there is a lack of serial studies where the angiographic course is documented early (6 months) after initiation of therapy followed by a longer period of follow-up.",lack serial studies angiographic documented 6 months initiation therapy period follow-up,C0332268|C0031082|C0947630|C0002978|C1301725|G0000000|C0439231|C0589507|C0039798|C0439531|C0589120
"Quantitative coronary angiography was performed at inclusion, and at 6-and 24-month follow-up.",quantitative coronary angiography performed inclusion 6-and 24-month follow-up,C0392762|C0018787|C0002978|C0884358|C0007637|G0000000|C0450371|C0589120
"Quantitative coronary angiography: Angiograms were taken after administration of 0.6 mg sublingual nitroglycerin on a biplane isocentric Philips Polydiagnost C-arm and L-ARC Optimus (Best, The Netherlands) system and recorded on cine film.",quantitative coronary angiography angiograms administration 0 6 sublingual nitroglycerin biplane isocentric philips polydiagnost c-arm l-arc optimus netherlands system recorded cine film,C0392762|C0018787|C0002978|C0002978|C0001554|G0000000|G0000000|C0001565|C0017887|G0000000|C1881275|G0000000|G0000000|C0446516|C0439394|G0000000|C0027778|C0449913|C0034869|C1979871|C0086296
"This presumption is underlined by the observation that in group A only 18 of 70 patients had a total of 24 unscheduled hospitalizations, whereas in group B, 33 unscheduled hospitalizations were necessary in 28 of 56 patients due to cardiovascular events (p ?- 0.009; odds ratio 3.0, confidence intervals 1.4 to 6.3).",presumption underlined observation 18 70 patients total 24 unscheduled hospitalizations 33 unscheduled hospitalizations 28 56 patients cardiovascular events 0 009 odds ratio 3 0 confidence intervals 1 4 6 3,C3640893|G0000000|C0302523|C0450371|C0450371|C0030705|C0439175|C0450371|C1699701|C0019993|C0450371|C1699701|C0019993|C0450371|C0450371|C0030705|C0007226|C0441471|G0000000|C1442061|G0000000|C0456603|G0000000|G0000000|C0237529|C1272706|G0000000|G0000000|G0000000|G0000000
In group B there was no significant change in lipid levels during the study.,change lipid levels study,C0392747|C0023779|C0441889|C0557651
"Minimal lumen diameter in group A increased by 0.05 ?? 0.20 mm after 6 months and 0.13 ?? 0.29 mm after 24 months, whereas it decreased by 0.08 ?? 0.20 mm and 0.18 ?? 0.27 mm, respectively, in group B (p a????a?? 0.004 at 6 months and p <0.001 at 24 months).",minimal lumen diameter increased 0 05 0 20 mm 6 months 0 13 0 29 mm 24 months decreased 0 08 0 20 mm 0 18 0 27 mm 0 004 6 months <0 001 24 months,C0547040|C0524461|C1301886|C0205217|G0000000|C0450371|G0000000|C0450371|G0000000|G0000000|C0439231|G0000000|C0450371|G0000000|C0450371|G0000000|C0450371|C0439231|C0205216|G0000000|C0450371|G0000000|C0450371|G0000000|G0000000|C0450371|G0000000|C0450371|G0000000|G0000000|C1442061|G0000000|C0439231|G0000000|C1442061|C0450371|C0439231
"Total cholesterol was significantly reduced in the intensive therapy group by an average of 20% and LDL cholesterol by 28% (p ??0.001) over the whole study period, whereas in group B, both values remained close to baseline during the whole study.",total cholesterol reduced intensive therapy average 20% ldl cholesterol 28% 0 001 study period values remained close baseline study,C0439175|C0008377|C0392756|C0162425|C0039798|C1510992|C0450371|G0000000|C0008377|C0450371|G0000000|C1442061|C0557651|C0439531|C0042295|G0000000|C0587267|C0168634|C0557651
"We conclude that pravastatin-based therapy initiated immediately after an acute coronary syndrome is well tolerated and safe, lessens coronary atherosclero-sis, and has a pronounced clinical benefit.",conclude pravastatin-based therapy initiated acute coronary syndrome tolerated safe lessens coronary atherosclero-sis pronounced clinical benefit,C0917903|C0085542|C0039798|C1548602|C0205178|C0018787|C0039082|G0000000|G0000000|G0000000|C0018787|C1704647|G0000000|C0205210|C0814225
"Triglycerides, HDL-cholesterol, and Lp(a) levels remained unchanged in both groups (Table 2).",triglycerides hdl-cholesterol lp levels remained unchanged table 2,C0041004|C0023822|C0037943|C0441889|G0000000|C0442739|C0039224|G0000000
"After 24 months, a complete series of 3 evaluable angiograms (at start, and at follow-up after 6 and 24 months) could be measured for 31 of 51 patients in group A (with a total of 77 non-angioplasty stenoses) and in 27 of 46 patients in group B (with a total of 72 stenoses).",24 months complete series 3 evaluable angiograms start follow-up 6 24 months measured 31 51 patients total 77 non-angioplasty stenoses 27 46 patients total 72 stenoses,C0450371|C0439231|C0205197|C0205549|G0000000|C1516986|C0002978|C0439659|C0589120|G0000000|C0450371|C0439231|C0444706|C0450371|C0450371|C0030705|C0439175|C0450371|C1518422|C1261287|C0450371|C0450371|C0030705|C0439175|C0450371|C1261287
"Patients ??75 years old, diabetics (fasting blood glucose ??125 mg/dl), patients with postcoro-nary artery bypass graft, known malignant disease, serious kidney or liver dysfunction (creatimine ??1.5 mg/dl, alanine aminotransferase and aspartate amino-transferase ??2 times normal value), or women of child-bearing age not using a reliable form of contra",patients 75 diabetics fasting blood glucose 125 mg/dl patients postcoro-nary artery bypass graft malignant disease kidney liver dysfunction creatimine 1 5 mg/dl alanine aminotransferase aspartate amino-transferase 2 times normal women child-bearing age reliable form contra,C0030705|C0450371|C0241863|C0015663|C0005767|C0017725|C1442061|C0439269|C0030705|G0000000|C0003842|C0741847|C0181074|C0205282|C0012634|C0022646|C0023884|C0031847|G0000000|G0000000|G0000000|C0439269|C0001898|C0002594|C0085845|C0040676|G0000000|C0040223|C0205307|C0043210|C0008059|C0001779|C3858758|C0348078|G0000000
METHODS Patients and therapy: Patients with total cholesterol of ??200 to ??400 mg/dl and low-density lipoprotein (LDL) cholesterol of ??130 to ??300 mg/dl (after exclusion of secondary forms of hyperlipidemia) with an acute myocardial infarction (defined by new Q waves and increase of enzymes of ??3-fold the normal value) and/or who underwent emergency percutane-ous transluminal coronary balloon angioplasty due to severe or unstable angina pectoris (defined by clinical symptoms and electrocardiographic [ECG] alterations during rest and/or exercise) were included in this study.,methods patients therapy patients total cholesterol 200 400 mg/dl low-density lipoprotein ldl cholesterol 130 300 mg/dl exclusion secondary forms hyperlipidemia acute myocardial infarction defined waves increase enzymes 3-fold normal and/or underwent emergency percutane-ous transluminal coronary balloon angioplasty severe unstable angina pectoris defined clinical symptoms electrocardiographic ecg alterations rest and/or exercise included study,C0025663|C0030705|C0039798|C0030705|C0439175|C0008377|C1442061|C1442061|C0439269|C0205251|C0023820|G0000000|C0008377|C1442061|C1442061|C0439269|C0680251|C0027627|C0348078|C0020473|C0205178|C0027061|C0021308|C1704788|C0678544|C0442805|C0014442|C0332462|C0205307|G0000000|G0000000|C0013956|G0000000|C0522520|C0018787|C0336867|C0162577|C0205082|C0443343|C0002962|G0000000|C1704788|C0205210|C0683368|C0013798|C1623258|C1515926|C0035253|G0000000|C0015259|C0332257|C0557651
This calculation was performed under the expectation of a smaller difference in cholesterol levels between the groups than observed and was derived from studies using much less sensitive methods for quantification of angiograms.,calculation performed expectation difference cholesterol levels observed derived studies sensitive methods quantification angiograms,C1441506|C0884358|C0679138|C1705241|C0008377|C0441889|C1441672|C1441547|C0947630|C0020517|C0025663|C1709793|C0002978
"In group B, there were comparable angiograms for 38 of 51 patients with a total of 113 measurable non-angioplasty stenoses.",comparable angiograms 38 51 patients total 113 measurable non-angioplasty stenoses,G0000000|C0002978|C0450371|C0450371|C0030705|C0439175|C1442061|C1513040|C1518422|C1261287
The occurrence and the extent of increases in MLD with iintensive therapy (Tx) (A) are higher than with standard care (B).,occurrence extent increases mld iintensive therapy tx standard care,C0243132|C0439792|C0205217|C0023522|G0000000|C0039798|C0041403|C1442989|C1947933
Quantitative coronary angiography by automatic contour detection of the repeated twofold magnified coronary segment was performed by a geometric edge differentiation technique and a minimal cost algorithm.,quantitative coronary angiography automatic contour detection repeated twofold magnified coronary segment performed geometric edge differentiation technique minimal cost algorithm,C0392762|C0018787|C0002978|C0205554|C0302821|C1511790|C0205341|G0000000|G0000000|C0018787|C0441635|C0884358|C0449829|C0205154|C0007589|C0449851|C0547040|C0010186|C0002045
All but 2 interventions in 2 patients in group A were due to clinical angina pectoris and/or a positive stress test.,2 interventions 2 patients clinical angina pectoris and/or positive stress test,G0000000|C0886296|G0000000|C0030705|C0205210|C0002962|G0000000|G0000000|C0439178|C0038435|C0022885
"In group B, there were increases by ??0.3 mm in 7 of 72 stenoses and decreases by ??0.3 mm in 20 of 72 stenoses (p ??0.001) (Figure 2).",increases 0 3 mm 7 72 stenoses decreases 0 3 mm 20 72 stenoses 0 001 figure 2,C0205217|G0000000|G0000000|G0000000|G0000000|C0450371|C1261287|C0442797|G0000000|G0000000|G0000000|C0450371|C0450371|C1261287|G0000000|C1442061|G0000000|G0000000
Another patient died from primary ventricular fibrillation before taking the first dose of pravastatin.,patient died primary ventricular fibrillation dose pravastatin,C0030705|C0011065|C0205225|C0018827|C0232197|C0178602|C0085542
"There were 27 coronary interventions in 24 of 56 patients in group B (3 coronary bypass grafts, 21 had coronary angioplasty).",27 coronary interventions 24 56 patients 3 coronary bypass grafts 21 coronary angioplasty,C0450371|C0018787|C0886296|C0450371|C0450371|C0030705|G0000000|C0018787|C0741847|C0332835|C0450371|C0018787|C0162577
For There were no differences in baseline values between the groups.,differences baseline values,C1705241|C0168634|C0042295
"Even under the ""worst-case assumption"" that none of the 9 patients had had a severe adverse cardiovascular event, the result would still be significant (p ??0.02, odds ratio 0.4, confidence intervals 0.2 to 0.8) in favor of intensive therapy.",worst-case assumption 9 patients severe adverse cardiovascular event result 0 02 odds ratio 0 4 confidence intervals 0 2 0 8 favor intensive therapy,C1522166|G0000000|G0000000|C0030705|C0205082|G0000000|C0007226|C0441471|C1274040|G0000000|C0450371|G0000000|C0456603|G0000000|G0000000|C0237529|C1272706|G0000000|G0000000|G0000000|G0000000|C0309049|C0162425|C0039798
"In addition, some patients refused to agree to control angiography (1 of group A and 2 patients of group B after 6 months and 7 patients of group A and 8 patients of group B after 24 months, respectively).",addition patients refused agree control angiography 1 2 patients 6 months 7 patients 8 patients 24 months,C0332287|C0030705|C1548564|C3641827|C0243148|C0002978|G0000000|G0000000|C0030705|G0000000|C0439231|G0000000|C0030705|G0000000|C0030705|C0450371|C0439231
"The minimal lumen diameter increased with continued intensive treatment by 0.13 ?? 0.29 mm in group A, whereas in group B it decreased further by 0.18 ?? 0.27 mm from baseline values (p ??0.001).",minimal lumen diameter increased continued intensive treatment 0 13 0 29 mm decreased 0 18 0 27 mm baseline values 0 001,C0547040|C0524461|C1301886|C0205217|C0549178|C0162425|C0039798|G0000000|C0450371|G0000000|C0450371|G0000000|C0205216|G0000000|C0450371|G0000000|C0450371|G0000000|C0168634|C0042295|G0000000|C1442061
"After 2 years, 29 patients of 56 patients in group B, but only 16 of 70 patients in group A, experienced a clinical end point (p a????a?? 0.005; odds ratio 0.28, confidence intervals 0.13 to 0.6).",2 29 patients 56 patients 16 70 patients experienced clinical 0 005 odds ratio 0 28 confidence intervals 0 13 0 6,G0000000|C0450371|C0030705|C0450371|C0030705|C0450371|C0450371|C0030705|C0237607|C0205210|G0000000|C1442061|G0000000|C0456603|G0000000|C0450371|C0237529|C1272706|G0000000|C0450371|G0000000|G0000000
"In group B, only 13 of 56 patients received any antilipidemic medication, but only for a short time and with inadequate effects.",13 56 patients received antilipidemic medication short time inadequate effects,C0450371|C0450371|C0030705|C1514756|G0000000|C0013227|C1282927|C0040223|C0205412|C1280500
"In our study, patients were randomized, on average, 6 days after an acute myocardial infarction and/or per-cutaneous transluminal coronary angioplasty secondary to unstable angina, to pravastatin (combined, when necessary , with cholestyramine and/or nicotinic acid) to achieve low-density lipoprotein cholesterol levels of <130 mg/dl (group A, n a????a?? 70).",study patients randomized average 6 days acute myocardial infarction and/or per-cutaneous transluminal coronary angioplasty secondary unstable angina pravastatin combined cholestyramine and/or nicotinic acid achieve low-density lipoprotein cholesterol levels <130 mg/dl 70,C0557651|C0030705|C0034656|C1510992|G0000000|C0439228|C0205178|C0027061|C0021308|G0000000|C3887962|C0522520|C0018787|C0162577|C0027627|C0443343|C0002962|C0085542|C0205195|C0008402|G0000000|C0028040|C0001128|G0000000|C0205251|C0023820|C0008377|C0441889|C1442061|C0439269|C0450371
Baseline characteristics in both groups were well matched (Table 1).,baseline characteristics matched table 1,C0168634|C1521970|C0150103|C0039224|G0000000
"Thus, an investigator bias with respect to interventions can be excluded.",investigator bias respect interventions excluded,C0035173|C0242568|C0679133|C0886296|C1554077
"Thus, a selection bias cannot be totally excluded, even if the risk profile between the groups was equally distributed.",selection bias totally excluded risk profile equally distributed,C0036576|C0242568|G0000000|C1554077|C0035647|C1979963|G0000000|C1704711
All patients signed an informed consent form.,patients signed informed consent form,C0030705|C1519316|C1522154|C1511481|C0348078
Randomization was stratified for gender and reason for inclusion (infarction and/or coronary angioplasty).,randomization stratified gender reason inclusion infarction and/or coronary angioplasty,C0034656|C0205363|C0079399|C0392360|C0007637|C0021308|G0000000|C0018787|C0162577
After 6 months the minimal lumen diameter increased by 0.05 ?? 0.20 mm in group A and decreased by 0.08 ?? 0.20 mm in group B (p ?- 0.004).,6 months minimal lumen diameter increased 0 05 0 20 mm decreased 0 08 0 20 mm 0 004,G0000000|C0439231|C0547040|C0524461|C1301886|C0205217|G0000000|C0450371|G0000000|C0450371|G0000000|C0205216|G0000000|C0450371|G0000000|C0450371|G0000000|G0000000|C1442061
Antilipidemic therapy was determined by the family physician in the control group because placebo treatment was considered unethical when the study was initiated.,antilipidemic therapy determined family physician control placebo treatment considered unethical study initiated,G0000000|C0039798|G0000000|C0015576|C0031831|C0243148|C0032042|C0039798|C0750591|G0000000|C0557651|C1548602
"There are limitations to our study: most notably due to ethical considerations, it was an open study.",limitations study notably ethical considerations study,C0449295|C0557651|G0000000|C0026531|C0518609|C0557651
"The objectives of this prospective open-label, randomized, single center study were to compare the effects of cholesterol lowering therapy initiated immediately after an event with the effects of usual outpatient treatment on the course of coronary atherosclerosis and clinical outcome.",objectives prospective open-label randomized single center study compare effects cholesterol lowering therapy initiated event effects usual outpatient treatment coronary atherosclerosis clinical outcome,C0018017|C0023981|C1709323|C0034656|C0037179|C0205099|C0557651|C1707455|C1280500|C0008377|C0441994|C0039798|C1548602|C0441471|C1280500|C3538928|C0029921|C0039798|C0018787|C0003850|C0205210|C1274040
"In a multivariate stepwise regression analysis that included age (??65 and ??65 years), gender, history of infarction, hypertension, smoking status, reason for inclusion, and therapy (group A or B), only group A treatment was significant for clinical outcome (p ?- 0.006; odds ratio 3.0, confidence intervals 1.4 to 6.5).",multivariate stepwise regression analysis included age 65 65 gender history infarction hypertension smoking status reason inclusion therapy treatment clinical outcome 0 006 odds ratio 3 0 confidence intervals 1 4 6 5,G0000000|G0000000|C0684320|C0002778|C0332257|C0001779|C0450371|C0450371|C0079399|C0019664|C0021308|C0020538|C0037369|C0449438|C0392360|C0007637|C0039798|C0039798|C0205210|C1274040|G0000000|C1442061|G0000000|C0456603|G0000000|G0000000|C0237529|C1272706|G0000000|G0000000|G0000000|G0000000
"A further limitation is the small number of evaluable follow-up angiograms, partially due to poor film quality.",limitation evaluable follow-up angiograms partially poor film quality,C0449295|C1516986|C0589120|C0002978|G0000000|C0032854|C0086296|C0332306
Secondary prevention of coronary heart disease by an-tilipidemic therapy beginning at >3 months after an acute coronary syndrome is well documented.,secondary prevention coronary heart disease an-tilipidemic therapy 3 months acute coronary syndrome documented,C0027627|C0199176|C0018787|C0018787|C0012634|G0000000|C0039798|G0000000|C0439231|C0205178|C0018787|C0039082|C1301725
"In controls (group B, n a????a?? 56), antilipidemic therapy was determined by family physicians.",controls 56 antilipidemic therapy determined family physicians,C0243148|C0450371|G0000000|C0039798|G0000000|C0015576|C0031831
Lipid values were provided to the family physicians without recommendations.,lipid values provided family physicians recommendations,C0023779|C0042295|C1999230|C0015576|C0031831|C0034866
The other patients did not tolerate the combination therapy because of side effects from cholestyramine or nicotinic acid.,patients tolerate combination therapy effects cholestyramine nicotinic acid,C0030705|G0000000|C0205195|C0039798|C1280500|C0008402|C0028040|C0001128
"A selection bias with respect to angiography, however, seems to be improbable, because the proportion of patients within a valuable series of angiograms was comparable in both groups at 6 months and at 24 months.",selection bias respect angiography improbable proportion patients valuable series angiograms comparable 6 months 24 months,C0036576|C0242568|C0679133|C0002978|C1546986|C1709707|C0030705|G0000000|C0205549|C0002978|G0000000|G0000000|C0439231|C0450371|C0439231
"Only 13 patients in group B received any antilipidemic drugs: 8 were on statin therapy, and 5 patients were on miscellaneous medications but also not for more than a few months.",13 patients received antilipidemic drugs 8 statin therapy 5 patients miscellaneous medications months,C0450371|C0030705|C1514756|G0000000|C0013227|G0000000|C0360714|C0039798|G0000000|C0030705|C0205395|C0013227|C0439231
"In group A, there were 12 coronary interventions in 11 of 70 patients, including 1 coronary bypass grafting.",12 coronary interventions 11 70 patients including 1 coronary bypass grafting,C0450371|C0018787|C0886296|C0450371|C0450371|C0030705|C0332257|G0000000|C0018787|C0741847|C0332835
By request we know from the Bureau of Vital Statistics that these 9 patients were alive at the end of the 2-year investigational period.,request bureau vital statistics 9 patients alive 2-year investigational period,C1272683|G0000000|C0442732|C0038215|G0000000|C0030705|C0376558|C0439234|C1517586|C0439531
"In Group A, in 23 of 77 stenoses, the lumen diameter increased, and in 6 of 77 stenoses it decreased.",23 77 stenoses lumen diameter increased 6 77 stenoses decreased,C0450371|C0450371|C1261287|C0524461|C1301886|C0205217|G0000000|C0450371|C1261287|C0205216
Kaplan-Meier curves for major cardiovascular events.,kaplan-meier curves major cardiovascular events,G0000000|C0205134|C0205082|C0007226|C0441471
econdary prevention studies have shown that treatment with 3-hydroxymethyl-3-glutaryl coenzyme A reductase inhibitors may prevent recurrent coronary events by reducing elevated cholesterol levels.,econdary prevention studies treatment 3-hydroxymethyl-3-glutaryl coenzyme reductase inhibitors prevent recurrent coronary events reducing elevated cholesterol levels,G0000000|C0199176|C0947630|C0039798|G0000000|C0009235|C0030016|C0243077|C0309872|C2945760|C0018787|C0441471|C0392756|C0205250|C0008377|C0441889
Patients with an acute infarction were included only if their lipids could be determined within 8 hours after onset of symptoms; those in the balloon angioplasty group with a history of infarction were included only when the infarction was ??3 months earlier.,patients acute infarction included lipids determined 8 hours onset symptoms balloon angioplasty history infarction included infarction 3 months earlier,C0030705|C0205178|C0021308|C0332257|C0023779|G0000000|G0000000|C0439227|C0206132|C0683368|C0336867|C0162577|C0019664|C0021308|C0332257|C0021308|G0000000|C0439231|C1279919
"Two patients of group B had primary ventricular fibrillation, but had successful out-of-hospital resuscitation.",patients primary ventricular fibrillation successful out-of-hospital resuscitation,C0030705|C0205225|C0018827|C0232197|C0597535|C3844314|C0035273
"In each group, 1 patient developed a new peripheral arterial occlusion and 1 suffered an ischemic stroke.",1 patient developed peripheral arterial occlusion 1 suffered ischemic stroke,G0000000|C0030705|G0000000|C0205100|C0003842|C0011382|G0000000|C0683278|C0475224|C0038454
"The evaluation, however, of angiographic data were perfomed in a blinded manner, as were the decisions for intervention during the study.",evaluation angiographic data perfomed blinded manner decisions intervention study,C0220825|C0002978|C1511726|G0000000|C0150108|G0000000|C0679006|C0886296|C0557651
All women requiring induction of labour at or beyond term (37-42 weeks of gestation) were assessed for entry into the study.,women requiring induction labour term 37-42 weeks gestation assessed entry study,C0043210|G0000000|C0205263|C0022864|C0233324|C0450371|C0439230|C0032961|C1516048|C1705654|C0557651
"The median number of doses was also signi??cantly less in the vaginal misoprostol group, 1 (range 1-3), compared with the oral group, 2 (range 1-8), (P , 0.0001).",median doses signicantly vaginal misoprostol 1 range 1-3 compared oral 2 range 1-8 0 0001,C0549183|C0178602|G0000000|C0042232|C0085174|G0000000|C1514721|G0000000|C1707455|C0442027|G0000000|C1514721|G0000000|G0000000|G0000000
"There were more caesarean sections in the vaginal misoprostol group, but the difference was not statistically signi??cant.",caesarean sections vaginal misoprostol difference statistically signicant,C3841297|C0152060|C0042232|C0085174|C1705241|C0038215|G0000000
These ??nd-ings concur with those of others 14?16 .,nd-ings concur 1416,G0000000|G0000000|G0000000
A sample size of 148 (74 women in each group) was calculated using a two-tailed alpha of 0.05 and a power of 95%.,sample size 148 74 women calculated two-tailed alpha 0 05 power 95%,C0370003|C0456389|C1442061|C0450371|C0043210|C0444686|C0205448|C0439095|G0000000|C0450371|C0032863|C0450371
"Although this ??nding is worrisome, it is important to point out that only one infant in the vaginal group required intubation (for heavy meconium), and that according to ACOG criteria, none of the infants in either group was asphyxiated.",nding worrisome infant vaginal required intubation heavy meconium acog criteria infants asphyxiated,G0000000|G0000000|C0021270|C0042232|C1514873|C0021925|C0439539|C0025047|C1515938|C0243161|C0021270|G0000000
"Some of q RCOG 2001 Br J Obstet Gynaecol 108, pp.",rcog 2001 br obstet gynaecol 108,G0000000|G0000000|C1704648|G0000000|G0000000|C1442061
"Vaginal misoprostol recipients required signi??cantly less oxytocin augmentation [50.0% vs 78.2%; P ?? 0.0004, RR ?? 0.57 (0.43-0.76)].",vaginal misoprostol recipients required signicantly oxytocin augmentation 50 0% 78 2% 0 0004 rr 0 57 0 43-0 76,C0042232|C0085174|C1709854|C1514873|G0000000|C0030095|C1293122|C0450371|G0000000|C0450371|G0000000|G0000000|G0000000|G0000000|G0000000|C0450371|G0000000|C0450371|C0450371
Tachysystole was identi??ed in seven women in the oral group and in six women in the vaginal group.,tachysystole identied women oral women vaginal,C2985339|G0000000|C0043210|C0442027|C0043210|C0042232
"After informed consent was obtained, the women were assigned to an induction method by opening the next sequentially numbered opaque envelope.",informed consent women assigned induction method sequentially numbered opaque envelope,C1522154|C1511481|C0043210|C1516050|C0205263|C0025663|G0000000|C0449788|C0029053|C1622204
This study shows that women who receive misoprostol vaginally require less dosing and experience faster induction-to-delivery times with less need for oxytocin augmentation when compared with a similar group of women receiving oral misoprostol.,study women receive misoprostol vaginally require dosing experience faster induction-to-delivery times oxytocin augmentation compared women receiving oral misoprostol,C0557651|C0043210|C1514756|C0085174|G0000000|G0000000|G0000000|C0237607|C0015663|C0205263|C0040223|C0030095|C1293122|C1707455|C0043210|C1514756|C0442027|C0085174
"A higher proportion of infants in the vaginal group required positive pressure ventilation, compared with the oral group (three infants in the oral group vs 13 infants in the vaginal group; P ?? 0.01, RR ?? 1.70 (1.27-2.27)), however, there was only one infant in the vaginal group who required intubation for heavy meconium.",proportion infants vaginal required positive pressure ventilation compared oral infants oral 13 infants vaginal 0 01 rr 1 70 1 27-2 27 infant vaginal required intubation heavy meconium,C1709707|C0021270|C0042232|C1514873|C0439178|C0033095|C0035203|C1707455|C0442027|C0021270|C0442027|C0450371|C0021270|C0042232|G0000000|C0450371|G0000000|G0000000|C0450371|G0000000|C0450371|C0450371|C0021270|C0042232|C1514873|C0021925|C0439539|C0025047
"This randomised trial addresses the impact of route of delivery of misoprostol on inductionto-delivery time, caesarean section rates, and neonatal outcomes.",randomised trial addresses impact route delivery misoprostol inductionto-delivery time caesarean rates neonatal outcomes,G0000000|C0008976|C0376649|C1825598|C0013153|C0011209|C0085174|C0011209|C0040223|C3841297|C0871208|C1552240|C1274040
"In contrast to dinoprostone, misoprostol is a stable compound that does not require refrigeration.",contrast dinoprostone misoprostol stable compound require refrigeration,C0009924|C0012472|C0085174|C0205360|C0205198|G0000000|C0034957
; tachysystole (contraction pattern of more than six contractions in ten minutes) 22 ;,tachysystole contraction pattern contractions ten minutes 22,C2985339|C1140999|C0449774|C1140999|C0014518|C0439232|C0450371
Other outcome measures included caesarean delivery; hypertonus (prolonged uterine contraction lasting more than two minutes) hyperstimulation (hypertonus or tachysystole in the context of an abnormal fetal heart rate tracing requiring intervention) 22 ; and failed induction (cervix unfavourable for amniotomy after 48 hours or eight doses of misoprostol).,outcome measures included caesarean delivery hypertonus prolonged uterine contraction lasting minutes hyperstimulation hypertonus tachysystole context abnormal fetal heart rate tracing requiring intervention 22 failed induction cervix unfavourable amniotomy 48 hours doses misoprostol,C1274040|C0079809|C0332257|C3841297|C0011209|C0026826|C0439590|C0042149|C1140999|C1517741|C0439232|G0000000|C0026826|C2985339|C0449255|C0205161|C0015965|C0018787|C0871208|G0000000|G0000000|C0886296|C0450371|C0231175|C0205263|C0007874|C3640815|G0000000|C0450371|C0439227|C0178602|C0085174
It is interesting to note that hypertonus or tachysystole was not noted in any of these ??ve cases.,note hypertonus tachysystole ve,C1316572|C0026826|C2985339|C0042469
Categorical variables were compared using Fisher's exact test for small sample sizes and x 2 test for large sample sizes.,categorical variables compared fishers exact test sample sizes 2 test sample sizes,C0683312|C0439828|C1707455|C0325045|C2828393|C0022885|C0370003|C0456389|G0000000|C0022885|C0370003|C0456389
"After randomisation, seven women were identi??ed as being ineligible, based on the stated exclusion criteria.",randomisation women identied ineligible based stated exclusion criteria,C0034656|C0043210|G0000000|C1512714|C1527178|C1301808|C0680251|C0243161
Further studies are required to substantiate these observations.,studies required substantiate observations,C0947630|C1514873|G0000000|C0302523
From July 1997 to May 1998 a total of 167 women provided consent to participate in the trial and were randomised into two groups: one group to receive misoprostol orally and the other group to receive misoprostol vaginally.,july 1997 1998 total 167 women provided consent participate trial randomised receive misoprostol orally receive misoprostol vaginally,C3829447|G0000000|G0000000|C0439175|C1442061|C0043210|C1999230|C1511481|G0000000|C0008976|G0000000|C1514756|C0085174|C0442027|C1514756|C0085174|G0000000
The study was designed as a prospective randomised trial.,study designed prospective randomised trial,C0557651|C1707689|C0023981|G0000000|C0008976
"Misoprostol, a prostaglandin E 1 analogue, is indicated for protection against gastric ulcers, but administered prenatally causes uterine contractions.",misoprostol prostaglandin 1 analogue protection gastric ulcers administered prenatally uterine contractions,C0085174|C0033554|G0000000|C0243071|C1545588|C0038351|C0041582|C1521801|G0000000|C0042149|C1140999
There is only one woman who had a non-reassuring fetal heart tracing prior to the onset of labour (after the second dose of vaginal misoprostol).,woman non-reassuring fetal heart tracing prior onset labour dose vaginal misoprostol,C0043210|C1518422|C0015965|C0018787|G0000000|C0332152|C0206132|C0022864|C0178602|C0042232|C0085174
This infant required no investigations other than for hyperbilirubinemia and had no further admissions to hospital.,infant required investigations hyperbilirubinemia admissions hospital,C0021270|C1514873|C1261322|C0020433|C0184666|C0019994
Many women in our centre have indicated a preference for an oral medication for this purpose.,women centre preference oral medication purpose,C0043210|C0205099|C0558295|C0442027|C0013227|C1285529
"Labour induction at term commonly involves a combination of cervical ripening with dinoprostone (a prostaglandin E 2 analogue administered vaginally or intracervically), amniotomy, and intravenous oxytocin.",labour induction term commonly involves combination cervical ripening dinoprostone prostaglandin 2 analogue administered vaginally intracervically amniotomy intravenous oxytocin,C0022864|C0205263|C0233324|G0000000|G0000000|C0205195|C0027530|C1160534|C0012472|C0033554|G0000000|C0243071|C1521801|G0000000|G0000000|G0000000|C0348016|C0030095
The results of this study suggest that vaginal misoprostol is associated with shorter induction-to-delivery times than oral misoprostol.,study vaginal misoprostol shorter induction-to-delivery times oral misoprostol,C0557651|C0042232|C0085174|C1282927|C0205263|C0040223|C0442027|C0085174
"In contrast, ??ve women in the vaginal group required emergency section for non-reassuring fetal heart rate tracings, but these were not in association with tachysystole or hypertonus.",contrast ve women vaginal required emergency non-reassuring fetal heart rate tracings association tachysystole hypertonus,C0009924|C0042469|C0043210|C0042232|C1514873|C0013956|C1518422|C0015965|C0018787|C0871208|G0000000|C0004083|C2985339|C0026826
Maternal and neonatal demographic data are presented in Table 1.,maternal neonatal demographic data table 1,C2347083|C1552240|C0011298|C1511726|C0039224|G0000000
"The study was reviewed and approved by the Research Ethics Board of Queen's University, Kingston, Ontario, Canada.",study reviewed approved ethics board queens university kingston ontario canada,C0557651|C0282443|C0205540|C0015000|C0972401|G0000000|C0041740|G0000000|C0029040|C0006823
Resuscitation was de??ned as the need for positive pressure ventilation or intubation.,resuscitation dened positive pressure ventilation intubation,C0035273|G0000000|C0439178|C0033095|C0035203|C0021925
The primary outcome measure was the interval from start of induction (administration of ??rst dose) to delivery.,primary outcome measure interval start induction administration rst dose delivery,C0205225|C1274040|C0079809|C1272706|C0439659|C0205263|C0001554|C1425219|C0178602|C0011209
Data concerning their method of induction and outcomes were not collected.,data method induction outcomes collected,C1511726|C0025663|C0205263|C1274040|C1516695
"Recently, a few studies have demonstrated the ef??cacy of oral misoprostol for cervical ripening, comparable with that of vaginal misoprostol 14?18",studies demonstrated efcacy oral misoprostol cervical ripening comparable vaginal misoprostol 1418,C0947630|G0000000|G0000000|C0442027|C0085174|C0027530|C1160534|G0000000|C0042232|C0085174|G0000000
The main outcome measure was induction to delivery time.,main outcome measure induction delivery time,C0205225|C1274040|C0079809|C0205263|C0011209|C0040223
No one in either group was identi??ed as having hypertonus.,identied hypertonus,G0000000|C0026826
"Research exploiting this adverse effect has shown misoprostol to be superior to conventional methods for induction, resulting in shorter inductionto-delivery intervals, without any increase in adverse outcomes 2?11,13 .",exploiting adverse misoprostol superior conventional methods induction shorter inductionto-delivery intervals increase adverse outcomes 211 13,G0000000|G0000000|C0085174|C1282910|C0439858|C0025663|C0205263|C1282927|C0011209|C1272706|C0442805|G0000000|C1274040|C1442061|C0450371
NS ?? not statistically signi??cant (P $ 0.05).,ns statistically signicant 0 05,C0038944|C0038215|G0000000|G0000000|C0450371
These envelopes were prepared by the study pharmacist using random number tables with randomisation in blocks of four.,envelopes prepared study pharmacist random tables randomisation blocks,C1622204|C4082130|C0557651|C0031323|C0034656|C0039224|C0034656|C0028778
Design Randomised trial.,design randomised trial,C1707689|G0000000|C0008976
A 300-minute (5-hour) difference in induction-to-delivery time between the two groups was considered clinically signi??cant.,300-minute 5-hour difference induction-to-delivery time considered clinically signicant,C1442061|C0439227|C1705241|C0205263|C0040223|C0750591|G0000000|G0000000
Normally distributed continuous variables were compared using the Student's t test and non-Gaussian continuous variables were compared using the MannWhitney U test.,distributed continuous variables compared students test non-gaussian continuous variables compared mannwhitney test,C1704711|C0549178|C0439828|C1707455|C0038492|C0022885|C1518422|C0549178|C0439828|C1707455|G0000000|C0022885
Induction to delivery time was eight hours faster in women who received misoprostol vaginally.,induction delivery time hours faster women received misoprostol vaginally,C0205263|C0011209|C0040223|C0439227|C0015663|C0043210|C1514756|C0085174|G0000000
Future investigations are required to determine optimum dosing and the need for hospital admission.,future investigations required determine optimum dosing hospital admission,C0016884|C1261322|C1514873|G0000000|C2698651|G0000000|C0019994|C0184666
"At $0.15 (Canadian dollars) per dose, misoprostol is signi??cantly cheaper than dinoprostone, $40 per dose.",0 15 canadian dollars dose misoprostol signicantly cheaper dinoprostone 40 dose,G0000000|C0450371|C0238884|C0562019|C0178602|C0085174|G0000000|G0000000|C0012472|C0450371|C0178602
22,22,C0450371
The bene??ts of vaginal misoprostol held true when nulliparous and multiparous women were analysed separately.,benets vaginal misoprostol held true nulliparous multiparous women analysed separately,G0000000|C0042232|C0085174|C0675390|C0205238|C0425979|C0026751|C0043210|G0000000|G0000000
The indications for emergency caesarean section for ??ve women in the vaginal misoprostol group included non-reassuring fetal heart tracings such as the presence of late decelerations or prolonged bradycardia.,indications emergency caesarean ve women vaginal misoprostol included non-reassuring fetal heart tracings presence late decelerations prolonged bradycardia,C0392360|C0013956|C3841297|C0042469|C0043210|C0042232|C0085174|C0332257|C1518422|C0015965|C0018787|G0000000|C0150312|C0205087|C0011100|C0439590|C0428977
This study does not have the power to detect a difference in fetal outcomes even if such difference exists.,study power detect difference fetal outcomes difference exists,C0557651|C0032863|C0442726|C1705241|C0015965|C1274040|C1705241|C2987476
1?13,113,C1442061
Maternal and neonatal demographic data.,maternal neonatal demographic data,C2347083|C1552240|C0011298|C1511726
"It appears that although vaginal misoprostol may be superior to oral misoprostol by effecting faster delivery, at least two studies have identi??ed a higher rate of uterine hyperstimulation and non-reassuring fetal heart rate tracings with vaginal misoprostol 15,16 .",appears vaginal misoprostol superior oral misoprostol effecting faster delivery studies identied rate uterine hyperstimulation non-reassuring fetal heart rate tracings vaginal misoprostol 15 16,C0700364|C0042232|C0085174|C1282910|C0442027|C0085174|C1280500|C0015663|C0011209|C0947630|G0000000|C0871208|C0042149|G0000000|C1518422|C0015965|C0018787|C0871208|G0000000|C0042232|C0085174|C0450371|C0450371
"After a maximum of eight doses of misoprostol, another method was to be used (intracervical Foley catheter or intracervical dinoprostone gel) if the cervix failed to become favourable for amniotomy, or if spontaneous rupture of membranes or active labour did not occur.",maximum doses misoprostol method intracervical foley catheter intracervical dinoprostone gel cervix failed favourable amniotomy spontaneous rupture membranes active labour occur,C0806909|C0178602|C0085174|C0025663|C0444978|G0000000|C0085590|C0444978|C0012472|C0017243|C0007874|C0231175|C3640814|G0000000|C0205359|C1881712|C0025255|C0205177|C0022864|C1709305
Neonatal outcome measures included infant Apgar scores; umbilical cord blood gases; the need for neonatal resuscitation; and neonatal asphyxia.,neonatal outcome measures included infant apgar scores umbilical cord blood gases neonatal resuscitation neonatal asphyxia,C1552240|C1274040|C0079809|C0332257|C0021270|C0741195|C0449820|C0041638|C1550235|C0005767|C0017110|C1552240|C0035273|C1552240|C0004044
"There were no signi??cant differences between the two groups with respect to birth asphyxia, mean umbilical cord artery and vein pH or buffer base.",signicant differences respect birth asphyxia umbilical cord artery vein ph buffer base,G0000000|C1705241|C0679133|C0005615|C0004044|C0041638|C1550235|C0003842|C0042449|C0450407|C0006353|C0002055
"Although no statistically signi??cant differences were identi??ed between the two routes with respect to non-reassuring fetal heart rate tracings, caesarean deliveries, and neonatal resuscitation, there was a trend toward higher rates in the vaginal misoprostol group.",statistically signicant differences identied routes respect non-reassuring fetal heart rate tracings caesarean deliveries neonatal resuscitation trend rates vaginal misoprostol,C0038215|G0000000|C1705241|G0000000|C0449444|C0679133|C1518422|C0015965|C0018787|C0871208|G0000000|C3841297|C0011209|C1552240|C0035273|C1521798|C0871208|C0042232|C0085174
The signi??cant differences in outcome held true when nulliparous and multiparous women were analysed separately.,signicant differences outcome held true nulliparous multiparous women analysed separately,G0000000|C1705241|C1274040|C0675390|C0205238|C0425979|C0026751|C0043210|G0000000|G0000000
"There was a signi??cantly higher number of infants in the vaginal misoprostol group with 1 minute Apgar scores ,7.",signicantly infants vaginal misoprostol 1 minute apgar scores 7,G0000000|C0021270|C0042232|C0085174|G0000000|C0439232|C0741195|C0449820|G0000000
Only a few randomised controlled trials have compared oral and vaginal misoprostol for induction of labour at term 14? 18 .,randomised controlled trials compared oral vaginal misoprostol induction labour term 14 18,G0000000|C2587213|C0008976|C1707455|C0442027|C0042232|C0085174|C0205263|C0022864|C0233324|C0450371|C0450371
There were no differences between the two routes of administration with respect to rates of hyperstimulation or neonatal asphyxia.,differences routes administration respect rates hyperstimulation neonatal asphyxia,C1705241|C0449444|C0001554|C0679133|C0871208|G0000000|C1552240|C0004044
Women randomised to oral misoprostol also underwent vaginal examinations prior to each dose.,women randomised oral misoprostol underwent vaginal examinations prior dose,C0043210|G0000000|C0442027|C0085174|G0000000|C0042232|C0031809|C0332152|C0178602
"The study participants, attending staff and residents were unaware of the blocked randomisation and group assignment was concealed until the envelope was opened.",study participants attending staff residents unaware blocked randomisation assignment concealed envelope,C0557651|C0679646|C1547429|C0851286|C1320928|C0150114|C0028778|C0034656|C1516050|C0443189|C1622204
"Several recent studies have demonstrated that misoprostol, when administered vaginally, is also effective for induction of labour To date, several studies have shown vaginal misoprostol to be as effective, or even more effective, than traditional methods of cervical ripening and induction of labour using dinoprostone and oxytocin 2?13 .",studies demonstrated misoprostol administered vaginally effective induction labour studies vaginal misoprostol effective effective traditional methods cervical ripening induction labour dinoprostone oxytocin 213,C0947630|G0000000|C0085174|C1521801|G0000000|C1280519|C0205263|C0022864|C0947630|C0042232|C0085174|C1280519|C1280519|C0443324|C0025663|C0027530|C1160534|C0205263|C0022864|C0012472|C0030095|C1442061
"However, the cervix was considered favourable for amniotomy if the cervix was .2 cm dilated with .50% effacement, soft, and mid-toanterior position.",cervix considered favourable amniotomy cervix 2 cm dilated 50% effacement soft mid-toanterior position,C0007874|C0750591|C3640814|G0000000|C0007874|G0000000|G0000000|C0700124|C0450371|C0552443|C0205358|C0444598|C0733755
"The patient was then transferred from the antepartum ward to labour and delivery, and all decisions with respect to amniotomy and/or oxytocin augmentation were made by the resident or attending staff.",patient transferred antepartum ward labour delivery decisions respect amniotomy and/or oxytocin augmentation resident attending staff,C0030705|C0348011|C0456336|C1305702|C0022864|C0011209|C0679006|C0679133|G0000000|G0000000|C0030095|C1293122|C1320928|C1547429|C0851286
The second infant had a cord artery pH of 7.0 and buffer base of 31.5.,infant cord artery ph 7 0 buffer base 31 5,C0021270|C1550235|C0003842|C0450407|G0000000|G0000000|C0006353|C0002055|C0450371|G0000000
A standard deviation of 506 minutes was derived from a previous publication describing vaginal misoprostol for induction of labour 9 .,standard deviation 506 minutes derived previous publication describing vaginal misoprostol induction labour 9,C1442989|C0012727|C1442061|C0439232|C1441547|C0205156|C0034036|G0000000|C0042232|C0085174|C0205263|C0022864|G0000000
There was no signi??cant difference between the two groups with respect to secondary induction outcomes as presented in Table 3.,signicant difference respect secondary induction outcomes table 3,G0000000|C1705241|C0679133|C0027627|C0205263|C1274040|C0039224|G0000000
Setting Tertiary Care hospital.,setting tertiary care hospital,C0542559|C0205372|C1947933|C0019994
"None of the women reported adverse effects such as diarrhea, nausea or vomiting during the induction process.",women reported adverse effects diarrhea nausea vomiting induction process,C0043210|C0684224|G0000000|C1280500|C0011991|C0027497|C0042963|C0205263|C1184743
"In the oral group, seven cord artery and four vein samples were unavailable, and in the vaginal group, ??ve cord artery and two vein samples were unavailable.",oral cord artery vein samples unavailable vaginal ve cord artery vein samples unavailable,C0442027|C1550235|C0003842|C0042449|C0370003|C0686905|C0042232|C0042469|C1550235|C0003842|C0042449|C0370003|C0686905
"No data are available for women excluded from entry to this study, and caution is advised when extrapolating these data to patients with a previous uterine scar, oligohydramnios, or intrauterine growth restriction.",data women excluded entry study caution advised extrapolating data patients previous uterine scar oligohydramnios intrauterine growth restriction,C1511726|C0043210|C1554077|C1705654|C0557651|G0000000|G0000000|G0000000|C1511726|C0030705|C0205156|C0042149|C0241158|C0079924|C0694756|C0018270|C0443288
"One-and ??ve-minute Apgar scores were 5 and 10, respectively.",one-and ve-minute apgar scores 5 10,C0205447|C0042469|C0741195|C0449820|G0000000|C0450371
Larger studies are required to adequately address the risk of caesarean section.,larger studies required adequately address risk caesarean,C0549177|C0947630|C1514873|G0000000|C0376649|C0035647|C3841297
The use of an oral medication for cervical ripening is appealing.,oral medication cervical ripening appealing,C0442027|C0013227|C0027530|C1160534|C0680651
"Neonatal asphyxia has been de??ned by the American College of Obstetricians and Gynaecologists (ACOG) as the presence of severe acidosis, umbilical cord artery pH ,7.00, with a ??ve-minute Apgar score 0-3, and neonatal neurologic sequelae 23 .",neonatal asphyxia dened american college obstetricians gynaecologists acog presence severe acidosis umbilical cord artery ph 7 00 ve-minute apgar score 0-3 neonatal neurologic sequelae 23,C1552240|C0004044|G0000000|C0596070|C0557806|C0334897|C0237419|C1515938|C0150312|C0205082|C0001122|C0041638|C1550235|C0003842|C0450407|G0000000|C0450371|C0042469|C0741195|C0449820|G0000000|C1552240|C0205494|C0243088|C0450371
None of the women in the oral group required emergency caesarean section.,women oral required emergency caesarean,C0043210|C0442027|C1514873|C0013956|C3841297
Data are presented as mean [SD] or n (%).,data sd %,C1511726|C2699239|G0000000
"Statistical signi??cance was assigned to P values ,0.05.",statistical signicance assigned values 0 05,C0038215|G0000000|C1516050|C0042295|G0000000|C0450371
Neonatal outcomes are presented in  Table 1.,neonatal outcomes table 1,C1552240|C1274040|C0039224|G0000000
This infant also required positive pressure ventilation at delivery and was admitted under paediatrics (not in the neonatal intensive care unit) for two days postpartum but had no clinical sequelae of asphyxia.,infant required positive pressure ventilation delivery admitted paediatrics neonatal intensive care unit days postpartum clinical sequelae asphyxia,C0021270|C1514873|C0439178|C0033095|C0035203|C0011209|C0184666|C0030755|C1552240|C0162425|C1947933|C0439148|C0439228|C0086839|C0205210|C0243088|C0004044
She required no investigations and at the time of writing has had no further admissions to hospital.,required investigations time writing admissions hospital,C1514873|C1261322|C0040223|C0043266|C0184666|C0019994
"There is increasing evidence that misoprostol, administered either vaginally or orally, is as effective as conventional methods for induction of labour at term 2?14 .",increasing evidence misoprostol administered vaginally orally effective conventional methods induction labour term 214,C0442808|C3887511|C0085174|C1521801|G0000000|C0442027|C1280519|C0439858|C0025663|C0205263|C0022864|C0233324|C1442061
"A higher rate of non-reassuring fetal heart tracings and uterine hyperstimulation associated with vaginal misoprostol compared with oral misoprostol has been reported 15,16 .",rate non-reassuring fetal heart tracings uterine hyperstimulation vaginal misoprostol compared oral misoprostol reported 15 16,C0871208|C1518422|C0015965|C0018787|G0000000|C0042149|G0000000|C0042232|C0085174|C1707455|C0442027|C0085174|C0684224|C0450371|C0450371
"Other indications for induction included maternal discomfort, maternal super??cial thrombophlebitis, and predicted macrosomia based on estimated fetal weight.",indications induction included maternal discomfort maternal supercial thrombophlebitis predicted macrosomia based estimated fetal weight,C0392360|C0205263|C0332257|C2347083|C0231218|C2347083|G0000000|C0040046|C0681842|C0158915|C1527178|C0750572|C0015965|C0005910
The neonatal outcomes in this study warrant discussion.,neonatal outcomes study warrant discussion,C1552240|C1274040|C0557651|G0000000|C0557061
"This infant required positive pressure ventilation at delivery  and was admitted under her family physician for two days postpartum, but she had no clinical sequelae of asphyxia.",infant required positive pressure ventilation delivery admitted family physician days postpartum clinical sequelae asphyxia,C0021270|C1514873|C0439178|C0033095|C0035203|C0011209|C0184666|C0015576|C0031831|C0439228|C0086839|C0205210|C0243088|C0004044
There was no difference between oral and vaginal misoprostol with respect to 5-minute Apgar scores.,difference oral vaginal misoprostol respect 5-minute apgar scores,C1705241|C0442027|C0042232|C0085174|C0679133|C0439232|C0741195|C0449820
"There were two infants in the vaginal group and none in the oral group with an umbilical cord artery pH ,7.0.",infants vaginal oral umbilical cord artery ph 7 0,C0021270|C0042232|C0442027|C0041638|C1550235|C0003842|C0450407|G0000000|G0000000
"In the vaginal group, the ??rst infant had a cord artery pH of 6.97 and buffer base of 29.1.",vaginal rst infant cord artery ph 6 97 buffer base 29 1,C0042232|C1425219|C0021270|C1550235|C0003842|C0450407|G0000000|C0450371|C0006353|C0002055|C0450371|G0000000
Active labour was de??ned as cervical dilatation of $3 cm associated with repetitive uterine contractions 21 .,active labour dened cervical dilatation 3 cm repetitive uterine contractions 21,C0205177|C0022864|G0000000|C0027530|C0012359|G0000000|G0000000|G0000000|C0042149|C1140999|C0450371
"However, there were signi??cantly more infants in the vaginal group with one-minute Apgar scores less than 7 (9 infants in the oral group compared with 21 infants in the vaginal group, P ?? 0.03).",signicantly infants vaginal one-minute apgar scores 7 9 infants oral compared 21 infants vaginal 0 03,G0000000|C0021270|C0042232|C0205447|C0741195|C0449820|G0000000|G0000000|C0021270|C0442027|C1707455|C0450371|C0021270|C0042232|G0000000|C0450371
Participants One hundred and sixty-seven women requiring induction of labour.,participants sixty-seven women requiring induction labour,C0679646|C3816724|C0043210|G0000000|C0205263|C0022864
These women were excluded before receiving misoprostol for labour induction.,women excluded receiving misoprostol labour induction,C0043210|C1554077|C1514756|C0085174|C0022864|C0205263
All 160 women eligible for the trial received the medication by the route they were assigned and none of them withdrew from the study.,160 women eligible trial received medication route assigned withdrew study,C1442061|C0043210|C1548635|C0008976|C1514756|C0013227|C0013153|C1516050|C2349954|C0557651
Primary induction outcome results are presented in Table 2.,primary induction outcome table 2,C0205225|C0205263|C1274040|C0039224|G0000000
Secondary outcome measures included effects of the medication on uterine activity (e.g.,secondary outcome measures included effects medication uterine activity,C0027627|C1274040|C0079809|C0332257|C1280500|C0013227|C0042149|C0205177
Bishop's pre-labour scoring system was not used to determine if the cervix was favourable for amniotomy as it is not standard practice to use this system in our centre because of the subjectivity of scoring.,bishops pre-labour scoring system determine cervix favourable amniotomy standard practice system centre subjectivity scoring,C0649610|C0332152|C0449820|C0449913|G0000000|C0007874|C3640814|G0000000|C1442989|C0237607|C0449913|C0205099|C0439655|C0449820
Student's t test was used for comparison of normally distributed continuous variables and the Mann-Whitney U test was used for non-Gaussian distributed continuous variables.,students test comparison distributed continuous variables mann-whitney test non-gaussian distributed continuous variables,C0038492|C0022885|C1707455|C1704711|C0549178|C0439828|G0000000|C0022885|C1518422|C1704711|C0549178|C0439828
"One-and ??ve-minute Apgar scores were 1 and 5, respectively.",one-and ve-minute apgar scores 1 5,C0205447|C0042469|C0741195|C0449820|G0000000|G0000000
All inductions were carried out on an inpatient basis.,inductions carried inpatient basis,C0857127|C0206243|C0021562|C1527178
"There were 13 infants (15.9%) from the vaginal group, compared with three infants (3.8%) in the oral group who needed resuscitation in the form of positive pressure ventilation.",13 infants 15 9% vaginal compared infants 3 8% oral resuscitation form positive pressure ventilation,C0450371|C0021270|C0450371|G0000000|C0042232|C1707455|C0021270|G0000000|G0000000|C0442027|C0035273|C0348078|C0439178|C0033095|C0035203
Women received 50 mg of misoprostol orally or vaginally every six hours until one of the following outcomes had occurred: cervix favourable for amniotomy (cervix dilated .,women received 50 misoprostol orally vaginally hours outcomes occurred cervix favourable amniotomy cervix dilated,C0043210|C1514756|C0450371|C0085174|C0442027|G0000000|C0439227|C1274040|C1709305|C0007874|C3640814|G0000000|C0007874|C0700124
Fisher's exact and x 2 tests were used for comparison of categorical variables.,fishers exact 2 tests comparison categorical variables,C0325045|C2828393|G0000000|C0022885|C1707455|C0683312|C0439828
"Despite the efficacy of misoprostol, in common with other prostaglandins, tachysystole, tonic contractions and hyperstimulation syndrome are complications that cause concern.",efficacy misoprostol common prostaglandins tachysystole tonic contractions hyperstimulation syndrome complications concern,C1280519|C0085174|C0205214|C0033554|C2985339|C3543842|C1140999|G0000000|C0039082|C0009566|C2699424
This analysis found the incidence of tachysystole to be dose related.,analysis incidence tachysystole dose,C0002778|C0021149|C2985339|C0178602
It was assumed it would be clinically relevant if we could half this figure.,assumed clinically relevant half figure,C3242379|G0000000|C2347946|C2825407|G0000000
The endpoint studied was the proportion of patients undelivered 12 h after receiving misoprostol or placebo.,endpoint studied proportion patients undelivered 12 receiving misoprostol placebo,C2349179|C0557651|C1709707|C0030705|G0000000|C0450371|C1514756|C0085174|C0032042
In 60??80% it w x will occur after 37 weeks of gestation 1 .,6080% occur 37 weeks gestation 1,G0000000|C1709305|C0450371|C0439230|C0032961|G0000000
"The proportion of undelivered patients within 12 h of treatment was significantly reduced in the ?? misoprostol group, with a p-value -0.0001 see .",proportion undelivered patients 12 treatment reduced misoprostol p-value -0 0001,C1709707|G0000000|C0030705|C0450371|C0039798|C0392756|C0085174|C1709380|G0000000|G0000000
"However, a vaginal approach may be better avoided: the use of intravenous oxytocin alone for IOL in the presence of PROM has been shown to be associated with a significant reduction in maternal febrile morbidity when compared to vaginal prostaglandin.",vaginal approach avoided intravenous oxytocin iol presence prom reduction maternal febrile morbidity compared vaginal prostaglandin,C0042232|C0449445|G0000000|C0348016|C0030095|C0281658|C0150312|C0015944|C0301630|C2347083|C0015967|C0026538|C1707455|C0042232|C0033554
Women who were more than 37 weeks preg-( )nant were eligible if the leakage of liquor in the absence of labor was confirmed with a positive nitrazine or ferning test on sterile speculum examination.,women 37 weeks preg- nant eligible leakage liquor absence labor confirmed positive nitrazine ferning test sterile speculum examination,C0043210|C0450371|C0439230|G0000000|G0000000|C1548635|C0015376|C0002638|C0332197|C0022864|C0521093|C0439178|G0000000|C0334212|C0022885|C0021359|C0037816|G0000000
Further research should also examine a 4-h instead of a 6-h dosage interval keeping in mind that the serum concentration of oral misoprostol falls steeply after 2 h.,examine 4-h 6-h dosage interval keeping mind serum concentration oral misoprostol falls steeply 2,G0000000|C0033727|C0033727|C0178602|C1272706|C0333118|C0229992|C0229671|C0004268|C0442027|C0085174|C0000921|G0000000|G0000000
The null hypothesis was rejected.,null hypothesis rejected,C0456148|C1512571|C1548437
There were no statistically significant differences in the occurrence of major CTG abnormali-?? ties three patients in the misoprostol group and .,statistically differences occurrence major ctg abnormali- ties patients misoprostol,C0038215|C1705241|C0243132|C0205082|G0000000|G0000000|C0453920|C0030705|C0085174
Misoprostol is a synthetic prostaglandin El analogue currently registered as a protector of the gastric mucosa.,misoprostol synthetic prostaglandin el analogue registered protector gastric mucosa,C0085174|C1883254|C0033554|C1416870|C0243071|C1514821|C1709739|C0038351|C0026724
"Major CTG abnormalities were defined as late and variable decelerations, baseline tachycardia ) 160 beats per minute with decelerations or reduced variability of -5 beats per minute around the baseline, or a persistent bradycardia of -105 beats per minute.",major ctg abnormalities defined late variable decelerations baseline tachycardia 160 beats minute decelerations reduced variability -5 beats minute baseline persistent bradycardia -105 beats minute,C0205082|G0000000|C0000768|C1704788|C0205087|C0439828|C0011100|C0168634|C0039231|C1442061|G0000000|C0439232|C0011100|C0392756|C2827666|G0000000|G0000000|C0439232|C0168634|C0205322|C0428977|C1442061|G0000000|C0439232
Induction of labor in the presence of an unfavorable cervix may result in a more painful labor w x 4 .,induction labor presence unfavorable cervix result painful labor 4,C0205263|C0022864|C0150312|C3640815|C0007874|C1274040|C0030193|C0022864|G0000000
"If labor did not occur within 12 h of entering the study, further management took place at the discretion of resident staff according to standard protocols.",labor occur 12 entering study management discretion resident staff standard protocols,C0022864|C1709305|C0450371|C1522196|C0557651|C0001554|G0000000|C1320928|C0851286|C1442989|C0442711
The baby had 1-and 5-min apgar scores of 9 and 10.,baby 1-and 5-min apgar scores 9 10,C0021270|G0000000|C0702093|C0741195|C0449820|G0000000|C0450371
No adverse effects on mother or baby could be observed.,adverse effects mother baby observed,G0000000|C1280500|C0026591|C0021270|C1441672
Vaginal Misoprostol reaches the peak plasma concentration between 1 and 2 h and then the levels decline slowly and w x unpredictably 17 .,vaginal misoprostol reaches peak plasma concentration 1 2 levels decline slowly unpredictably 17,C0042232|C0085174|C0596012|C0444505|C0032105|C0004268|G0000000|G0000000|C0441889|G0000000|C0439834|G0000000|C0450371
No adverse effects could be demonstrated.,adverse effects demonstrated,G0000000|C1280500|G0000000
Written consent was obtained from all participants.,written consent participants,C0043266|C1511481|C0679646
Other outcomes,outcomes,C1274040
The reasons for exclusion were as follows.,reasons exclusion,C0392360|C0680251
Approval for this study was obtained from the University of Cape Town Ethics and Research Committee.,approval study university cape town ethics committee,C0205540|C0557651|C0041740|C0453952|C0557750|C0015000|C2699414
In the misoprostol groups 33 patients 70% ?? .,misoprostol 33 patients 70%,C0085174|C0450371|C0030705|C0450371
A lower dose might be preferable for parous patients.,lower dose preferable parous patients,C0441994|C0178602|G0000000|G0000000|C0030705
This patient did not receive hexoprenaline but had an emergency cesarean section for fetal distress.,patient receive hexoprenaline emergency cesarean fetal distress,C0030705|C1514756|C0019476|C0013956|C3841297|C0015965|C0231303
"In cases of hyperstimulation syndrome 10 a??m of hexoprenalin was mandatory, as well as fetal blood sampling and further appropriate management or emergency cesarean section.",hyperstimulation syndrome 10 hexoprenalin mandatory fetal blood sampling management emergency cesarean,G0000000|C0039082|C0450371|G0000000|C1514873|C0015965|C0005767|C0441621|C0001554|C0013956|C3841297
The main complication of PROM at term is maternal and neonatal infection.,main complication prom term maternal neonatal infection,C0205225|C0009566|C0015944|C0233324|C2347083|C1552240|C0009450
Misoprostol group: one ?? patient was below the age of consent she did not .,misoprostol patient age consent,C0085174|C0030705|C0001779|C1511481
There was no statistically significant difference in ?? .,statistically difference,C0038215|C1705241
Ngai w x et al.,ngai al,G0000000|C0202311
It has been shown to ripen the cervix and induce labor in a number of studies w x since 1992 7??15 .,ripen cervix induce labor studies 1992 715,C1160534|C0007874|C0205263|C0022864|C0947630|G0000000|C1442061
"Although the overall bioavailability of misoprostol is approximately three times less when administered orally compared to the vaginal route, it's biophysical profile may be more favorable, when the oral route is chosen: peak plasma concentrations are achieved within 1 h, fall steeply after 2 h and remain low.",bioavailability misoprostol times administered orally compared vaginal route biophysical profile favorable oral route chosen peak plasma concentrations achieved 1 fall steeply 2 remain low,C0005508|C0085174|C0040223|C1521801|C0442027|C1707455|C0042232|C0013153|C0005553|C1979963|C3640814|C0442027|C0013153|C1707391|C0444505|C0032105|C0086045|G0000000|G0000000|C0085639|G0000000|G0000000|G0000000|C0205251
Fifteen ?? .,fifteen,C3715153
Grand Multipara and patients with antepartum hemorrhage were also excluded from recruitment.,grand multipara patients antepartum hemorrhage excluded recruitment,G0000000|G0000000|C0030705|C0456336|C0019080|C1554077|C2949735
Of those patients one had to undergo a cesarean section for fetal distress.,patients undergo cesarean fetal distress,C0030705|G0000000|C3841297|C0015965|C0231303
The ranges for the medication-delivery intervals are wide in both groups.,ranges medication-delivery intervals wide,C1514721|C0013227|C1272706|C0332464
The monitoring used was identical to routine clinical use in patients undergoing IOL.,monitoring identical routine clinical patients undergoing iol,C0150369|C0205280|C0205547|C0205210|C0030705|G0000000|C0281658
No statistically significant difference was noted in the numbers or indications for cesarean sec-?? .,statistically difference indications cesarean sec-,C0038215|C1705241|C0392360|C3841297|G0000000
Over 60% of patients with prelabor rupture of mem-?? .,60% patients prelabor rupture mem-,C0450371|C0030705|G0000000|C1881712|G0000000
"Although it did not reach statistical significance, there were fewer than half the number of cesarean sections in the misoprostol group: 7.7% vs. 16% in the placebo group.",reach statistical significance fewer half cesarean sections misoprostol 7 7% 16% placebo,C2584321|C0038215|C0237881|C0205388|C2825407|C3841297|C0152060|C0085174|G0000000|G0000000|C0450371|C0032042
There were no significant differences between ?? .,differences,C1705241
"It must be seen in the context of an economically exhausted hospital budget, were beds and time are precious.",context economically exhausted hospital budget beds time precious,C0449255|C0013556|C0392674|C0019994|C0006347|C0004916|C0040223|G0000000
"As a consequence 13% of the patients in the misoprostol group were delivered within 2 h, which is consistent with the diagnosis of precipitate labor.",consequence 13% patients misoprostol delivered 2 consistent diagnosis precipitate labor,C0686907|C0450371|C0030705|C0085174|C1705822|G0000000|C0332290|C0011900|C1882443|C0022864
The null hypothesis was: in PROM patients the proportion of women undelivered after 12 h is no ?? different when treated with oral misoprostol two .,null hypothesis prom patients proportion women undelivered 12 treated oral misoprostol,C0456148|C1512571|C0015944|C0030705|C1709707|C0043210|G0000000|C0450371|C1522326|C0442027|C0085174
PROM to delivery interval in minutes see Fig.,prom delivery interval minutes fig,C0015944|C0011209|C1272706|C0439232|C0349966
"With regard to the mode of delivery there has been no advantage demonstrated for either prostaglandins, oxytocin or expectant managew x ment in the setting of PROM 5 .",regard mode delivery advantage demonstrated prostaglandins oxytocin expectant managew ment setting prom 5,G0000000|C1513371|C0011209|G0000000|G0000000|C0033554|C0030095|C0679138|G0000000|C1538994|C0542559|C0015944|G0000000
The hospital stay in the misoprostol group was significantly shorter.,hospital stay misoprostol shorter,C0019994|G0000000|C0085174|C1282927
"Patients were excluded from the study if they had a scarred uterus, multiple pregnancy, nonvertex presentation, symptoms and signs of chorioamnionitis, severe gestational proteinuric hyper-?? tension or, underlying medical conditions cardiac .",patients excluded study scarred uterus multiple pregnancy nonvertex presentation symptoms signs chorioamnionitis severe gestational proteinuric hyper- tension underlying medical conditions cardiac,C0030705|C1554077|C0557651|C0008767|C0042149|C0439064|C0032961|G0000000|C0449450|C0683368|C0220912|C0008495|C0205082|C0439671|G0000000|C0424295|C0233494|G0000000|C0199168|C0012634|C0018787
"The statistical analysis was performed applying the Student t-test, the Mann??Whitney U-test and the Chi-square test where appropriate.",statistical analysis performed applying student t-test mannwhitney u-test chi-square test,C0038215|C0002778|C0884358|C1632850|C0038492|C0871472|G0000000|C0022885|C1552646|C0022885
"One case of hyperstimulation syndrome was reported in the misoprostol group, this was also the only patient who developed tachysystole in both groups.",hyperstimulation syndrome reported misoprostol patient developed tachysystole,G0000000|C0039082|C0684224|C0085174|C0030705|G0000000|C2985339
"A non-significant tendency towards decreased use of intravenous antibiotics could be observed in the misoprostol group, though it is not clear if ?? antibiotics were used therapeutically for develop-.",non-significant tendency decreased intravenous antibiotics observed misoprostol antibiotics therapeutically develop-,C1518422|G0000000|C0205216|C0348016|C0003232|C1441672|C0085174|C0003232|G0000000|G0000000
Placebo group: one patient had unconfirmed rupture of membranes and two folders were unobtainable.,placebo patient unconfirmed rupture membranes folders unobtainable,C0032042|C0030705|C1547326|C1881712|C0025255|C1555709|G0000000
The cervical status was not assessed.,cervical status assessed,C0027530|C0449438|C1516048
The trial was discontinued after the interim analysis.,trial discontinued interim analysis,C0008976|C1444662|C2827738|C0002778
The taste of the two preparations was different.,taste preparations,C0039336|C1521827
"The risk of being undelivered 24 and 48 h after PROM was significantly less in patients treated with misoprostol, the P-values are 0.038 and 0.0002.",risk undelivered 24 48 prom patients treated misoprostol p-values 0 038 0 0002,C0035647|G0000000|C0450371|C0450371|C0015944|C0030705|C1522326|C0085174|C1709380|G0000000|C1442061|G0000000|G0000000
"By analyzing the data of more patients further information about the safety of misoprostol could have been collected, but to assess the incidence of a relatively rare complication, far more patients are required.",analyzing data patients safety misoprostol collected assess incidence rare complication patients required,G0000000|C1511726|C0030705|C0036043|C0085174|C1516695|C1516048|C0021149|C0521114|C0009566|C0030705|C1514873
There was no difference in the incidence of ?? postpartum hemorrhage more than 500 ml blood .,difference incidence postpartum hemorrhage 500 blood,C1705241|C0021149|C0086839|C0019080|C1442061|C0005767
Different views exist regarding the timing and the method of induction of ?? .,views exist timing method induction,C0449911|C2987476|C0449243|C0025663|C0205263
"The data collection sheets were reviewed by the principal investigator, who was not involved in patient management.",data collection sheets reviewed principal investigator involved patient management,C1511726|C1516698|C0439643|C0282443|C0205225|C0035173|C1314939|C0030705|C0001554
"Chorioamnionitis after PROM is clinically diagnosed in approximately 10% of patients after 4 days of conservative management, w x compared to 1% among controls 2,3 .",chorioamnionitis prom clinically diagnosed 10% patients 4 days conservative management compared 1% controls 2 3,C0008495|C0015944|G0000000|C0011900|C0450371|C0030705|G0000000|C0439228|G0000000|C0001554|C1707455|G0000000|C0243148|G0000000|G0000000
The incidence of tachysystole in this study was 2%.,incidence tachysystole study 2%,C0021149|C2985339|C0557651|G0000000
"It is also necessary to evaluate the efficacy of a smaller dose, which might decrease the incidence of precipitate labor, especially in relation to the parity of the woman.",evaluate efficacy dose decrease incidence precipitate labor relation parity woman,C0220825|C1280519|C0178602|C0392756|C0021149|C1882443|C0022864|C0080103|C0030563|C0043210
This study was not designed to exclude possible harmful effects on the baby as a result of rapid labor.,study designed exclude harmful effects baby result rapid labor,C0557651|C1707689|C0332196|G0000000|C1280500|C0021270|C1274040|C0456962|C0022864
"This is much lower than that reported in w x similar studies 14,15 .",lower reported studies 14 15,C0441994|C0684224|C0947630|C0450371|C0450371
There were no reports of fetal blood sampling or amnioinfusion.,reports fetal blood sampling amnioinfusion,C0684224|C0015965|C0005767|C0441621|C0262671
The meta-analysis also showed a significantly decreased cesarian section rate in the misoprostol group compared to other methods of induction ?? .,meta-analysis decreased cesarian rate misoprostol compared methods induction,C0282458|C0205216|C3841297|C0871208|C0085174|C1707455|C0025663|C0205263
In the placebo group ?? only one patient was delivered within 2 h she had .,placebo patient delivered 2,C0032042|C0030705|C1705822|G0000000
Cesarean section for failed IOL was usually performed if the patient was not in active labor 12 h after the first vaginal prostaglandin application.,cesarean failed iol performed patient active labor 12 vaginal prostaglandin application,C3841297|C0231175|C0281658|C0884358|C0030705|C0205177|C0022864|C0450371|C0042232|C0033554|C0185125
Recruitment took place from July 1997 to June 1998.,recruitment july 1997 june 1998,C2949735|C3829447|G0000000|C3829443|G0000000
"This protocol consisted of two doses of 1 mg prostaglandin E2 vaginal gel applied to the posterior vaginal fornix, 6 h apart, followed by intravenous oxytocin if the progress of labor was not adequate.",protocol consisted doses 1 prostaglandin e2 vaginal gel applied posterior vaginal fornix 6 intravenous oxytocin progress labor adequate,C0442711|C0332529|C0178602|G0000000|C0033554|C1704625|C0042232|C0017243|C4048755|C0205095|C0042232|C0152334|G0000000|C0348016|C0030095|C1272688|C0022864|C0205410
The cost of treatment is also relevant to the choice of method of IOL.,cost treatment relevant choice method iol,C0010186|C0039798|C2347946|C0008300|C0025663|C0281658
"A problem with misoprostol, as with other oxytocics, is that its action cannot be predicted.",misoprostol oxytocics action predicted,C0085174|C0030094|C0441472|C0681842
"However definite statements about the safety can only be made when much larger numbers of patients are recruited, taking into account the relatively uncommon occurrence of adverse effects.",definite statements safety larger patients recruited account uncommon occurrence adverse effects,C0439544|C1710187|C0036043|C0549177|C0030705|G0000000|C2741673|C0522498|C0243132|G0000000|C1280500
PROM to medication see Table 2 .,prom medication table 2,C0015944|C0013227|C0039224|G0000000
Patients ?? .,patients,C0030705
"Consequently, also the PROM to delivery in-?? .",prom delivery in-,C0015944|C0011209|G0000000
Intravenous access was avoided.,intravenous access avoided,C0348016|C0444454|G0000000
Prompt IOL avoids w x expensive prolonged hospitalization 6 .,prompt iol avoids expensive prolonged hospitalization 6,C0871157|C0281658|G0000000|C0680864|C0439590|C0019993|G0000000
"There was no difference in the reported incidence of nausea or elevated temperature during the first 12 h after entering the trial or patient acceptabil-?? ity at discharge the patients were asked to qualify their experience as positive, acceptable or .",difference reported incidence nausea elevated temperature 12 entering trial patient acceptabil- ity discharge patients qualify experience positive acceptable,C1705241|C0684224|C0021149|C0027497|C0205250|C0005903|C0450371|C1522196|C0008976|C0030705|G0000000|G0000000|C0012621|C0030705|G0000000|C0237607|C0439178|C1879533
Patient acceptability was not adequately tested and may form the basis for further study.,patient acceptability adequately tested form basis study,C0030705|C0814633|G0000000|C0392366|C0348078|C1527178|C0557651
"Previous studies were mainly based on the vaginal application, which results in a much higher bioavailability, as well as a longer and more irregular half-life.",previous studies based vaginal application bioavailability irregular half-life,C0205156|C0947630|C1527178|C0042232|C0185125|C0005508|C0205271|C0018517
Randomisation occurred by using computer generated numbers.,randomisation occurred computer generated,C0034656|C1709305|C0009622|C3146294
This correlates well w x with the findings of Sanchez-Ramos 16 who found an overall decrease in the cesarean section ?? .,correlates findings sanchez-ramos 16 decrease cesarean,G0000000|C2607943|G0000000|C0450371|C0392756|C3841297
Statistical significance was defined as a P-value less than 0.05.,statistical significance defined p-value 0 05,C0038215|C0237881|C1704788|C1709380|G0000000|C0450371
The incidence of neonatal infection with PROM is 2??4% but the use of antibiotics is more ?? .,incidence neonatal infection prom 24% antibiotics,C0021149|C1552240|C0009450|C0015944|C0450371|C0003232
Other data were also recorded as listed in Section 3.,data recorded listed 3,C1511726|C0034869|C0745732|G0000000
"The treatment to delivery interval was signifi-?? cantly reduced, the median time being 7.5 h 445 .",treatment delivery interval signifi- cantly reduced median time 7 5 445,C0039798|C0011209|C1272706|G0000000|G0000000|C0392756|C0549183|C0040223|G0000000|G0000000|C1442061
A normal non-stress cardiotocograph ?? .,normal non-stress cardiotocograph,C0205307|C1518422|C0179625
None of the studies describing tachysystole showed adverse neonatal outcomes.,studies describing tachysystole adverse neonatal outcomes,C0947630|G0000000|C2985339|G0000000|C1552240|C1274040
For these neonates no adverse effects could be demonstrated.,neonates adverse effects demonstrated,C0021289|G0000000|C1280500|G0000000
Sanches-Ramos et al.,sanches-ramos al,G0000000|C0202311
A Medline electronic database search prior to July 1998 showed only two studies using misoprostol specifically for IOL in PROM.,medline electronic database search prior july 1998 studies misoprostol iol prom,C0025141|C0013850|C0242356|C1552603|C0332152|C3829447|G0000000|C0947630|C0085174|C0281658|C0015944
Parous patients may be predisposed to precipitate labor; it was an unproven clinical observation that these women were more sensitive to misoprostol and this merits further study.,parous patients predisposed precipitate labor unproven clinical observation women sensitive misoprostol merits study,G0000000|C0030705|C0231203|C1882443|C0022864|C0456370|C0205210|C0302523|C0043210|C0020517|C0085174|G0000000|C0557651
These findings are consistent with other studies which show that early induc-?? .,findings consistent studies induc-,C2607943|C0332290|C0947630|G0000000
CTG test was also required.,ctg test required,G0000000|C0022885|C1514873
The randomization code was ?? .,randomization code,C0034656|C0009219
There was no statistically significant difference in the proportion of patients delivered ?? .,statistically difference proportion patients delivered,C0038215|C1705241|C1709707|C0030705|C1705822
This decision was justified by a large and significant difference in the main outcome already before the estimated number of patients had been reached.,decision justified difference main outcome estimated patients reached,C0679006|C1552821|C1705241|C0205225|C1274040|C0750572|C0030705|C2584321
For the odds ratio with confidence intervals of the preceding data please refer to Fig.,odds ratio confidence intervals preceding data refer fig,G0000000|C0456603|C0237529|C1272706|C0332152|C1511726|C0205543|C0349966
"To avoid these complications, labor is usually induced once PROM is confirmed.",avoid complications labor induced prom confirmed,G0000000|C0009566|C0022864|C0205263|C0015944|C0521093
With the alpha set at 5% 91 patients were required in each arm of the study to have 80% power to detect the specified difference.,alpha set 5% 91 patients required arm study 80% power detect difference,C0439095|C0036849|G0000000|C0450371|C0030705|C1514873|C0446516|C0557651|C0450371|C0032863|C0442726|C1705241
"The doses varied widely from 100 to 25 a??g, either as a single dose or at 2??6-h intervals.",doses varied 100 25 single dose 26-h intervals,C0178602|G0000000|C1442061|C0450371|C0037179|C0178602|C0450371|C1272706
Only the pharmacist was aware which group contained the active medication.,pharmacist aware contained active medication,C0031323|C0004448|C0332256|C0205177|C0013227
The sample size was based on the assumption that approximately 40% of women would be undelivered after 24 h of PROM.,sample size based assumption 40% women undelivered 24 prom,C0370003|C0456389|C1527178|G0000000|C0450371|C0043210|G0000000|C0450371|C0015944
Seven patients were excluded.,patients excluded,C0030705|C1554077
Misoprostol costs approximately 1% of the commercially available vaginal prostaglandin preparations and is stable at room temperature.,misoprostol costs 1% commercially vaginal prostaglandin preparations stable temperature,C0085174|C0010186|G0000000|G0000000|C0042232|C0033554|C1521827|C0205360|C0005903
The data were analyzed after exclusion of these seven cases.,data analyzed exclusion,C1511726|C0936012|C0680251
The patients drew consecutively numbered opaque envelopes containing either two 100-a??g ?? .,patients drew consecutively numbered opaque envelopes 100-g,C0030705|G0000000|G0000000|C0449788|C0029053|C1622204|C1442061
"This study was a randomized placebo controlled trial carried out at a secondary referral hospital in Cape Town, South Africa.",study randomized placebo controlled trial carried secondary referral hospital cape town south africa,C0557651|C0034656|C0032042|C2587213|C0008976|C0206243|C0027627|C0034927|C0019994|C0453952|C0557750|C1710133|C0001737
The vaginal route has been most comw x monly used 7??11 .,vaginal route comw monly 711,C0042232|C0013153|G0000000|G0000000|C1442061
Patients in active labor had vaginal examinations performed regularly and further management took place according to standard labor ward policies.,patients active labor vaginal examinations performed regularly management standard labor ward policies,C0030705|C0205177|C0022864|C0042232|C0031809|C0884358|G0000000|C0001554|C1442989|C0022864|C1305702|C0242456
The level of expression of HER2 was determined by immunohistochemical analysis in a central laboratory.,level expression her2 determined immunohistochemical analysis central laboratory,C0441889|C0185117|G0000000|G0000000|C1441616|C0002778|C0205099|C0022877
"Of the 235 patients who received trastuzumab, 216 (92 percent) received at least 80 percent of the planned infusions and fewer than 5 percent required a delay in treatment or a reduction in doses of the chemotherapy.",235 patients received trastuzumab 216 92 percent received 80 percent planned infusions fewer 5 percent required delay treatment reduction doses chemotherapy,C1442061|C0030705|C1514756|C0728747|C1442061|C0450371|C0439165|C1514756|C0450371|C0439165|C1301732|C0574032|C0205388|G0000000|C0439165|C1514873|C0205421|C0039798|C0301630|C0178602|C0013216
Written informed consent was obtained from all patients.,written informed consent patients,C0043266|C1522154|C1511481|C0030705
"The addition of trastuzumab was also associated with a significantly lower rate of death at one year (22 percent, as compared with 33 percent in the group given chemotherapy alone; P=0.008).",addition trastuzumab lower rate death 22 percent compared 33 percent chemotherapy p=0 008,C0332287|C0728747|C0441994|C0871208|C0011065|C0450371|C0439165|C1707455|C0450371|C0439165|C0013216|C0369773|C1442061
"Eighteen patients (15 in the subgroup given an anthracycline, cyclophosphamide, and trastuzumab and 3 in the subgroup given paclitaxel and trastuzumab) had clinical signs of cardiac dysfunction.",eighteen patients 15 subgroup anthracycline cyclophosphamide trastuzumab 3 subgroup paclitaxel trastuzumab clinical signs cardiac dysfunction,C3715206|C0030705|C0450371|C1079230|C0003234|C0010583|C0728747|G0000000|C1079230|C0144576|C0728747|C0205210|C0220912|C0018787|C0031847
"In this context, the risks of trastuzumab will necessitate great caution in its use, especially when it is combined with an anthracycline.",context risks trastuzumab necessitate caution combined anthracycline,C0449255|C0035647|C0728747|G0000000|G0000000|C0205195|C0003234
Drs.,drs,C3887968
"Doxorubicin or epirubicin plus cyclophosphamide or paclitaxel was administered once every three weeks for six cycles, and additional cycles were administered at the investigator's discretion.",doxorubicin epirubicin cyclophosphamide paclitaxel administered weeks cycles additional cycles administered investigators discretion,C0013089|C0014582|C0010583|C0144576|C1521801|C0439230|C1511572|C1524062|C1511572|C1521801|C0035173|G0000000
The risk of death was reduced by 18 to 20 percent in the subgroups given trastuzumab (Table 2).,risk death reduced 18 20 percent subgroups trastuzumab table 2,C0035647|C0011065|C0392756|C0450371|C0450371|C0439165|C1079230|C0728747|C0039224|G0000000
Adverse Events,adverse events,G0000000|C0441471
"The 27 percent incidence of cardiac dysfunction among patients who were given an anthracycline, cyclophosphamide, and trastuzumab and the 13 percent incidence among those who were given paclitaxel and trastuzumab exceeded the expected incidence of less than 7 percent associated with cumulative doses of doxorubicin of up to 550 mg per square meter.",27 percent incidence cardiac dysfunction patients anthracycline cyclophosphamide trastuzumab 13 percent incidence paclitaxel trastuzumab exceeded expected incidence 7 percent cumulative doses doxorubicin 550 square meter,C0450371|C0439165|C0021149|C0018787|C0031847|C0030705|C0003234|C0010583|C0728747|C0450371|C0439165|C0021149|C0144576|C0728747|G0000000|C1517001|C0021149|G0000000|C0439165|C1511559|C0178602|C0013089|C1442061|C0205120|C0475209
Shak and Fuchs are former employees of and stockholders in Genentech.,shak fuchs employees stockholders genentech,G0000000|G0000000|C0024752|G0000000|C0331820
"As of the data-cutoff date of December 31, 1997, a total of 388 (83 percent) of the 469 patients had discontinued the study, including 173 (74 percent) of the 235 patients assigned to receive chemotherapy plus trastuzumab and 215 (92 percent) of the 234 patients assigned to receive chemotherapy alone.",data-cutoff december 31 1997 total 388 83 percent 469 patients discontinued study including 173 74 percent 235 patients assigned receive chemotherapy trastuzumab 215 92 percent 234 patients assigned receive chemotherapy,C1511726|C3830550|C0450371|G0000000|C0439175|C1442061|C0450371|C0439165|C1442061|C0030705|C1444662|C0557651|C0332257|C1442061|C0450371|C0439165|C1442061|C0030705|C1516050|C1514756|C0013216|C0728747|C1442061|C0450371|C0439165|C1442061|C0030705|C1516050|C1514756|C0013216
The benefit of trastuzumab plus paclitaxel does not appear to be attributable to the poor outcomes in the group given paclitaxel alone.,benefit trastuzumab paclitaxel attributable poor outcomes paclitaxel,C0814225|C0728747|C0144576|C0596130|C0032854|C1274040|C0144576
"A growth factor receptor gene, 5-7 human epidermal growth factor receptor ( HER2 ), is amplified in 25 to 30 percent of breast cancers and in these cases the encoded protein is present in abnormally high levels in the malignant cells.",growth factor receptor gene 5-7 human epidermal growth factor receptor her2 amplified 25 30 percent breast cancers encoded protein abnormally levels malignant cells,C0018270|C1521761|C0597357|C0017337|G0000000|C0086418|C0014520|C0018270|C1521761|C0597357|G0000000|G0000000|C0450371|C0450371|C0439165|C0006141|C0006826|C0679058|C0033684|G0000000|C0441889|C0205282|C0007634
Supported by Genentech.,supported genentech,C1521721|C0331820
"On the detection of disease progression, patients were given the We enrolled 469 patients between June 1995 and March 1997 (Table 1); 5 patients were never treated: 2 declined treatment, 1 died before treatment was begun, 1 had disease progression at enrollment, and 1 was enrolled inadvertently.",detection disease progression patients enrolled 469 patients june 1995 march 1997 table 1 5 patients treated 2 declined treatment 1 died treatment begun 1 disease progression enrollment 1 enrolled inadvertently,C1511790|C0012634|C0242656|C0030705|G0000000|C1442061|C0030705|C3829443|G0000000|C3829202|G0000000|C0039224|G0000000|G0000000|C0030705|C1522326|G0000000|G0000000|C0039798|G0000000|C0011065|C0039798|C0439659|G0000000|C0012634|C0242656|C1516879|G0000000|G0000000|G0000000
"Adding trastuzumab to the chemotherapy regimen did not increase the risk of other adverse events related to chemotherapy, and in no patient were antibodies against trastuzumab detected.",adding trastuzumab chemotherapy regimen increase risk adverse events chemotherapy patient antibodies trastuzumab detected,C1883712|C0728747|C0013216|C0040808|C0442805|C0035647|G0000000|C0441471|C0013216|C0030705|C0003241|C0728747|C0442726
Stratification *Twenty of these patients received epirubicin rather than doxorubicin.,stratification *twenty patients received epirubicin doxorubicin,C1514983|C0724000|C0030705|C1514756|C0014582|C0013089
Efficacy,efficacy,C1280519
"The median duration of follow-up was 30 months (range, 30 to 51).",median duration follow-up 30 months range 30 51,C0549183|C0449238|C0589120|C0450371|C0439231|C1514721|C0450371|C0450371
"Indeed, one large upcoming trial of adjuvant trastuzumab will evaluate a non-anthracycline-based regimen for this reason.",upcoming trial adjuvant trastuzumab evaluate non-anthracycline-based regimen reason,G0000000|C0008976|C0001551|C0728747|C0220825|C1518422|C0040808|C0392360
R ESULTS OF AN I NTENTION -TO -T REAT A NALYSIS OF THE E ND P OINTS.,esults ntention -to -t reat nalysis oints,G0000000|G0000000|C0040363|C2603360|G0000000|G0000000|C0028912
The response-evaluation committee assessed the tumor response in 446 patients: 99 percent of the 452 patients who had an assessment after the base-line evaluation and 95 percent of the 469 patients who enrolled in the study.,response-evaluation committee assessed tumor response 446 patients 99 percent 452 patients assessment base-line evaluation 95 percent 469 patients enrolled study,C0871261|C2699414|C1516048|C0027651|C0871261|C1442061|C0030705|C0450371|C0439165|C1442061|C0030705|C1261322|C0168634|C0220825|C0450371|C0439165|C1442061|C0030705|G0000000|C0557651
"Chemotherapy consisted of an anthracycline (doxorubicin at a dose of 60 mg per square meter of body-surface area or epirubicin at a dose of 75 mg per square meter) plus cyclophosphamide (at a dose of 600 mg per square meter) for patients who had never before received an anthracycline, or paclitaxel (at a dose of 175 mg per square meter) for patients who had received adjuvant (postoperative) anthracycline.",chemotherapy consisted anthracycline doxorubicin dose 60 square meter body-surface epirubicin dose 75 square meter cyclophosphamide dose 600 square meter patients received anthracycline paclitaxel dose 175 square meter patients received adjuvant postoperative anthracycline,C0013216|C0332529|C0003234|C0013089|C0178602|C0450371|C0205120|C0475209|C0489451|C0014582|C0178602|C0450371|C0205120|C0475209|C0010583|C0178602|C1442061|C0205120|C0475209|C0030705|C1514756|C0003234|C0144576|C0178602|C1442061|C0205120|C0475209|C0030705|C1514756|C0001551|C0032790|C0003234
The duration of response was defined as the time from the first response to disease progression or death.,duration response defined time response disease progression death,C0449238|C0871261|C1704788|C0040223|C0871261|C0012634|C0242656|C0011065
T ABLE 1.,1,G0000000
"The most important adverse event was cardiac dysfunction, which occurred in 27 percent of the group given an anthracycline, cyclophosphamide, and trastuzumab; 8 percent of the group given an anthracycline and cyclophosphamide alone; 13 percent of the group given paclitaxel and trastuzumab; and 1 percent of the group given paclitaxel alone.",adverse event cardiac dysfunction occurred 27 percent anthracycline cyclophosphamide trastuzumab 8 percent anthracycline cyclophosphamide 13 percent paclitaxel trastuzumab 1 percent paclitaxel,G0000000|C0441471|C0018787|C0031847|C1709305|C0450371|C0439165|C0003234|C0010583|C0728747|G0000000|C0439165|C0003234|C0010583|C0450371|C0439165|C0144576|C0728747|G0000000|C0439165|C0144576
"In the group given paclitaxel and trastuzumab, the increase in the interval between randomization and disease progression was greater among patients who had a Karnofsky score of 90 or more at base line.",paclitaxel trastuzumab increase interval randomization disease progression patients karnofsky score 90 base,C0144576|C0728747|C0442805|C1272706|C0034656|C0012634|C0242656|C0030705|C0206065|C0449820|C0450371|C0002055
The addition of trastuzumab to the chemotherapy regimen increased the frequency of leukopenia and anemia (Table 4).,addition trastuzumab chemotherapy regimen increased frequency leukopenia anemia table 4,C0332287|C0728747|C0013216|C0040808|C0205217|C0376249|C0023530|C0002871|C0039224|G0000000
The response-evaluation committee assessed the tumor response in 446 patients: 99 percent of the 452 patients who had an assessment after the base-line evaluation and 95 percent of the 469 patients who enrolled in the study.,response-evaluation committee assessed tumor response 446 patients 99 percent 452 patients assessment base-line evaluation 95 percent 469 patients enrolled study,C0871261|C2699414|C1516048|C0027651|C0871261|C1442061|C0030705|C0450371|C0439165|C1442061|C0030705|C1261322|C0168634|C0220825|C0450371|C0439165|C1442061|C0030705|G0000000|C0557651
CI denotes confidence interval.,ci denotes confidence interval,C0008107|G0000000|C0237529|C1272706
"The adjuvant (postoperative) use of trastuzumab will be an important research topic, but since many patients with early-stage breast cancer can be cured by surgery and radiotherapy, the cardiotoxicity of trastuzumab will be a critical consideration.",adjuvant postoperative trastuzumab topic patients early-stage breast cancer cured surgery radiotherapy cardiotoxicity trastuzumab critical consideration,C0001551|C0032790|C0728747|C1522168|C0030705|C2363430|C0006141|C0006826|C1880198|C0038894|C0034619|C0876994|C0728747|C1511545|C0518609
